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ABSTRACT 
 
CHRISTINE POWELL:  Improving Linkage of Hepatic Toxicity and Pathology Endpoints with 
Toxicogenomics 
(Under the direction of Ivan Rusyn, M.D., Ph.D.) 
 
 
The science of toxicology is directed toward understanding the mechanisms by 
which environmental agents cause adverse health effects in humans. Traditional 
methodologies to assess toxicity have relied on observable adverse effects which have 
proven to be useful diagnostic indicators; however, frequently they do not provide 
mechanistic insight necessary to unravel the complex biological networks responsible for the 
development of disease. Toxicogenomics, a sub-discipline of toxicology which examines the 
global genomic response of organisms to a toxic insult, when applied in parallel with 
classical toxicological endpoints can advance the field by providing molecular markers of 
exposure and response, and defining disease processes. Thus, we hypothesize that 
molecular signatures defining disease mechanisms and early effects of exposure can be 
phenotypically anchored to biomarkers of oxidative stress and DNA damage. In Aim 1, a 
molecular signature of incipient toxicity for an acute sub-toxic dose of acetaminophen was 
phenotypically anchored to oxidative stress markers based on its mechanism of 
hepatotoxicity. The detection of early changes in a biologic process at doses and times with 
no apparent clinical signs of toxicity provides an improved basis to develop predictive 
markers of effect. In Aim 2, molecular signatures were identified that temporally modeled 
disease pathology and oxidative stress for a choline-deficient model of rodent hepatocellular 
carcinoma (HCC). Measures of oxidative DNA damage established a temporal linkage 
between fibrosis and accumulation of DNA lesions, processes that may contribute to 
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hepatocyte transformation. Moreover, comparison of rat and human HCC expression 
profiles, regardless of etiology, demonstrated that advanced stages of liver disease 
converge onto a common and indistinguishable phenotype. In Aim 3, gene expression 
profiling combined with measures of oxidative stress established that dietary fatty acids can 
have a profound yet differential effect on oxidative stress in the liver mediated by their ability 
to activate PPARα. Many environmental exposures exhibit human toxicity and disease 
through oxidative-stress signaling pathways. Thus, dietary fatty acids can markedly 
influence sensitivity or resistance to disease. In summary, toxicogenomics moves the field of 
toxicology beyond traditional approaches by linking the critical molecular events caused by 
exposure to environmental factors with disease.   
  v 
 
DEDICATION 
 
To my parents, Teresa and T.D. Powell,  
whose love and support made all this possible 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  vi 
 
ACKNOWLEDGEMENTS 
 
I give my sincere appreciation to my mentor, Dr. Ivan Rusyn, for his years of support, 
wisdom and words of encouragement. I am deeply appreciative for the knowledgeable 
advice and recommendations contributed by my committee: Dr. Richard S. Paules, Dr. 
James A. Swenberg, Dr. David W. Threadgill, and Dr. Michael Wheeler. I am indebted to the 
members of Dr. Ivan Rusyn’s laboratory:  Mrs. Blair Bradford, Ms. Amanda Burns, Mr. Dan 
Gatti, Ms. Alison Hege, Mrs. Oksana Kosyk, Ms. Pamela Ross and Ms. Courtney Woods.  
I would not have been able to complete the work presented here without the contributions 
and assistance from the many people I was so fortunate to have collaborated with. It is my 
great pleasure to recognize the following individuals and their respectable institutions: 
• Mr. Robert Schoonhoven, Mrs. Pat Upton, Dr. Jun Nakamura, Dr. Gunnar Boysen 
and Dr. Kerry-Ann Da Costa of University of North Carolina at Chapel Hill 
• Dr. Alexandra N. Heinloth, Dr. Gary A. Boorman and Dr. Michael L. Cunningham of 
the National Institute of Environmental Health Sciences 
• Dr. Ayumi Denda of Department of Nara Medical University 
• Dr. Fumiyuki Uematsu and Dr. Dai Nakae of Sasaki Foundation 
• Mr. Joel S. Parker of Constella Health Sciences 
• Dr. Edward K. Lobenhofer of Paradigm Array Labs 
 
 
 
 
  vii 
 
TABLE OF CONTENTS 
 
 Page 
LIST OF TABLES ………………………………………………………………………………..xiii    
LIST OF FIGURES ………………………………………………………………………………xiv 
LIST OF ABBREVIATIONS AND SYMBOLS ……………………………………………...... xvi  
CHAPTERS 
I. Introduction ……………………………………………………………………………… 1  
A. Integrating toxicogenomics with current toxicology testing  
methods to advance risk assessment ……………………………………….. 2 
 
1) Toxicogenomics defined .…………………………………………….. 2 
2) Phenotypic anchoring of toxicogenomic data ……………………. 3 
3) Moving the field of toxicogenomics forward ………………………. 4 
B. Oxidative Stress ……………………………………………………………… 5 
1) Oxidative stress as a common general mechanism of  
toxicity and disease …………………………………………………. 5 
2) Reactive oxygen species and biomolecules ……………………… 7 
 2.1 DNA …………………………………………………………… 8 
 2.2 Proteins ………………………………………………………. 10 
 2.3 Lipids ………………………………………………………….. 11 
3) Mechanisms of DNA repair …………………………………………. 12 
4) Oxidative DNA damage and cancer ……………………………….. 13 
  viii 
 
5) Measurements of oxidative damage ……………………………….. 15 
 5.1 Detection and quantification of 8-hydroxy-deoxy- 
guanosine by LC-MS/MS …………………………………… 16 
 5.2 Apurinic/apyrimidinic (AP) sites …………………………. …17 
 5.3 Expression of DNA repair genes as a biomarker 
of oxidative DNA damage  ……………………………….…. 18 
 5.4 Immunohistochemical detection of oxidative damage …. . 18 
 5.5 Glutathione …………………………………………………….18  
C. Rationale and Specific Aims …………………………………………………. 19 
II. Phenotypic anchoring of acetaminophen-induced oxidative stress  
with gene expression profiles in rat liver …………………………………………….  24 
A. Abstract ………………………………………………………………………… 25 
B. Introduction ……………………………………………………………………. 26 
C. Materials and Methods ……………………………………………………..... 28 
Animals and treatments …………………………………………………. 28 
Determination of liver tissue GSH levels ………………………………. 28 
Immunohistochemistry …………………………………………………… 28 
Isolation of DNA ………………………………………………………….. 29 
AP sites ……………………………………………………………………. 30 
Detection and quantification of 8-OH-dG by capillary liquid 
chromatography-mass spectrometry/mass spectrometry ……………. 30 
 
Ribonuclease protection assays ………………………………………... 31 
Statistical analysis ………………………………………………………... 32 
D. Results …………………………………………………………………………. 32 
E.   Discussion …………………………………………………………………….. 35 
III. Temporal correlation of pathology and DNA damage with gene  
  ix 
 
expression in a choline-deficient model of rat liver injury …………………………. 50 
A. Abstract ………………………………………………………………………… 51 
B. Introduction ……………………………………………………………………. 52 
C. Experimental Procedures ……………………………………………………. 53 
Animals and treatments …………………………………………………. 54 
RNA isolation ……………………………………………………………… 54 
Microarray experiments …………………………………………………. 54 
Microarray data analysis ………………………………………………… 54 
RNase Protection Assays ………………………………………………. 55 
Detection of apurinic/apyrimidinic sites and oxidized purines ………. 55 
D. Results and Discussion ……………………………………………………… 55 
Hierarchical analysis of gene expression data distinguishes  
CS- and CD-treated groups …………………………………………… 55 
Identification of gene clusters temporally expressed in liver  
of CD-treated rats ……………………………………………………….56 
Gene expression patterns reveal CD attributes to altered 
lipid metabolism ………………………………………………………… 57  
Gene expression patterns show that CD activates apoptotic  
pathways ………………………………………………………………… 58 
Gene expression patterns reveal CD mediates tissue repair  
through activation of hepatic stellate cells …………………………… 59 
Gene expression reveals liver injury transition states in CD rats …. 60 
CD-induced hepatocarcinogenesis is preceded by oxidative  
stress to DNA …………………………………………………………… 61 
CD-induced rat HCC and human HCCs are similar at the level  
of gene expression …………………………………………………….. 63 
Gene expression distinguishes between causal and consecutive  
events in liver disease …………………………………………………. 64 
 
IV. PPARα-regulated molecular networks are responsible for the differential  
  x 
 
effects of dietary fatty acids on oxidative stress and DNA damage in  
mouse liver …………………………………………………………………………. 74 
A. Abstract ………………………………………………………………………… 75 
B. Introduction ……………………………………………………………………. 76 
C. Materials and Methods ……………………………………………………….. 78 
Animals and treatments …………………………………………………78 
Extraction and measurement of fatty acids ………………………….. 79 
RNA isolation ……………………………………………………………. 79 
Microarrays ……………………………………………………………… 79  
RNase protection assays ……………………………………………… 80 
Determination of liver tissue glutathione levels …………………….. 81 
Immunohistochemistry ………………………………………………… 81 
DNA isolation …………………………………………………………… 81 
Detection and quantification of 8-OH-dG by capillary LC-MS/MS … 82 
Electrophoretic mobility shift assay for PPARα …………………….. 82 
Acyl-CoA oxidase activity ……………………………………………… 83 
D. Results …………………………………………………………………………. 83 
Effects of dietary fatty acid treatments on liver  
morphology and biochemistry …………………………………………. 83 
Temporal and treatment-dependent changes in  
gene expression ………………………………………………………… 84 
Gene expression analysis reveals discordant effect  
on anti-oxidant defense genes by ω-3 and ω-6 PUFA ……………. 85 
High-fat diets rich in ω-6 PUFA cause pro-oxidant state  
in mouse liver …………………………………………………………...  86 
Activation of PPARα plays a role in the differential effects  
of ω-3 and ω-6 PUFA ………………………………………………….  88 
  xi 
 
E. Discussion ………………………………………………………………………. 89 
V. Discussion …………………………………………………………………………. 109 
A. Conclusion and Perspectives …………………………………………… 110 
1) Predictive markers of early effect …………………………………110 
2) Assessing degree of conservation for  
mechanisms of toxicity ……………………………………………. 111 
3) Identification of best-fit animal models through  
comparative genomics ……………………………………………. 112 
4) Improving the linkage between oxidant-induced hepatic  
toxicity and HCC …………………………………………………… 113 
5) Role of dietary oils as vehicles to conduct  
toxicological studies ……………………………………………….. 114 
B. Challenges and Limitations ………………………………………………….. 115 
1) Study limitations …………………………………………………….115 
2) Current challenges and limitations of  
toxicogenomic studies …………………………………………….. 117 
2.1 Standardization of toxicogenomic protocols  
and data analysis …………………………………………... 117 
2.2 Gene expression is a limited biological measurement …. 119 
2.3 Interpretation of toxicogenomic data requires  
phenotypic anchoring ……………………………………….. 120 
C. Future Directions ………………………………………………………………121 
D. Summary ………………………………………………………………………. 122 
Appendices …………………………………………………………………………………….. 123 
Appendix 1 Gene lists of cellular pathways evoked by choline  
deficiency in rat liver ………………………………………………… 124 
Appendix 2 Biological processes associated with liver injury transition  
 states in choline deficient rats ……………………………………… 139 
Appendix 3 Gene list of orthologous genes shared between rat and  
human HCCs ………………………………………………………… 158 
  xii 
 
Appendix 4 Unsupervised hierarchical clustering of 15,866 genes in liver 
distinguishes between choline sufficient (CS) and choline  
deficient (CD) treated rats …………………………………………... 172 
  Appendix 5 KEGG-annotated pathways that are significantly enriched  
      in CD rats ………………………………………………………………173 
References ……………………………………………………………………………………… 174 
  xiii 
 
LIST OF TABLES 
 
Table 2.1 rGSH concentration in rat liver following APAP treatment …………………41 
 
Table 2.2 Expression of DNA repair genes in rat liver after treatment with  
an overtly toxic dose (1500 mg/kg) of APAP ………………………………. 42 
 
Table 3.1 Expression of DNA repair genes in rat liver after treatment with  
control choline-sufficient (CS) or choline-deficient (CD) diets ……………. 66 
 
Table 4.1 Diet formulations ……………………………………………………………… 96 
 
Table 4.2 Effect of high-fat ω-3 and ω-6 PUFA diets on hepatic morphology ……… 97 
 
Table 4.3 Fatty acid composition of liver total lipids following treatment with 
high-fat diets of either corn oil or fish oil ……………………………………. 98 
 
Table 4.4 Effects of high-fat ω-3 and ω-6 PUFA diets on liver glutathione  
content ………………………………………………………………………… 99 
 
Table 4.5 Expression of base excision DNA repair genes are induced by  
high-fat diets rich in ω-6 PUFA ……………………………………………… 100 
 
  xiv 
 
LIST OF FIGURES 
 
Figure 1.1 Schematic diagram of types of DNA damage that may be induced  
by reactive oxygen species ………………………………………………….. 22 
 
Figure 1.2 Schematic diagram of base excision repair pathways for removal  
of oxidized DNA lesions formed as a result of a chemical exposure  
that causes oxidative stress …………………………………………………. 23 
 
Figure 2.1 A sub-toxic dose of APAP significantly increases nitrotyrosine  
protein adducts in rat liver ……………………………………………………. 43 
 
Figure 2.2 Rat liver genomic DNA significantly accumulates 8-OH-dG adducts  
after 6 h treatment with subtoxic and overtly toxic doses of APAP ……… 45 
 
Figure 2.3 A subtoxic dose of APAP significantly accumulates 8-OH-dG DNA  
adducts in rat liver as measured by capillary LC-MS/MS ………………… 46 
 
Figure 2.4 APAP has no effect on the accumulation of AP sites in rat liver …………. 47 
 
Figure 2.5 APAP does not promote lipid peroxidation in rat liver …………………….. 48 
 
Figure 2.6 Phenotypic anchors of gene expression profiling for oxidative stress 
are reflective of the proposed mechanism of APAP-induced  
hepatotoxicity …………………………………………………………………. 49 
 
Figure 3.1 Pathological stages of liver disease progression in a rat model  
of HCC ………………………………………………………………………….. 67 
 
Figure 3.2 Hierarchical clustering of choline-sufficient (CS) and choline- 
deficient (CD) liver samples using “intrinsic” gene set ……………………. 68 
 
Figure 3.3 Supervised hierarchical clustering of altered cellular and molecular  
pathways associated with choline deficiency ………………………………. 69 
 
Figure 3.4 Venn diagram illustrating the distribution of gene alterations between  
liver injury transition states in choline-deficient rats ………………………. 70 
 
Figure 3.5 Temporal expression of oxidative stress genes in rat liver evoked  
by a choline-deficient diet …………………………………………………….. 71 
 
Figure 3.6 Choline deficiency promotes the accumulation of oxidative DNA  
lesions in rat liver ……………………………………………………………… 72 
 
Figure 3.7 Clustering analysis of rat and human hepatocellular carcinomas  
(HCCs) …………………………………………………………………………. 73 
 
Figure 4.1 Temporal and treatment-dependent changes in gene expression  
in mouse liver following treatment with high-fat diets of ω-3  
  xv 
 
and ω-6 PUFA ………………………………………………………………… 101 
 
Figure 4.2 A high-fat diet of ω-3 PUFA leads to an induction of anti-oxidant  
defense genes in mouse liver ……………………………………………….. 103 
 
Figure 4.3 The type of PUFA influences the degree of accumulation of  
8-OH-dG DNA adducts in liver compared to control low-fat diet …………104 
 
Figure 4.4 Gene expression phenotypes in livers from mice given a high-fat  
diet of ω-3 PUFA or PPARα agonist, WY-14,643, are similar …………… 105 
 
Figure 4.5 Activation of PPARα in liver with ω-3 PUFA dietary treatment ………….. 106 
 
Figure 4.6 Gene expression modulation of PPARα-regulated networks by PUFA  .. 107
  xvi 
 
LIST OF ABBREVIATIONS AND SYMBOLS 
 
8-OH-dG 8-hydroxy-deoxyguanosine 
ALT  alanine aminotransferase 
AP  apurinic/apyrimidinic  
Ape  apurinic/apyrimidinic endonuclease 1 
APAP  acetaminophen 
ARP  aldehyde reactive probe 
BER  base excision repair 
CD  choline deficient/choline deficiency 
CS  choline sufficient L-amino acid defined 
DAG  1,2-sn-diacylglycerol 
EPA  Environmental Protection Agency 
EMSA  electromobility shift assay 
FDA  Food and Drug Administration 
FDR  false discovery rate 
GO  gene ontology 
GSH  glutathione 
 
H2O2  hydrogen peroxide 
 
HBV  hepatitis B virus 
 
HCC  hepatocellular carcinoma 
 
HCV  hepatitis C virus 
 
HNE  4-hydroxynonenal 
 
HSC  hepatic stellate cells 
 
MDA  malondialdehyde 
 
Mgmt  O6-methylguanine DNA methyltransferase 
  xvii 
 
Mpg  N-methylpurine DNA glycosylase 
 
NAPQI  N-acetyl-p-benzoquinone imine 
 
NO·  nitric oxide 
 
NOEL  no observable effect level 
 
O2·  superoxide anion 
 
Ogg1  8-oxoguanine DNA glycosylase 1 
 
·OH  hydroxyl radical 
 
ONOO- peroxynitrite 
 
Parp  poly (ADP-ribose) polymerase 
 
PC  phosphotidylcholine 
 
PCNA  proliferating cell nuclear antigen 
 
PKC  protein kinase C 
 
PPARα peroxisome proliferator-activated receptor alpha 
 
Pol β  polymerase (DNA directed) β 
 
Pol δ  polymerse (DNA directed) δ 
 
PUFA  polyunsaturated fatty acids 
 
ROS  reactive oxygen species 
 
SAM  significance analysis of microarrays 
TRC  Toxicogenomics Research Consortium 
ω  omega 
 
WY  WY-14643; 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid 
 
 
 
 
CHAPTER I 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
Excerpts of text in this chapter are reproduced with permission from 
Cancer Letters 229: 1-11 (2005) 
© 2005 
Elsevier Ireland Ltd 
  2 
 
A. INTEGRATING TOXICOGENOMICS WITH CURRENT TOXICOLOGY TESTING 
METHODS TO ADVANCE RISK ASSESSMENT 
 
1. Toxicogenomics Defined 
The science of toxicology is directed toward understanding the mechanisms by 
which individual environmental agents cause their effects in humans. Due to technical 
limitations, the evolution of toxicological science has been relatively slow and was 
accomplished one chemical or one mechanism of action at a time. In addition to chemicals 
and drugs, there are other environmental factors and stressors, such as radiation, biological 
agents, and dietary and lifestyle factors that alone or by interaction contribute to the 
development of disease. The complex effects of the environment must be characterized to a 
progressively greater depth for us to understand their biochemical and genetic impact on the 
cells in which adverse effects are manifested. Thus, new technologies such as genomics, 
the science of characterizing genes, including variation and gene regulation, and their 
functions in cells and tissues would contribute greatly to the advancement of toxicology. 
Toxicogenomics, a sub-discipline of toxicology, elucidates how the entire genome is 
involved in biological responses of organisms exposed to environmental toxicants/stressors. 
Toxicogenomics gets its strength from the combination of disciplines and a mixture of 
traditional and innovative research methods.  Genetic susceptibility and the environmental 
stressors that instigate disease in humans is the focus of much research and are of 
importance to regulatory agencies. New methods to characterize environmental agents, 
their cellular and molecular mechanisms, and ultimately their effect on a whole genome 
scale, are being closely examined by regulatory agencies for integration into their decision 
making strategies (1).  At the present state of development for the field of toxicogenomics, 
the major advances in understanding toxic effects will still be made one chemical, agent, or 
mechanism at a time. The promise of this new technology is such that it can be used to 
generate data on large numbers of chemicals and exposure conditions and to develop an 
  3 
 
unprecedented knowledge base that can be used to guide future research, improve 
environmental health, and aid in regulatory decisions (2, 3).  
 
2. Phenotypic Anchoring of Toxicogenomic Data 
The results of the gene expression profiling studies can serve as a guide in the 
search for specific genes/proteins that could be used as biomarkers of incipient toxicity, or 
can predict the pathological changes that are yet to be realized by morphological analysis. 
The linkage of candidate biomarkers (e.g., genes and metabolites) to the actual causal 
processes that lead to specific toxic effects can be accomplished through studies involving 
morphological and ultrastructural analysis of the changes, in situ hybridization, 
immunohistochemistry, and the laser-capture microdissection of cells to relate the 
expression of the putative biomarkers to the specific cells that have undergone these 
adverse events (4). For example, studies from the National Center for Toxicogenomics have 
demonstrated the capability of identifying signature patterns of altered gene expression that 
can be used to predict the classes of chemicals that an animal was exposed to based on an 
initial training set of chemicals (5, 6). This work led to the hypothesis that it is possible to 
define signature patterns of altered gene expression that indicate specific adverse effects of 
chemical, drug, or environmental exposures. The idea is that once signatures are identified 
using large-scale global microarray analysis, it will then be possible to develop smaller multi-
chemical and multi-pathway arrays that can be used to assess the potential toxicity of 
chemicals in a rapid, prospective manner. The so called “phenotypic anchoring” of gene 
expression data to toxicological and pathological indices is required to remove some of the 
subjectivity of conventional molecular expression analyses. It also helps to distinguish the 
toxicological effect signal from other gene expression changes that may be unrelated to 
toxicity, such as the varied pharmacological or therapeutic effects of a compound. This 
distinction could mean better insights into pathways of toxicity and disease processes and 
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their mechanisms that have been heretofore unattainable. 
 
3. Moving the Field of Toxicogenomics Forward 
 Predicting adverse health outcomes in humans resulting from chemical exposure has 
traditionally relied on observable, treatment related adverse events. The adverse event may 
include gross changes in body or organ weight, histopathological observations, changes in 
clinical chemistry or hematological parameters, or more commonly, a combination of all of 
the above. These endpoints have proven to be useful diagnostic indicators; however, 
frequently they do not provide mechanistic insight necessary to unravel the complex 
biological networks responsible for the pathogenesis and progression of disease. Moreover, 
these measures are insensitive to detect low-level toxicity or pre-clinical stages of disease 
which can lead to inaccurate hazard assessment (7). Since changes in cellular responses 
brought about by chemical exposure are thought to precede morphological changes, 
alterations in gene expression may serve as early, sensitive indicators of potential toxicity 
compared to currently employed methods. Toxicogenomic studies applied in parallel with 
traditional measures of toxicity can establish important linkages between altered gene 
transcripts and the pathological sequelae of events leading to toxicity. Information generated 
from such data sets has the potential to provide insights into mode of action and to identify 
sensitive biomarkers of exposure. Unfortunately, much of the available toxicogenomic data 
that has been published to date, with few exceptions, has been limited to a qualitative 
description of alterations in gene transcripts with little or no correlation to toxicity or 
contribution to the elucidation of mechanisms of toxicity (8).  
The gene signature itself provides little information for understanding the underlying 
mechanism of toxicity or disease. Assigning biological function (i.e., functional genomics) to 
gene sets and uncovering how their gene products work together under normal homeostatic 
conditions and after perturbation by environmental agents are needed to define the complex 
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exposure-disease relationship. The Gene Ontology (GO) Consortium has developed three 
vocabularies to describe gene products as a function of their biological processes, their 
cellular components, and their molecular/biochemical function. Graphical user interfaces 
such as GoMiner (9) work with GO to identify global molecular and biochemical trends in 
gene expression data. Then, and most importantly, gene functionality can be phenotypically 
anchored to measures of toxicity to uncover how sets of genes and their products work 
together in health and disease. Integrating functional genomics with phenotypic anchors of 
toxicity presents us with an opportunity to define at unprecedented levels of detail, the 
molecular events that precede and accompany toxicity, promising to shed light on toxic 
mechanisms that are presently poorly understood (10). The information gathered from such 
studies can further reduce the uncertainity factors that are weighted in determining the 
safety factor to prevent adverse health effects in humans. Regulatory agencies are watching 
this field closely but will be reluctant to accept such data sets until this field undergoes 
significiant scientific rigor. As such, proof-of-principle studies must be conducted using well 
characterized models of toxicity to establish toxicogenomics as a valuable and biologically 
meaningful tool in toxicology.  
 
B. OXIDATIVE STRESS 
 
1. Oxidative Stress as a Common General Mechanism of Toxicity and Disease 
Cells living in an oxygen-rich environment are inundated with various endogenous 
and exogenous sources of reactive oxygen species (ROS).  As a consequence of cellular 
metabolic and biochemical processes such as mitochondrial respiration, β-oxidation, and 
cytochrome P450 metabolism, there is a steady production of ROS in the cell (11).  
Additionally, inflammation, exposure to ultraviolet radiation, γ-irradiation, and the formation 
of reactive intermediates from xenobiotic metabolism serve as exogenous mediators of ROS 
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generation (12).  ROS are known to play dual role in biological systems, since they can be 
either harmful or beneficial to living systems (13). Beneficial effects involve physiological 
roles in the defense against infectious agents, in the function of numerous cellular signaling 
pathways, and at low concentrations the induction of a mitogenic response. However, 
oxidative stress can arise when the production of ROS exceeds the cell’s antioxidant 
capacity, resulting in damage to cellular macromolecules such as DNA, proteins, and lipids 
(14). As a result, cells have evolved numerous defense mechanisms to counteract and limit 
the levels of reactive oxidants and the cellular damage that can ensue (15). These include 
enzymatic reduction of ROS by superoxide dismutase, glutathione peroxidase, and 
catalase, as well as non-enzymatic quenching of ROS by vitamin E, vitamin C, β-carotene, 
and glutathione (16).  Besides these primary defense mechanisms, selective proteolysis of 
oxidatively damage proteins and various mechanisms of DNA repair act as secondary 
antioxidant systems to maintain the integrity of protein homeostasis and genetic information. 
Despite these defense responses against ROS, oxidative damage accumulates during the 
life cycle, and radical-mediated damage to DNA, proteins, and lipids has been proposed to 
play a key role in aging and the development of age-dependent diseases such as cancer, 
atherosclerosis, arthritis, neurodegenerative disorders, diabetes and other conditions. 
Moreover, exposure to exogenous sourcs of free radicals including drugs, environmental 
pollutants like ozone and polychlorinated biphenyls, cigarette smoke, and various fungal and 
bacterial toxins exhibit human toxicity and disease through oxidative stress-sensitive 
signaling pathways.  
While excessive ROS production clearly damages cells, low transcient levels of ROS 
play a major physiological role in regulating intracellular signaling pathways (17). The 
induction and propagation of intracellular signaling events is tightly regulated by the cellular 
redox state which ultimately is governed by ROS levels. Alterations in the redox state are 
primarily mediated through oxidation of protein sulfhydryl groups resulting in conformational 
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changes in proteins (18). Such changes mediate oxidants to stimulate receptor tyrosine 
kinases, even in the absence of ligand, as well as the downstream effectors in signal 
transduction pathways including ras, growth factor kinase, src/Abl kinase, c-jun-N-terminal 
kinase, mitogen activated protein kinase (MAPK) and phosphoinositide-3 kinase (PI-3) 
dependent signaling pathways (19-21). As a result, several redox-regulated transcription 
factors are activated including AP-1, NF-κB, p53, and HIF-1 (18, 22). These transcription 
factors control the expression of genes that modulate cell signaling, DNA synthesis, enzyme 
activation, selective gene expression, regulation of the cell cycle, and cell survival (23). 
Thus, the cellular redox potential is an important determinant of cell function and disruptions 
of redox balance may adversely affect the fate and function of the cell.  
 
2. Reactive Oxygen Species and Biomolecules 
2.1 DNA 
DNA damage as a result of oxidative stress is considered to be the most common 
insult affecting the genome (24, 25). DNA is a particularly sensitive cellular target because 
of the potential to create cumulative mutations that can disrupt cellular homeostasis.  
Oxidative DNA damage can include chemical and structural modifications to purine and 
pyrimidine bases and 2′-deoxyribose, and the formation of single- and double-strand breaks 
(26). Persistent oxidative DNA damage can result in either arrest or induction of 
transcription, induction of signaling transduction pathways, replication errors and genomic 
instability.  In a given cell, it is estimated that 105 oxidative DNA lesions are formed each day 
(27).  The exact number of oxidative DNA adducts is unknown but over 100 have been 
identified thus far; however, whether each of these adducts are produced in measurable 
amounts in vivo to be biological relevant remains to be determined (28-31). Oxidative stress-
induced mutations are suggested to play a major role in a number of chronic diseases 
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including carcinogenesis, neurodegenerative disorders, and cardiovascular disease (11, 26, 
32).   
In living cells, ROS are formed continuously as a consequence of both metabolic and 
biochemical reactions in addition to external factors.  These ROS include oxygen radicals 
such as superoxide (O2·), hydroxyl (·OH), peroxyl (RO2·), alkoxyl (RO·), and hydroperoxyl 
(HO2·); and non-radicals that possess strong oxidizing potential or are easily converted to 
radicals by transition metals that include singlet oxygen (1O2), hydrogen peroxide (H2O2), 
hypochlorous acid (HOCl), ozone (O3), and peroxynitrite (ONOO-).  DNA damage induced 
by ROS occurs by way of chemical and structural alterations to purine and pyrimidine bases 
and 2′-deoxyribose, and the formation of abasic sites and DNA strand breaks, see Figure 
1.1 (26). 
The interaction of reactive oxidants with DNA can occur in a variety of ways. For 
instance, some ROS do not interact at all with DNA bases, such as superoxide and 
hydrogen peroxide (33, 34).  Instead, they are believed to elicit their toxicity to DNA by 
conversion to hydroxyl radicals mediated by transition metal ions (e.g. iron and copper) 
through Haber-Weiss and Fenton reactions (35, 36).  The hydroxyl radical is highly reactive 
and does not diffuse more than a couple of molecular diameters before reacting with the 
closest cellular component (36, 37).  Therefore, in order to oxidize DNA directly, the hydroxyl 
radical must be generated immediately adjacent to nucleic acids.  An assortment of products 
could be generated from such reactions since the hydroxyl radical reacts with all bases by 
either addition or abstraction of hydrogen atoms (33). The most frequent base lesion 
produced is by addition of a hydroxyl radical to the C8 position of guanine to produce 8-oxo-
dG, a marker commonly measured to assess oxidative stress to DNA. This adduct is a 
mutagenic lesion that preferentially pairs with adenine rather than cytosine resulting in G:C 
to T:A transversions following replication (38, 39).   
Peroxynitrite is a strong DNA oxidizing and nitrating agent that is a product of the 
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coupling reaction of superoxide and nitric oxide.  Damage to DNA by peroxynitrite can 
include strand breaks, base oxidation, deamination of guanine and adenine, and nitration of 
guanine bases (40-42). Peroxynitrite has been demonstrated to oxidize purine bases with 
the formation of oxazolone, 8-oxo-7,8-dihydro-2’-deoxyadenosine, and 8-oxo-dG (43, 44). 
Moreover, it has been shown that peroxynitrite is at least a 1000 fold more reactive toward 
8-oxo-dG than normal 2’-deoxyguanosine generating secondary products of 2-deoxy-β-D-
erythro-pentofuranosyl derivatives of cyanuric, parabanic, and oxaluric acid (45, 46). 
Mutations induced by peroxynitrite using pSP189 shuttle vector were predominately G:C to 
T:A transversions after replication in both bacteria and mammalian cells (47). Activated 
macrophages produce both superoxide and nitric oxide; thus, they are a potential source of 
peroxynitrite.  Unlike the hydroxyl radical, peroxynitrite has the ability to diffuse across cells 
providing a potential linkage between chronic inflammation and carcinogenesis.   
Oxidants can react with the sugar moiety of DNA leading to the formation of 
apurinic/apyrimidinic (AP) sites and single- and double-strand breaks. The hydroxyl radical 
can abstract hydrogen atoms from all five carbon atoms of 2′-deoxyribose resulting in base 
loss and/or strand breakage (12).  Oxidative DNA adducts can promote cleavage of the N-
glycosidic bond with deoxyribose which can result in the formation of an AP site.  
Furthermore, deoxyribose oxidation leads to the formation of base propenal and 3-
phosphoglyceraldehyde which can react with DNA to form pyrimidopurinone (M1G) and 
etheno-adducts, respectively (48). 
Indirect mutagenicity of DNA can occur by lipid peroxidation, a process involving the 
oxidation of polyunsaturated fatty acids (PUFA). In the presence of transition metal ions, the 
generation of reactive carbonyl products, including epoxides and aldehydes, can be 
generated and then covalently bind to DNA.  These reactive substances damage DNA by 
forming exocyclic adducts (49, 50) which have been shown to have genotoxic and 
mutagenic effects.  For example, 4-hydroxynonenal (HNE) can form an etheno-DNA adduct 
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which can promote chromosomal aberrations and sister chromatid exchanges (51, 52) 
whereas, malondialdehyde (MDA) can give rise to M1G that is highly mutagenic resulting in 
base pair substitutions (51, 52).  
 
2.2 Proteins 
One of the hallmarks of chronic or severe oxidative stress is the accumulation of 
oxidized proteins, which tend to form high-molecular weight aggregates. Protein oxidation is 
important to cellular homeostasis in the fact that proteins serve vital roles in regulating cell 
structure, cell signaling, and the various enzymatic processes of the cell. Identification and 
mechanisms involved in the formation of protein oxidation products has been investigated 
both in vivo and in vitro using isolated amino acids and cell free extracts (53-55). The 
mechanisms involve metal catalyzed oxidation, oxidation induced cleavage, amino acid 
oxidation, and the conjugation of lipid peroxidation products.  
Metal-catalyzed oxidation of proteins is one of the most common mechanisms for 
inducing protein oxidation, especially for the introduction of carbonyl groups. This process 
requires the generation of H2O2 and the presence of transition metal ions such as iron or 
copper (56, 57). The ions bind to specific metal binding sites within the protein and through 
Fenton chemistries react with H2O2 to generate ·OH that then attacks nearby amino acid 
residues. Cleavage of peptide bonds can occur if the hydroxyl radical generated from H2O2 
abstracts a hydrogen atom from the polypeptide backbone forming a carbon-centered free 
radical (alkyl-radical). This radical can then cross-link with other alkyl radicals and form 
protein aggregates or can react with O2 to generate alkyl-peroxyl radical. The peroxyl 
radicals can then be converted to alkyl peroxides by reactions with the protonated from of 
superoxide. 
The side chains of all amino acids are susceptible to oxidation by ROS/RNS; 
however, the most sensitive amino acids are those with aromatic side chains (tyrosine, 
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tryptophan, or phenylalanine) and those containing sulfhydryl groups (histidine, methionine, 
and cysteine). ROS-induced oxidation of aromatic side-chain amino acids can occur through 
a variety of intermediates. For example, the oxidation of phenylalanine residues leads to the 
formation of mono- and di-hydroxy derivatives whereas tryptophan residues are converted 
to several hydroxyl-derivatives, to formylkynurenine and to nitrotryptophan (56). Tyrosine 
residues can be attacked by reactive nitrogen species generating 3-nitrotyrosine (58). In 
contrast to aromatic amino acids, cysteine and methionine residues are oxidized via 
reactions at the site of sulfhydryl residues (59). This oxidation is reversible as cross-linked 
derivatives can be repaired by disulfide exchange reactions catalyzed by thiol transferases.  
Protein carbonyls may be generated by the oxidation of several amino acid side 
chains by the formation of Michael adducts between lysine, histidine, and cysteine residues 
and α,β-unsaturated aldehydes (56). They can also be generated with reducing sugars or 
glycoxidation of lysine amino groups. Protein carbonyls can further react with the α-amino 
groups of lysine residues (60) forming intra- or inter-molecular cross-links which can 
promote the formation of protein aggregates.  
 
2.3 Lipids 
Lipid peroxidation is a process involving the oxidation of polyunsaturated fatty acids 
(PUFAs). The overall process consists of three stages: initiation, propagation, and 
termination. It is initiated by abstraction of a hydrogen atom that can be mediated by the 
hydroxyl, peroxyl, and alkoxyl radicals forming lipid hydroperoxides; however, these species 
are relatively short-lived (61).  Conversely, in the presence of transition metals the highly 
biologically reactive carbonyl products, including epoxides and aldehydes [e.g., 
crotonaldehyde, acrolein, 4-hydroxynonenal (HNE), and malondialdehyde (MDA)], can be 
produced and then diffuse from site of production and covalently bind to proteins and DNA 
(62).  
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The peroxidation of membrane lipids can be very damaging because it leads to 
alterations in the biological properties of cell membranes leading to inactivation of 
membrane bound receptors or enzymes which in turn may impair normal cellular functions. 
Moreover, it is an autocatalytic process which is terminated only by the recombination of 
radicals or depletion of substrate (63). Thus, the initial oxidation of only a few lipid molecules 
can result in significant tissue damage.  
 
3. Mechanisms of DNA Repair 
Systems of response to DNA damage that reduce the yield of mutations and 
chromosomal aberrations in damaged cells are collectively known as DNA repair.  Repair 
enzymes recognize and remove DNA adducts, correct the DNA sequence, and rejoin strand 
breaks.  The cell possesses a number of DNA repair mechanisms to deal with oxidative and 
alkylated DNA lesions, including direct damage reversal (via the enzyme O6-methylguanine-
DNA methyltransferase), base and nucleotide excision, and mismatch repair.  Mechanisms 
for repair of strand breaks include non-homologous end-joining and homologous 
recombination.   
It is believed that the predominant pathway used for removal of oxidized and many of 
the alkylated bases is base excision repair (BER), see Figure 1.2.  The process of BER is 
initiated by DNA glycosylases [e.g. 8-oxoguanine DNA glycosylase 1 (Ogg1), endonuclease 
III homolog 1 (NTH1), thymine glycol-DNA- glycosylase (NTH)] which are often promiscuous 
as far as their substrate specificity is concerned. The glycosylase hydrolyzes the N-
glycosylic bond between the oxidized base and sugar moiety thus releasing the free 
damaged base and giving rise to an AP site.  AP endonuclease (APE) acts upon the AP site 
generating a single strand break by cleaving the phosphodiester backbone 5′ to the AP site, 
leaving behind a 3′-hydroxyl group and a 5′-deoxyribose phosphate group (dRP).  At this 
point the BER pathway can proceed through two different sub-pathways:  short-patch and 
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long-patch BER. These pathways are differentiated by the enzymes involved and the 
number of nucleotides removed.  Short-patch BER replaces a single nucleotide by 
polymerase β (Pol β) and the newly synthesized DNA sealed by DNA ligase III/XRCC1 
heterodimer (64).  Long-patch BER inserts 2 to 13 nucleotides by concordant action of Pol 
β, PCNA, Fen 1, and ligase 1. 
 Even though DNA lesions and misincorporations are dealt with by a complex system 
of DNA repair enzymes, the process of repair proceeds through several intermediate steps 
that involve the formation of secondary lesions which are also mutagenic and clastogenic 
(i.e., abasic sites and single strand breaks) (65). There are a number of consequences of 
induction/deficiency in DNA repair that are important for the process of carcinogenesis.  
Although induction would lead to enhanced repair, it has been suggested that this can be 
deleterious and promote mutagenesis (66).  If enzymes that act consecutively on different 
steps of repair are up-regulated unevenly, a state of imbalanced DNA repair might occur 
and lead to accumulation of both mutagenic and clastogenic lesions (67, 68).  It should also 
be noted that not all polymerases have the same fidelity with some being more prone to 
introducing incorrect nucleotides (69). 
 
4.  Oxidative DNA Damage and Cancer 
Cancer pathogenesis is a multi-step process involving mutations in critical genes 
required for maintaining cellular homeostasis and the clonal expansion of these mutated 
cells (70). The foremost is the ability to induce DNA damage that can lead to mutations if 
replication proceeds without proper repair.  Oxidative stress-induced DNA damage can lead 
to mutations and is suspected to be a major cause of cancer (32, 71).  Furthermore, 
persistent oxidative DNA damage can alter signaling cascades, gene expression, induce or 
arrest transcription, and increase replication errors and genomic instability, all of which have 
been described in the progression of cancer development.   
  14 
 
Chronic inflammation from infection or injury is believed to contribute to about one in 
four of all cancer cases worldwide (72). Inflammation activates a variety of immune cells 
which induce a number of oxidant-generating enzymes such as NADPH oxidase, inducible 
nitric oxide synthase, and myeloperoxidase that are capable of producing high 
concentrations of ROS (e.g., superoxide anion, hydrogen peroxide, nitric oxide, and 
peroxynitrite).  The increased production of ROS can increase the yield of mutations in DNA 
and also serve as an intracellular signal to promote mitogenesis (73).  A number of viral and 
microbial diseases such as hepatitis C, Helicobacter pylori, and human papillomavirus are 
associated with an increased risk of liver, colon, and cervical cancer, respectively (74). 
Furthermore, they are all associated with an increase in the DNA adduct, 8-oxo-dG.  To 
reduce the cancer risk, treatment strategies have targeted to alleviate the inflammation (e.g., 
anti-inflammatory agents such as interferons) or oxidant production (e.g., antioxidants such 
as ascorbic acid, β-carotene, and α-tocopherol) (75, 76). 
Chlorinated compounds, metal ions, barbiturates, phorbol esters, aromatic 
hydrocarbons, and some peroxisome proliferators are chemical carcinogens that have been 
shown to induce oxidative stress and damage in vitro and in vivo (77).  The mode of action 
of many chemical carcinogens is by generating ROS through redox cycling via electron 
transfer groups such as quinones, metal complexes, aromatic nitro compounds, and 
conjugated imines.  Benzene is classified as a human carcinogen and inhalation or dermal 
occupational exposures have been associated with acute leukemia and lymphoma (78).  
While the mechanism of action for benzene is still not clearly understood, the induction of 
chromosomal aberrations in hematopoietic stem cells is believed to be a critical element.  
The metabolism of benzene produces a number of phenolic and quinone species that can 
undergo a one electron reduction to a very unstable semiquinone that rapidly reduces 
oxygen to superoxide, which regenerates the quinone and completes one redox cycle.  
Thus, this continuous cycle leads to an increase in ROS production and potential for 
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oxidative DNA damage. Measurements of the DNA adduct, 8-oxo-7,8-dihydro-2'-
deoxyguanine (8-oxo-dG), have been reported in cell cultures and bone marrow in vivo after 
treatment with benzene (79). 
The presence of multiple pathways of repair for DNA damage demonstrates its 
important role in maintaining genomic stability. Therefore, it would be expected that reduced 
enzymatic activity or a defective enzyme in DNA repair would increase the likelihood of 
mutations and as a result increase risk of disease.  Indeed, there are a number of hereditary 
diseases (e.g., Xeroderma Pigmentosum, Trichothiodystrophy, Cockayne’s Syndrome, and 
Fanconi’s Anemia), although extremely rare, that are characterized by an increased cancer 
risk due to deficiencies in nucleotide excision repair (NER).  For example, Xeroderma 
Pigmentosum is a human disease with multiple defects in the NER pathway responsible for 
the removal of UV radiation-induced DNA damage and thus, individuals with this disease 
have a 1000-fold increased risk of developing skin cancer compared to the general 
population. More common are subtle changes in DNA repair phenotype derived from single 
nucleotide polymorphisms (SNPs) that are increasingly considered as cancer susceptibility 
genes (80).  An increased risk of esophagus, lung, and prostate cancer has been linked to 
SNP S326C in the human Ogg1 DNA repair gene, responsible for the removal of oxidized 
guanines. Another repair gene, XRCC1 with a SNP R194W, has been linked to increased 
risk of bladder, breast, lung, and stomach cancer.   
 
5. Measurements of Oxidative Damage 
The measurements of oxidative stress and oxidative DNA damage are vast and as 
such can not be covered in depth in this chapter. Thus, we have limited the discussion to 
only those endpoints used in the research studies for this dissertation.  
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5.1 Detection and Quantification of 8-hydroxy-deoxyguanosine by LC-MS/MS 
The revelation of the ability of oxidants to damage DNA and the appreciation of its 
importance in disease has pressed the need for the development of sensitive analytical 
methods to detect and quantify levels of DNA adducts. The ability to draw any cause-and-
effect conclusions regarding the role of oxidative stress to DNA and a particular chemical 
agent or disease state depends on knowing the precise endogenous or control levels of 
adducts that are to be used as biomarkers. Unfortunately, determining the background 
levels for the most commonly occurring and measured DNA adduct, 8-oxo-dG, has been 
difficult to ascertain up until recent efforts by ESCODD. Historical reports by enzymatic and 
chromatographic methods used to assay this particular DNA adduct have basal level 
estimates spread over three orders of magnitude (81). Importantly, it was shown that the 
grossly inflated values were most likely due to erroneous oxidation during DNA isolation and 
processing which can be limited by the inclusion of radical scavengers (82). The introduction 
of this modification to these standard procedures has brought chromatographic values 
closer in line with enzymatic methods that do not require DNA isolation (e.g., Comet assay).  
However, there still remains an approximate seven-fold difference between these two 
methods in control levels for 8-oxo-dG.  It is likely that true endogenous levels for this DNA 
lesion are approximately 1 per million guanines.   
Technological advances in mass spectrometry in the past decade have led to the 
emergence of LC-MS/MS as the method of choice for detecting and quantifying DNA 
adducts.  Compared to HPLC-ECD, LC-MS/MS offers several advantages including the 
ability to provide structural information and the inclusion of internal standards resulting in 
greater specificity and improved quantitation. Recently, a capillary LC-MS/MS method has 
been developed for the detection and quantification for 8-oxo-dG. This method involves the 
enzymatic digestion of DNA with 15N5-8-oxo-dG as internal standard and is followed by 
either isolation of 8-oxo-dG by HPLC (20 to 50 µg DNA required) or immunoaffinity (only 2 to 
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10 µg DNA required) chromatography. The isolated fraction is injected into the LC-MS/MS 
using electrospray ionization (ESI), and measured by selective reaction monitoring (SRM).  
Reported endogenous 8-oxo-dG levels in calf thymus DNA, untreated rat liver, and human 
HeLa cells were consistently between 2 to 3 adducts per 106 dG (Swenberg, unpublished 
data).     
 
5.2 Apurinic/Apyrimidinic (AP) Sites 
Slot blot assays for sugar back-bone lesions are based on the ability of an aldehyde 
reactive probe (ARP) to recognize the open ring structure of 2′-deoxyribose formed when a 
base is lost (83).  Thus, this assay allows the measurement of abasic (AP) sites and with the 
addition of lesion-specific endonucleases (e.g., FPG or endonuclease III) allows detection of 
oxidized purines and pyrimidines. The measurement of AP sites is performed on isolated 
genomic DNA, followed by treatment with ARP, transferred to nitrocellulose membrane, 
reacted with streptavidin-conjugated horseradish peroxidase, and enzymatic activity 
measured by chemiluminescence. Quantification is based on an internal standard containing 
a known number of AP sites. This method can underestimate DNA damage if enzymatic 
reactions do not go to completion.          
 
5.3 Expression of DNA Repair Genes as a Biomarker of Oxidative DNA Damage     
While many analytical techniques that assess oxidative DNA damage at the level of 
base or sugar are vulnerable to technical difficulties, the expression of BER genes, a 
biological response to DNA damage, holds promise as a sensitive in vivo biomarker. 
Because this pathway encompasses broad specificity and multiple routes of repair, it allows 
greater sensitivity in the ability to detect oxidative DNA damage compared to previously 
mentioned analytical techniques. Studies measuring the expression of BER genes have 
been used to identify sources for DNA-damaging oxidants (84) as well as establishing links 
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between chronic inflammation, dysregulation of DNA repair, and microsatellite instability 
(85).  
 
5.4 Immunohistochemistical Detection of Oxidative Damage 
Antibodies specific for stable oxidative DNA and protein adducts can be visualized in 
cells in paraffin-embedded tissues and a qualitative assessment can be made using imaging 
software. There are a number of commercially available antibodies to measure oxidative 
modifications of DNA and proteins, including 8-OH-dG, 3-nitrotyrosine, HNE, and MDA.  
Antibodies are limited in specificity if there is cross-reactivity between structurally similar 
DNA adducts or with other constituents of the cell. Thus, the application of this method must 
include proper positive and negative controls for accurate interpretation of results.   
 
5.5 Glutathione 
 Glutathione (GSH) is an intracellular low-molecular weight thiol that protects cells 
from free radical attack by reducing disulfide bonds formed within cytoplasmic proteins to 
cysteines by acting as an electron donor.  It is found almost exclusively in its reduced form 
since the enzyme which reverts it from its oxidized form (GSSG), GSH reductase, is 
constitutively active and inducible upon oxidative stress. As a measure of sulhydryl status, 
GSH has been used as an indicator of the cellular redox state. Several methods have been 
developed to identify and quantify GSH in fluid and tissue samples including 
spectrophotometric and flurometric assays often applied to HPLC analysis, and more 
recently developed GC-MS and LC-MS techniques (86). There a number of commercially 
available high-throughput colormetric kits to measure GSH. The assay is based on the 
glutathione recycling system by 5-5’-dithiobis-2-nitrobenzoic acid (DTNB) and GSH 
reductase. DTNB and GSH react to generate 2-nitro-5-thiobenzoic acid and GSSG. Since 2-
nitro-5-thiobenzoic acid is a yellow colored product, GSH concentration can be determined 
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by measuring absorbance at 412nm. GSH can be regenerated by GSH reductase, and 
reacts with DTNB to generate more product which dramatically improves the sensitivity of 
total GSH detected.  
 
C. RATIONALE AND SPECIFIC AIMS 
A discord between adverse findings in clinical data with those generated using in 
vivo animal models fosters the search for better methods to evaluate chemical safety. This is 
especially true for the liver, as it has been found to have one of the poorest correlates 
between in vivo animal studies and human toxicities (87). Not surprisingly, drug-induced 
liver toxicity is one of the leading causes for the termination of clinical trials and removal of 
drugs from the market. As oxidative stress is recognized as common general mechanism of 
human toxicity and disease, it can be speculated that it has a role in the discordance of 
observable adverse effects between animals and humans. It is proposed that the 
information gathered from toxicogenomic studies has the potential to provide novel insights 
into the mode of action and generate markers of impending toxicity at doses and times that 
are currently unattainable. This information can then be used to more accurately model 
potential adverse effects across species ultimately improving the risk assessment process. 
Currently, genomic technologies have demonstrated their utility in classification (5, 6, 88) 
and diagnostics (89, 90), but significant contributions toward deciphering mechanisms of 
toxicity and aiding risk assessment have yet to materialize. This is not surprising, since most 
studies have failed to use appropriate bioinformatic tools to integrate disparate data sets as 
well as phenotypically anchor the data to adverse outcomes (8). Thus, we hypothesize that 
molecular signatures defining disease mechanisms and early effects of exposure can be 
phenotypically anchored to biomarkes of oxidative stress and DNA damage. To test this 
hypothesis, we proposed three specific aims each of which would evaluate a model of 
oxidant-induced liver injury to address a key toxicological question as described below.  
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Specific Aim 1. Current toxicology tests have limited ability to assess subtle forms of 
toxicity that may occur at low doses. Employing toxicogenoimc approaches has the ability to 
lower the no observable effect level (NOEL) detected compared to existing methods. 
Although this ability to observe subtle alterations at earlier times and/or lower doses has its 
advantages, it also presents itself with confounding implications in the ability to segregate 
different states of homeostasis from states of deregulation which may cause pathological 
effects. Recently, a proof-of-concept study (91) was conducted whereby rats administered 
the hepatotoxicant, APAP, found that a sub-toxic dose (150 mg/kg) elicits subtle alterations 
in gene transcripts related to oxidant stress that are exacerbated with toxic doses (1500 to 
2000 mg/kg). The livers from these animals demonstrated no apparent toxicity based on 
changes in histology or clinical chemistry. This study presented an opportunity to evaluate 
the validity of gene expression studies as a sensitive marker of incipient toxicity. Thus, in 
Aim 1 our hypothesis was that a gene signature for oxidative stress at a sub-toxic dose 
would be phenotypically anchored to markers of oxidative stress and DNA damage based 
on the proposed mechanism of APAP-induced hepatotoxicity.   
 
Specific Aim 2. The choline-deficient (CD) diet is an extensively studied non-
chemical-induced, non-genotoxic model of rodent hepatocellular carcinoma (HCC) that 
produces a well-defined temporal pattern of pathological changes involving the consecutive 
emergence of a fatty liver, apoptosis, compensatory proliferation, fibrosis, and cirrhosis that 
is markedly similar to the sequence of events typified by human HCC. As pathological 
processes are active events under genetic control, gene expression analysis provides a 
powerful means of monitoring these processes and identifying key molecular events 
required to achieve specific pathological outcomes. Oxidative stress is considered a critical 
mediator in the pathological sequence of events. Thus, it was our hypothesis in Aim 2 to 
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establish a temporal correlation of pathology and oxidative DNA damage in a CD-model of 
rat HCC using gene expression profiling.  
 
Specific Aim 3. An emerging issue in toxicology is the role of nutrition as a 
modulator of environmental exposures. This is of particular concern as over the past half 
century a significant proportion of the population in the U.S. is clinically defined as 
overweight or obese. It has been suggested that a temporal shift in ω-6:ω-3 PUFA intake 
ratios have contributed to the growing obesity epidemic (92); however, the mechanisms by 
which different dietary fatty acids affect the molecular processes of human disease have not 
been fully elucidated. Thus, it was our hypothesis in Aim 3 that a high-fat diet of ω-6 PUFA 
fed to mice would increase oxidative stress and oxidative DNA damage in the liver. As 
oxidative-stress signaling pathways are a common mechanism for human toxicity and 
disease, it would be expected that a diet that promotes a pro-oxidant state in tissues would 
impart some inherit susceptibility to disease. 
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Figure 1.1 
 
Schematic diagram of types of DNA damage that may be induced by reactive oxygen 
species 
 
Abbreviations: reactive oxygen species, ROS; 4-hydroxy-2-nonenal, 4-HNE; 
malondialdehyde, MDA; pyrimidopurinone, M1G; etheno-deoxyguanosine, edA; etheno-
deoxyadenosine, edA; human 8-oxoguanine DNA glycosylase 1, hOgg1; N-methylpurine 
DNA glycosylase, MPG; 2,6-diamino-4-hydroxy-5-formamidopyrimidine, FapyG; 8-oxo-7,8-
dihydro-2'-guanosine, 8-oxo-G. 
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Figure 1.2 
 
Schematic diagram of base excision repair pathways for removal of oxidized DNA 
lesions formed as a result of a chemical exposure that causes oxidative stress 
 
The sequence of modifications of DNA is depicted in bold, whereas the molecular events 
that occur at each step are shown in italics. The gene products that participate at each step 
of repair are also displayed. 
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A. Abstract 
Toxicogenomics provides the ability to examine in greater detail the underlying 
molecular events that precede and accompany toxicity, thus allowing prediction of 
adverse events at much earlier times compared to classical toxicological endpoints. 
Acetaminophen (APAP) is a pharmaceutical that has similar metabolic and toxic 
responses in rodents and humans. Recent gene expression profiling studies with APAP 
found an oxidative stress signature at a sub-toxic dose that we hypothesized can be 
phenotypically anchored to conventional biomarkers of oxidative stress. Liver tissue was 
obtained from experimental animals used to generate microarray data where male rats 
were given APAP at sub-toxic (150 mg/kg), or overtly toxic (1500 and 2000 mg/kg) 
doses and sacrificed at 6, 24, or 48 h. Oxidative stress in liver was evaluated by a 
diverse panel of markers that included assessing expression of base excision repair 
(BER) genes, quantifying oxidative lesions in genomic DNA, and evaluating protein and 
lipid oxidation. A sub-toxic dose of APAP produced significant accumulation of 
nitrotyrosine protein adducts. Both sub-toxic and toxic doses caused a significant 
increase in 8-hydroxy-deoxyguanosine (8-OH-dG) as well as significant decrease in 
glutathione (GSH) content. Only toxic doses of APAP significantly induced expression 
levels of BER genes. None of the doses examined resulted in a significant increase in 
the number of abasic sites or in the amount of lipid peroxidation. The accumulation of 
nitrotyrosine and 8-OH-dG adducts along with reduced GSH content in the liver 
phenotypically anchors the oxidative stress gene expression signature observed with a 
sub-toxic dose of APAP, lending support to the validity of gene expression studies as a 
sensitive and biologically-meaningful endpoint in toxicology.   
  26 
 
B. Introduction 
Toxicogenomics is an area in toxicology that elucidates how the entire genome is 
involved in biological responses of organisms exposed to environmental toxicants. 
Expectations for this new field have been high with promises of obtaining in much 
greater detail the molecular events that precede and accompany toxicity, thus allowing 
prediction of a toxic insult at much earlier stages than classical measures.  Initial studies 
have been encouraging with gene-specific signatures that predict and classify unknown 
hepatotoxicants based on a preliminary training set of chemicals (6). This work has led 
to the hypothesis that it is possible to define signature patterns of altered gene 
expression that indicate specific adverse effects of chemicals, drugs, or environmental 
exposures.  
In order for gene expression profiling to become a well recognized and valuable 
tool in toxicology, it should be characterized for its ability to reflect the results derived 
from classical toxicology assays (e.g., histopathology, and clinical chemistry) in a dose- 
and time-dependent manner (4). Such phenotypic anchoring removes subjectivity from 
interpretation of expression data by distinguishing between the toxicological effect signal 
from other gene expression changes that may be unrelated to toxicity, such as the 
therapeutic effects of a compound. Unfortunately, much of the available toxicogenomic 
data that has been published to date, with few exceptions, has been limited to a 
description of alterations in gene expression patterns.   
Toxicology studies, in themselves, are quite complex with sources of variability 
resulting from the dose and delivery of the chemical under study, the choice of animal 
species, and the differences in biological and pathological responses of various tissues 
(93).  The combination of this with the known technical variability in genomic studies (94) 
underscores the importance of careful validation of alterations in gene expression 
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patterns.  In most cases, expression data can be phenotypically anchored using 
classical toxicological methods; however, the apparent lack of sensitivity for most toxicity 
assays will make this difficult for altered expression patterns observed at sub-toxic 
doses. Thus, corroboration of such expression data sets will require the use of more 
sensitive, complex assays.  
The results of gene expression profiling studies can serve as a guide in the 
search for specific genes and/or proteins that could be used as biomarkers of incipient 
toxicity, or can predict the pathological changes that are yet to be realized by 
morphological analysis. Recently, a proof of concept study was designed whereby rats, 
the preferred model organism in toxicity testing, were administered the well 
characterized hepatotoxicant, acetaminophen (APAP), and demonstrated that alterations 
in expression patterns at a low, sub-toxic dose (i.e., no apparent toxicity was detected by 
histopathology or clinical chemistry) may reveal signs of subtle cellular injury that are 
exacerbated at higher doses (91).  Specifically, it was found that altered gene 
expression patterns were suggestive of mitochondrial dysfunction and oxidative stress 
and with increasing dose there was concomitant increase in the magnitude of response 
and number of genes represented within the same vital cellular pathways. However, the 
specificity of these gene expression changes to the mechanism of APAP hepatotoxicity 
cannot be discerned without further research.  Here, we have undertaken a study to 
substantiate these findings of a gene expression signature for oxidative stress by a sub-
toxic of APAP in rat liver using a panel of sensitive biomarkers of oxidative stress and 
oxidative DNA damage.  The results of our studies show that a reduction in glutathione 
(GSH) content in the liver alongside with the accumulation of nitrotyrosine protein 
adducts and 8-hydroxy-deoxyguanosine lesions in DNA, events known to be a part of 
the mode of action of APAP, provide good and early phenotypic anchors for gene 
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expression signature of APAP-induced oxidative stress, even at a sub-toxic dose. 
 
C. MATERIALS AND METHODS 
Animals and treatments 
The studies detailed herein were performed using liver tissues (stored at -80°C) 
from previously published report (91)  where male Fisher 344 rats were administered a 
single acute dose of acetaminophen by gavage at sub-toxic (150 mg/kg) or overtly toxic 
(1500 and 2000 mg/kg) doses in 0.5% aqueous methyl cellulose. Animals were 
sacrificed 6, 24, or 48 hrs following dosing at which point frozen and formalin-fixed liver 
samples were collected.  
Determination of Liver Tissue Glutathione Levels 
Approximately 50 mg frozen liver tissue was homogenized in 5% sulfosalicyclic 
acid, centrifuged at 8k x g for 10 min, and the supernatant assayed for reduced 
glutathione content following manufacturer’s protocol (BioVision, Mountain View, CA).  
Immunohistochemistry 
Formalin-fixed, paraffin-embedded sections (6 µm) were mounted on glass 
slides. Sections were deparaffinized in xylene, rehydrated in a series of graded alcohol 
concentrations, and placed in phosphate-buffered saline (PBS) with 1% Tween 20. 
Immunostaining was performed using DAKO EnVision System HRP (Dako Cytomation, 
Carpinteria, CA) with primary antibody [1:200 nitrotyrosine (Molecular Probes; Eugene, 
OR); 1:200 malondialdehyde (MDA; Alpha Diagnostic, San Antonio, TX); and 1:200 8-
hydroxyguanosine (Research Diagnostics; Flanders, NJ)] diluted in PBS containing 1% 
bovine serum albumin and incubated overnight at 4°C. Slides were counterstained with 
hematoxylin. In order to ensure the quantitative measurement of each immunoreaction, 
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all sections from each animal and group to be compared were processed in parallel. 
Antibody specificity was determined by incubating each antibody with its respective 
antigen before immunostaining. Quantitative analysis of immunostained liver sections 
was performed using BIOQUANT software (BIOQUANT Image Analysis, Nashville, TN) 
by averaging percent area stained to total area within pericentral regions at 200× with 
exception for 8-OH-dG where percentage of positively stained nuclei to total nuclei in 
pericentral regions was determined.   
Isolation of DNA 
DNA was extracted by a procedure slightly modified from the method reported 
previously (95). To minimize formation of oxidative artifacts during isolation, 2,2,6,6-
tetramethylpiperidinoxyl (TEMPO, 20 mM final concentration) was added to all solutions 
and all procedures were performed on ice. Briefly, frozen tissues were thawed and 
homogenized in PBS with a Tehran homogenizer (Wheaton Instruments, Millville, NJ). 
After centrifugation at 2,000 x g for 10 min, the nuclear pellets were incubated in lysis 
buffer (Applied Biosystems, Foster City, CA) overnight at 4°C with proteinase K (500 
mg/ml; Applied Biosystems). DNA was extracted twice with a mixture of 
phenol/chloroform/water followed by ethanol precipitation. The extracted DNA was 
incubated in PBS (pH 7.4) with RNase A followed by DNA precipitation with cold ethanol. 
Then, the DNA pellet was resuspended in sterilized double distilled water. The DNA 
solution was stored at -80°C until assayed. The DNA extraction method used in this 
study is unlikely to modify the original number of AP sites and single strand breaks in 
genomic DNA from intact tissues or cells, based on re-extraction data of DNA exposed 
to high concentrations of methylmethane sulfonate (Swenberg and Nakamura, 
unpublished).  
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Apurinic/apyrimidinic (AP) sites 
AP sites were measured following a procedure reported by Nakamura and 
Swenberg (83). Briefly, 8 µg of DNA in 150 µl of phosphate-buffered saline was 
incubated with 1 mM aldehyde reactive probe at 37°C for 10 min. After precipitation 
using cold ethanol, DNA was resuspended in TE buffer (10 mM Tris-HCl, pH 7.4, 
containing 1 mM EDTA). DNA (250 ng) in TE buffer was heat-denatured and loaded on 
a nitrocellulose membrane (110 ng DNA/slot, Hybond-C Super, Amersham Pharmacia 
Biotech, Piscataway, NJ). The nitrocellulose membrane was soaked with 5×SSC and 
then baked in a vacuum oven for 30 min. The membrane was preincubated with 10 ml of 
Tris-HCl containing bovine serum albumin for 15 min and then incubated in the same 
solution containing streptavidin-conjugated horseradish peroxidase at room temperature 
for 45 min. After rinsing the nitrocellulose membrane, the enzymatic activity on the 
membrane was visualized by enhanced chemiluminescence reagents (Amersham). The 
nitrocellulose filter was exposed to x-ray film, and the developed film analyzed using a 
Kodak Image Station 440. Quantitation was based on comparisons to internal standard 
DNA containing a known amount of AP sites.  
Detection and Quantification of 8-OH-dG by Capillary LC-MS/MS   
The measurement of 8-OH-dG by LC-MS/MS was adapted from the method 
described by Liao (96). To digest DNA into individual nucleosides, DNA (30 to 50 µg) 
was dissolved in 80 mM Tris-HCl buffer/20 mM MgCl2 (pH 7.0) with 2.75 pmoles [15N5]-
8-OH-dG internal standard prior to digestion with 40U of DNase I for 10 min at 37°C.  
Next, 2.7 mU of phosphodiesterase I and 2U of alkaline phosphatase were added and 
incubated for an additional 1h.  The released 8-OH-dG was purified by reverse phase 
HPLC using a Beckman Ultrasphere ODS C18 column (5 um, 4.6 x 250 mm, Beckman, 
Fullerton, CA).  The isocratic mobile phase was 7% MeOH in 10 mM ammonium formate 
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(pH 4.3) with a flow rate 1 mL/min. Fractions were collected 2 min preceding and 
following the elution of 8-OH-dG.  The quantitative analysis of 8-OH-dG by capillary LC-
electrospray-MS/MS was performed with an 1100 capillary high-performance liquid 
chromatograph (Agilent, Wilmington, DE) coupled to a TSQ-Quantum triple quad mass 
analyzer (ThermoFinnigan, San Jose, CA). A 3.5 µm Zorbax XDB-C18 column (0.3 mm 
x 150 mm; Agilent) was operated with a binary mobile phase of 2% 10 mM ammonium 
formate (pH 4.3) and 98% methanol followed by a linear gradient increase of methanol 
from 2% to 30% from 0 to 5 min, holding at 30% for 10 min, and immediate return to 
initial conditions that was held for 15 min. Both analyte and internal standard were 
detected by single reaction monitoring of the transition of nucleoside to base adduct m/z 
284.2 to 168.2 and m/z 289.2 to 173.2, respectively. MS conditions were as follows: 
spray voltage, 2200 V; heated capillary temperature, 350°C. All reagents were 
purchased from Sigma-Aldrich (St. Louis, MO) and were ACS grade or higher. 
Ribonuclease protection assays 
Total RNA was isolated using RNeasy total RNA (Qiagen, Valencia, CA) and 
dissolved in RNase-free water.  Samples were stored at -80°C until assayed.  The 
quality of preparations was determined using an Agilent Bio-Analyzer (Agilent 
Technologies, Palo Alto, CA).  The RNase protection assays were performed on 20 µg 
of individual total RNA samples using a RiboQuantTM multi-probe RNase protection 
assay kit (rBER, BD PharMingen, San Diego, CA) essentially as described elsewhere 
(84). Riboprobes were synthesized in the presence of [32P]dUTP to yield labeled 
antisense RNA probes. Protected fragments were separated on 5% polyacrylamide 
nucleic acid separation gels, dried and exposed to x-ray film. The intensity of protected 
bands was quantified using Kodak 1D Image Analysis Software (New Haven, CT) and 
normalized to the intensity of housekeeping gene L32.  
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Statistical analysis 
Results are reported as means + SD with n = 3 in each group.  Treatment groups 
were compared using one-way ANOVA analysis followed by Tukey’s multiple 
comparison post-hoc test, where appropriate.  A p<0.05 was selected before the study 
to determine statistical differences between groups.  
 
D. Results 
A previous toxicogenomic study of APAP-induced toxicity in rat liver revealed an 
oxidative stress signature with a sub-toxic dose at 6h that was also present after 
exposure to overtly toxic doses (91).  Specifically, this gene signature included the 
induction of cAMP inducible gene 1, heterogenous nuclear ribonucleoproteins A1/B1, 
phospholipase C gamma1, metallothionein (MT1a), phytoene dehydrogenase, and 
H2AX histone family. To substantiate the link of this oxidative stress gene expression 
signature to incipient liver toxicity, we examined the liver tissue from this earlier study to 
measure a diverse panel of endpoints for oxidative stress and DNA damage.  The 
previous study found that livers of animals treated with a sub-toxic (150 mg/kg) dose of 
APAP were histologically indistinguishable from controls. In contrast, rats treated with 
1500 and 2000 mg/kg exhibited mild to moderate centrilobular necrosis and 
inflammatory lesions that was most prominent at 24h and coincided with a significant 
increase in serum alanine aminotransferase (ALT) activity, (2952 IU/L ± 261 and 5047 ± 
728, respectively).   
Glutathione depletion by the reactive metabolite of APAP, N-acetyl-p-
benzoquinone imine (NAPQI), is thought to play an important causal role in APAP-
induced hepatotoxicity. As such, liver tissue from rats given a single acute dose by 
gavage of vehicle or APAP at sub-toxic, 150 mg/kg, or overtly toxic, 1500 mg/kg, doses 
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at 6 and 24 hrs post-dosing were analyzed for reduced GSH content. APAP treatment at 
sub-toxic and overtly toxic doses led to a 30 and 58% depletion of GSH content, 
respectively, compared to control animals at 6 hrs post-dosing (Table 2.1).  By 24 hrs, 
GSH content had returned to control levels.   
Peroxynitrite, an oxidant and nitrating species, is formed from the reaction of 
superoxide and nitric oxide (NO·) which can lead to the formation of 3-nitrotyrosine 
protein adducts (97, 98). Liver sections from rats given a single acute dose by gavage of 
vehicle or APAP at sub-toxic (150 mg/kg) or overtly toxic (1500 and 2000 mg/kg) doses 
were examined for the presence of nitrotyrosine protein adducts by 
immunohistochemistry. Control animals as well as those given an overtly toxic dose of 
APAP exhibited minimal to non-detectable levels of nitrotyrosine (Figure 2.1A, 2.1C-D); 
in contrast, rats given a sub-toxic dose of APAP exhibited extensive localized staining of 
hepatocytes within pericentral regions of the liver lobule (Figure 2.1B, 2.1E) which 
resolved to control levels by 48hrs. Microscopic examination showed the presence of 
nitrotyrosine adducts within both cellular and nuclear compartments of hepatocytes. 
Quantitative analysis of liver sections from control animals showed that nitrotyrosine 
comprised less than 5% of total cellular area in pericentral regions of the liver lobule as 
opposed to those given a sub-toxic dose of APAP where nitrotyrosine comprised 80% 
and 30% of total cellular area at 6 and 24 hrs post-dosing, respectively (Figure 2.1F).   
The covalent binding of NAPQI to mitochondrial proteins can lead to an 
increased production of reactive oxygen species (ROS) that can react with DNA (99).  
First, we examined 8-OH-dG, a widely-used marker of oxidative DNA damage, by 
immunohistochemical detection (Figures 2.2A-C). Microscopic examination of liver 
sections from control animals revealed sporadic distribution of positively stained nuclei 
but sections from animals given either sub-toxic or overtly toxic dose had a 
concentration of positively stained nuclei within the pericentral region (Figure 2.2D). 
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Image analysis was performed to determine the percentage of positively stained nuclei 
(Figure 2.2E).  Both sub-toxic and overtly toxic doses of APAP led to a significant 
accumulation of 8-OH-dG adducts at 6 hrs post-dosing. 
Then, we determined the amounts of 8-OH-dG after APAP treatment using a 
recently developed capillary LC-MS/MS method as described in Materials and Methods.  
A calibration curve was obtained by using 275.5 fmoles internal standard and variable 
amounts of 8-OH-dG ranging from 0.5 to 228 fmoles/µl. The ratio of the peak areas of 8-
OH-dG versus internal standard was plotted against the known amounts of 8-OH-dG 
yielding a linear calibration curve with a correlation coefficient of 1.0 (Figure 2.3A).  
Endogenous levels of 8-OH-dG in control rat liver were ~ 1 adduct per 106 dG (Figure 
2.3B), in agreement with recent consensus reports from European Standards Committee 
on Oxidative DNA Damage (100).  Analysis of liver tissues from rats treated with a sub-
toxic and overtly toxic dose of APAP found a 3 to 4-fold increase in 8-OH-dG adducts, 
respectively, over control (Figure 2.3B), confirming our results with immunohistochemical 
detection.   
It is believed that the predominant pathway used for removal of oxidized bases 
from DNA is the base excision repair (BER) pathway. A multi-probe RNase protection 
assay for BER enzymes was used, since this approach distinguishes the presence of 
multiple expressed DNA repair genes simultaneously from a single sample, thus 
allowing for sensitive comparative analysis of different mRNA products both within and 
between samples.  Sub-toxic dose - 150 mg/kg (data not shown), had no effect on 
expression of BER genes as compared to controls; however, a time- and dose-
dependent increase (1.5 to 3-fold) in mRNA for proliferating–cell nuclear antigen (Pcna), 
poly ADP-ribose polymerase (Parp), AP endonuclease 1, 8-oxoguanine DNA 
glycoslyase 1 (Ogg1), and polymerases β and δ was observed for 1500 mg/kg dose of 
APAP (Table 2.2).  In addition, expression of Mgmt, an enzyme involved in the direct 
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repair of alkylated guanine residues and not involved in repair of oxidative DNA lesions, 
was unaffected in all treatments examined, conferring specificity to BER pathway.  
Next, to determine whether the number of mutagenic and clastogenic 
apurinic/apyrimidinic (AP) sites was increased following exposure to APAP, AP sites 
were measured using a slot blot assay. AP sites can be generated spontaneously by 
chemical depurination of labile bases and enzymatically by DNA glycosylases in a 
process of BER. In addition, ROS may induce sugar lesions directly by hydrogen 
abstraction of deoxyribose, frequently resulting in oxidized AP sites (101). Although 
APAP at overtly toxic doses induced BER genes as shown above, there were no 
significant increases in the number of AP sites generated for any of the treatments 
(Figure 2.4).    
Through the metabolic activation of APAP, both superoxide and peroxynitrite are 
generated that subsequently may initiate lipid peroxidation by Fenton chemistry (97).  
Lipid peroxidation was evaluated by immunostaining for malondialdehyde (102) in liver 
sections from rats given vehicle, or a single acute dose by gavage of APAP at sub-toxic 
(150 mg/kg) and overtly toxic (1500 mg/kg) doses at 6, 24, or 48 hrs (Figure 2.5A-C).  
Quantitative image analysis (Figure 2.5D) found no statistically significant difference 
(one-way ANOVA, p<0.05) between treatment groups and controls.   
 
E. Discussion 
In the present study, we investigated whether altered gene expression patterns 
that are suggestive of oxidative stress at a sub-toxic dose of APAP, when no apparent 
toxicity was detected using routine histopathological and clinical chemistry 
measurements, could be phenotypically anchored by using a panel of sensitive 
biomarkers for oxidative stress and oxidative DNA damage.  Our results substantiate the 
previously reported gene expression profiling data (91) demonstrating that the sub-toxic 
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dose of APAP does induce oxidative stress as demonstrated by the significant 
accumulation of nitrotyrosine protein adducts and 8-OH-dG DNA lesions and the 
reduction in GSH content at 6 hrs post-dosing. This confirms that gene expression 
signatures can potentially serve as predictive indicators of toxicity with increasing 
expression and exacerbation of a gene signature. Thus, the data support the potential 
role of gene expression profiling as a sensitive and biologically-relevant endpoint in 
toxicology.  
APAP is a common over-the-counter medication used for its analgesic and 
antipyretic properties; however, it is also one of the leading causes of drug-induced liver 
failure (103). At pharmacological doses, APAP is metabolized by sulfation and 
glucuronidation, and to a lesser extent, by cytochrome CYP2E1 that produces a reactive 
metabolite, NAPQI, which is detoxified by conjugation with GSH (99, 104). APAP-
induced hepatotoxicity occurs when GSH reserves are exhausted allowing covalent 
binding of NAPQI to critical cellular proteins as APAP-cysteine adducts (105), ultimately 
disrupting their cellular function, see Figure 2.6.  Many of these covalently bound 
proteins are within the mitochondria (106) resulting in reduced respiration (107) and 
increased superoxide production (108). Superoxide either reacts with nitric oxide to 
produce peroxynitrite, which is responsible for protein nitration (109), or dismutates to 
hydrogen peroxide whereby it can oxidize cellular macromolecules. The presence of 
nitric oxide, which is induced by APAP (110), is thought to block propagation of lipid 
peroxidation (111). It has been postulated that loss of mitochondrial function and 
concomitant generation of oxidative stress are central to APAP-induced hepatotoxicity 
(112).  
It is well recognized that the metabolic activation of APAP leading to GSH 
depletion is an important step in APAP-induced liver toxicity. As expected, an overtly 
toxic dose of APAP given to rats significantly reduced GSH content to 60% less than 
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control at 6 hrs post-dosing. Most surprisingly, a sub-toxic dose also significantly 
reduced GSH, albeit to a lesser extent. These data support earlier gene expression 
studies for oxidant stress at sub-toxic dose although the  
A number of studies have reported elevated levels of nitrotyrosine protein 
adducts that precede and accompany APAP-induced hepatotoxicity in mice (109, 113).  
In this study, only rats given a sub-toxic dose of APAP, not overtly toxic doses, had 
significantly elevated levels of nitrotyrosine protein adducts in liver compared to controls. 
These data support the presence of oxidant stress as indicated by earlier gene 
expression studies for a sub-toxic dose of APAP but demonstrates that the oxidant 
species formed in the presence of sub-toxic and overtly toxic doses of APAP in the rat 
are not identical. It has been shown that nitration of tyrosine residues is not limited to 
peroxynitrite exposure but can occur via peroxidase enzymes such as glutathione 
peroxidase (114) which is impaired during APAP toxicity. Alternatively, it has been 
demonstrated that APAP is highly effective at preventing tyrosine nitration by 
peroxynitrite (115, 116). Thus, in this study overtly toxic doses of APAP, unlike sub-toxic 
doses, may be able to out compete tyrosine for peroxynitrite which may explain the 
differences observed with nitrotyrosine levels between these two dosing groups. 
Moreover, this data would suggest that nitrotyrosine is not associated with APAP-
induced hepatotoxicity in the rat; an observation that is in direct opposition to what has 
been observed in numerous studies with mice. This may well reflect a mechanistic 
difference in APAP metabolism between these two rodent species.   
The generation of ROS by either APAP metabolism or resulting mitochondrial 
damage can lead to direct or indirect oxidative DNA damage. Immunohistochemical and 
mass spectrometry methods found a significant accumulation of the potentially 
mutagenic DNA lesion, 8-OH-dG, at sub-toxic and overtly toxic doses of APAP.  
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Accumulation of 8-OH-dG lesions preceded the onset of hepatic injury as reported by 
ALT and histopathology. The formation of 8-OH-dG from APAP exposure potentially 
results from mitochondrial oxidant stress where both superoxide and peroxynitrite are 
produced and can either directly or indirectly oxidize guanines in DNA (35, 43).        
Recently, the quantified expression of base excision DNA repair (BER) genes 
was shown to be a sensitive in vivo biomarker of chemical-induced oxidative stress (84).  
Moreover, because this pathway encompasses broad specificity and multiple routes of 
repair, it allows greater sensitivity in the ability to detect oxidative DNA damage. The 
measurement of multiple genes involved in the BER pathway by an RNase protection 
assay was able to detect up-regulation of gene expression that correlated with the onset 
of centrilobular hepatic necrosis in addition to the rise and fall of ALT. However, the 
assay was unable to detect significant increases of BER genes at a sub-toxic dose 
where genomic profiling generated an oxidative stress signature that consisted primarily 
of genes that are involved in protecting the cell from oxidative stress.  It is known that the 
redox state of the cell is one of many mechanisms involved in activating transcription 
factors involved in regulating the expression of DNA repair genes (117). Thus, it may be 
that at sub-toxic doses of APAP the apparent increase in expression of anti-oxidants, 
such as metallothioneins, may be sufficient in maintaining a redox equilibrium.   
The accumulation of apurinic/apyrimidinic (AP) sites can result from oxidative 
DNA damage through an intermediary step of BER pathway, enzymatic cleavage, and 
chemical depurination. The induction of BER pathway and, in particular, AP 
endonuclease gene by APAP was not, however, corroborated by the accumulation of AP 
sites by any of the APAP treatments examined.  A lack of evidence for an increase in AP 
sites may be manifested in the limited dose and time regimens examined in this study.  
Since the development of APAP toxicity typically occurs within the first 6h of exposure, 
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the detection of abasic sites would be limited if repair occurred rapidly.  Alternatively, the 
repair pathway could involve another route whereby generation of an abasic site is 
obsolete.  The dissociation between expression of BER genes and accumulation of AP 
sites is not an unusual phenomenon and has been observed with other chemical 
hepatotoxicants (84).  
The role of lipid peroxidation in APAP-induced hepatotoxicity has been 
controversial (118-120). Mitochondrial dysfunction leads to both increased production of 
superoxide and formation of peroxynitrite that are both capable of initiating lipid 
peroxidation; however, biochemical studies have shown that nitric oxide can prevent the 
propagation of lipid peroxidation reactions (111).  This is supported by the fact that 
inhibiting nitric oxide production during APAP exposure leads to enhanced lipid 
peroxidation (120). Our studies revealed that lipid peroxidation, as measured by the 
presence of malondialdehyde, was not observed to be significant for any doses or times 
examined. Despite the generation of ROS/RNS by APAP, our work does not support the 
role of lipid peroxidation as a mediator of APAP-induced hepatotoxicity.    
It should be considered that alterations in gene expression that are potentially 
indicative of cellular injury with an adverse outcome but are unsubstantiated by classical 
measures of toxicity may be a mere reflection of the tissue’s capacity to cope.  As 
demonstrated in this study, an APAP-induced oxidant signature generated by a sub-toxic 
dose was corroborated using sensitive biomarkers for oxidative stress and DNA 
damage. However, the presence of genes having an anti-oxidant role within this 
signature may explain the lack of observable toxicity by classical measures. In order to 
discern whether gene expression alterations in critical cellular pathways represent 
benign homeostatic adjustments, indications of the potential for adverse effects or in fact 
represent adverse effects, especially at doses and times with no observable toxicity, will 
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require the application of more sophisticated and sensitive tools that provide a 
mechanistic link between a chemical and the observed toxic effect.   
In general, the acceptance of microarray expression data as a relevant endpoint 
in toxicological studies requires careful interpretation and validation. It has been 
suggested that this should be achieved using classical toxicological endpoints such as 
histopathology and clinical chemistry (121). One of the great promises of toxicogenomics 
is that it will be able to detect and predict toxicity at much earlier stages compared to 
existing methods; however, restricting validation of expression data to only classical 
endpoints, with their inherent lack of sensitivity, would bring the advancement of 
toxicogenomics as well as toxicology to an impasse. Most importantly, the enhanced 
sensitivity of microarray studies to detect subtle, early alterations in vital cellular 
pathways that may be indicative of adverse effects, but display no observable toxicity by 
conventional measures, can have serious ramifications in policy and regulatory decision 
making.  
In summary, we show that incipient signs of oxidative stress can be observed 
with a sub-toxic dose of APAP based on the significant accumulation of both 
nitrotyrosine protein adducts and 8-OH-dG DNA lesions, markers anchored on the 
mechanism of APAP-induced liver toxicity. The use of sensitive biomarkers of oxidative 
stress and oxidative DNA damage revealed not only that mechanistic differences may 
exist in APAP metabolism between sub-toxic and overtly toxic doses in rats but also 
among rodent species. Gene expression profiling is a sensitive tool capable of detecting 
subtle cellular disturbances at doses and times unobtainable by classical toxicological 
measures. Thus, it has the potential to serve an essential role in predicative toxicology 
by generating gene signatures as biomarkers of incipient toxicity.  
  41 
 
Table 2.1 
Reduced glutathione concentration in rat liver following acetaminophen treatment 
 µmoles rGSH/g liver 
Time Control 150 mg/kg 1500 mg/kg
6h 5.5 ± 0.43 3.8 ± 0.13* 2.3 ± 0.15* 
24h 5.2 ± 0.68 5.9 ± 0.02 4.6 ± 0.75 
 
Rats were administered a single acute dose of acetaminophen by gavage at sub-
toxic (150 mg/kg) or overtly toxic (1500 mg/kg) doses in 0.5% aqueous methyl 
cellulose (vehicle control). Liver tissue collected at 6 or 24h post-dosing was 
analyzed for reduced glutathione (rGSH) content as described in Materials and 
Methods. Hepatic rGSH concentration is expressed as µmoles/g liver ± standard 
deviation from 3 animals per group. *Statistical difference (p < 0.01) from control 
group using one-way ANOVA followed by Tukey’s multiple comparison post-hoc 
test. 
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Table 2.2 
Expression of DNA repair genes in rat liver after treatment with an overtly toxic 
dose (1500 mg/kg) of acetaminophen 
 
DNA Repair Gene Control 6h 24h 48h 
Ogg1, 8-oxoguanine  DNA 
glycosylase 1 3.8 ± 0.8 3.9 ± 0.8 8.2 ± 2.8* 10.2 ± 1.5* 
Mpg, N-methylpurine DNA 
glycosylase 6.0 ± 0.4 5.2 ± 1.3 4.8 ± 2.7 4.0 ± 0.8 
Ape, purinic/apyrimidinic 
endonuclease 1 23.5 ± 1.4 21.6 ± 5.2 34.8 ± 2.8* 30.8 ± 1.7 
Pol β, polymerase (DNA 
directed) β 13.2 ± 0.9 11.9 ± 1.3 18.7 ± 1.8* 15.8 ± 1.2 
Pol δ, polymerase (DNA 
directed) δ 1.5 ± 0.3 1.7 ± 1.7 6.0 ± 1.6* 8.8 ± 2.8* 
Pcna, proliferating cell 
nuclear antigen   20.7 ± 2.1 22.5 ± 2.6 33.6 ± 7.9 50.9 ± 7.6* 
Parp, poly (ADP-ribose) 
polymerase 15.3 ± 0.5 21.4 ± 1.3* 27.6 ± 3.8* 29.1 ± 1.6* 
Mgmt, O6-methylguanine 
DNA ethyltransferase  29.8 ± 1.3 24.1 ± 5.7 32.2 ± 6.6 32.1 ± 0.1 
 
 
Total RNA was isolated from liver samples and analyzed by RNase protection 
assay.  The results are mean ± standard deviation from 3 animals per group. The 
relative expression of each gene was normalized to the expression of the 
housekeeping gene L32. The control is pooled RNA from three biological 
replicates and then 6, 24, and 48h time points averaged together. The results from 
animals given a sub-toxic dose of APAP (150 mg/kg) are not presented since they 
were not significantly different from controls. *Statistical difference (p < 0.05) from 
control group using one-way ANOVA followed by Tukey’s multiple comparison 
post-hoc test. 
  43 
 
Figure 2.1 
 
A Sub-toxic dose of acetaminophen significantly increases nitro-tyrosine protein 
adducts in rat liver 
 
Representative micrographs (200×) of liver tissue from rats immunostained for 
nitrotyrosine after treatment with (A) methyl cellulose control or (B) 150 mg/kg 
acetaminophen at 6, 24, and 48hrs post-dosing and (C) 1500 mg/kg and (D) 2000 mg/kg 
acetaminophen at 6 hrs post-dosing*. Representative micrograph (40×) of liver tissue 
from rats after treatment with 150 mg/kg acetaminophen demonstrating centralobular 
localization of nitrotyrosine staining (D). Immunostained liver sections for control (□) and 
150 mg/kg (■) APAP were quantified by averaging percent area stained to total area at 
200× in pericentral regions (F).  Data are presented as mean + SD, n = 3 biological 
replicates per group.  Data significantly different from control, p < 0.01, is denoted by 
asterisk.  *Analysis of overtly toxic doses of APAP at 24 and 48 hrs post-dosing was not 
performed due to the extensive presence of necrotic tissue that often stains non-
specifically. CV, central vein; PV, portal vein. 
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Figure 2.2 
Rat liver genomic DNA significantly accumulates 8-OH-dG adducts after 6 hrs 
treatment with sub-toxic and overtly toxic doses of acetaminophen 
 
Representative micrographs (200×) of liver tissue immunostained for 8-OH-dG from rats 
treated with (A) methyl cellulose control, (B) 150 mg/kg, or (C) 1500 mg/kg 
acetaminophen 6 hrs post-dosing. Representative micrograph (40×) of liver tissue from 
rats after treatment with 150 mg/kg acetaminophen demonstrating centralobular 
localization of 8-OH-dG adducts (D). Immuno-stained liver sections for control (□), 150 
mg/kg (■), or 1500 mg/kg (■) APAP were quantified by averaging percent nuclei stained 
to total nuclei within pericentral regions at 200× (E).  Data are presented as mean + SD, 
n = 3 biological replicates per group.  Data significantly different from control, p < 0.05, is 
denoted by asterisk. ND = not determined. CV, central vein; PV, portal vein. 
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Figure 2.3 
A sub-toxic dose of APAP significantly accumulates 8-OH-dG DNA adducts in rat 
liver as measured by capillary LC-MS/MS 
 
(A) Standard calibration curve for 8-OH-dG by capillary LC-MS/MS.  The ratio of the 
peak areas of 8-OH-dG (AS) to 275.5 fmoles [15N5]-8-OH-dG (AI) as the internal 
standard plotted against the amount of 8-OH-dG ranging from 5.5 to 228 fmoles/µl. (B) 
Quantitative measure of 8-OH-dG DNA adducts in rat liver from control (□), 150 mg/kg 
(■), or 1500 mg/kg (■) APAP. Data are presented as mean ± SD from 3 animals per 
group.  *Statistical difference (p < 0.05) from control group using one-way ANOVA 
followed by Tukey’s multiple comparison post-hoc test. 
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Figure 2.4 
Acetaminophen has no effect on the accumulation of apurinic/apyrimidinic (AP) 
sites in rat liver 
 
The number of AP sites in genomic DNA isolated from livers of control (□) and 150 
mg/kg (■), or 1500 mg/kg (■) APAP at 6, 24, and 48h. The control is pooled RNA from 
three biological replicates and then 6, 24, and 48h time points averaged together. Data 
is given as mean + SD, n = 3.  Statistical analysis by one-factor ANOVA (p < 0.05) found 
no significant difference between acetaminophen treated groups and control. 
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Figure 2.5 
Acetaminophen does not promote lipid peroxidation in rat liver 
Representative micrographs (200×) of liver tissue immunostained for malondialdehyde 
from rats treated with (A) methyl cellulose control, (B) 150 mg/kg, or (C) 1500 mg/kg 
acetaminophen 6 hrs post-dosing. Immunostained liver sections for control (□), 150 
mg/kg (■), or 1500 mg/kg (■) APAP were quantified by averaging percent area stained 
to total area at 200× in pericentral regions (D).  Data are presented as mean + SD, n = 3 
biological replicates per group. Statistical analysis by one-factor ANOVA (p < 0.05) found 
no significant difference between acetaminophen treated groups and control. ND = not 
determined. 
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Figure 2.6 
 
Phenotypic anchors of gene expression profiling for oxidative stress are a 
reflection of the proposed mechanism of APAP-induced hepatotoxicity 
 
APAP is metabolized by cytochrome P450s to a reactive metabolite, N-acetyl-p-
benzoquinone imine (NAPQI), which depletes glutathione (GSH) and covalently binds to 
cellular proteins as APAP-cysteine adducts.  Mitochondrial injury leads to increased 
production and release of reactive oxygen and nitrogen species that promotes oxidative 
stress and DNA damage. The depletion of GSH and coupling reaction of superoxide (O2·-
) and nitric oxide (NO·) leads to formation of peroxynitrite (ONOO-) that reacts with 
protein tyrosine residues.  It has been proposed that the production of NO·, induced by 
APAP, terminates lipid peroxidation propagation. The concomitant loss of mitochondrial 
function and generation of oxidative stress are postulated to have a central role in 
APAP-induced hepatoxicity.  The sequence of events involved in APAP-induced 
hepatatoxicity are shown in bold, whereas the markers of oxidative stress and oxidative 
DNA damage measured in this study are shown in italics. ∗, markers that anchored gene 
expression signature suggestive of oxidative stress with a sub-toxic dose of APAP.  The 
scheme is a summation of previously published reports on APAP-induced hepatotoxicity, 
see Discussion. 
 
 
 
CHAPTER III 
 
 
 
 
 
TEMPORAL CORRELATION OF PATHOLOGY AND DNA DAMAGE WITH GENE 
EXPRESSION IN A CHOLINE-DEFICIENT MODEL OF RAT LIVER INJURY 
 
 
 
 
 
 
 
 
 
 
 
The text of this chapter is reproduced with permission from 
Hepatology 42(5): 1137-1147 (2005) 
© 2005 
American Association for the Study of Liver Diseases
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A. Abstract 
Hepatocellular carcinoma (HCC) is the terminal event in chronic liver diseases 
that include repeated cycles of cellular injury and regeneration. While much is known 
about the cellular pathogenesis and etiologic agents leading to HCC, the molecular 
events are not well understood.  The choline-deficient (CD) model of rodent HCC 
involves the consecutive emergence of a fatty liver, apoptosis, compensatory 
proliferation, fibrosis, and cirrhosis that is markedly similar to the sequence of events 
typified by human HCC. Moreover, oxidative stress is thought to play a pivotal role in the 
progression of the disease. Here, we hypothesize that gene expression profiling can 
temporally mirror the histopathology and oxidative DNA damage observed with this 
model. We show that clusters of highly co-regulated genes representing distinct cellular 
pathways for lipid biosynthesis and metabolism, apoptosis, cell proliferation and tissue 
remodeling temporally correlate with the well-defined sequential emergence of 
pathological alterations in the progression of liver disease. Additionally, an oxidative 
stress signature was observed which was corroborated in a time-dependent manner with 
increases in oxidized purines and abasic sites in DNA. Collectively, expression patterns 
were strongly driven by pathology demonstrating that patterns of gene expression in 
advanced stages of liver disease are primarily driven by histopathological changes and 
to a much lesser degree by the original etiological agent. In conclusion, gene expression 
profiling coupled with the CD model of HCC provides a unique opportunity to unveil the 
molecular events associated with various stages of liver injury and carcinogenesis and to 
distinguish between causal and consecutive changes.   
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B. Introduction  
The choline deficient (CD) diet is an extensively studied non-chemical induced, 
non-genotoxic model of rodent hepatocellular carcinoma (HCC) that produces a well-
defined temporal pattern of pathological changes (Figure 3.1). It is characterized by an 
initial increase in triglycerides resulting in macro-vesicular fat deposition (steatosis) that 
quickly diffuses throughout the entire liver within 4 to 5 days (122). By 4 weeks, 
increased fat storage and oxidative stress are thought to contribute to hepatocellular 
injury which prompts apoptosis (123) and is coupled with compensatory liver 
regeneration (124). Fibrosis develops as activated hepatic stellate cells increase 
collagen production disrupting liver architecture, and eventually leads to cirrhosis by 30 
weeks of treatment (125). Lastly, carcinomas develop with a 100% incidence by 52 
weeks (126). The sequence of pathological events is remarkably similar to the 
progression of human HCC associated with hepatitis B (HBV) and C (HCV) viral 
infections, non-alcoholic fatty liver disease, and alcohol abuse.   
 The development and progression of HCC in the CD model is not well 
understood due to the complexity of genetic and epigenetic events that occur in 
hepatocytes. Nevertheless, repeated cycles of hepatocyte injury and regeneration, 
oxidative stress to DNA (127), chronic activation of protein kinase C (128), activation of 
arachidonic acid cascade, in particular cyclooxygenase-2 (129), and hypomethylation of 
c-fos, c-myc, and c-Ha-ras (130, 131) have been reported to occur. However, the 
definitive role of each of these processes in disrupting liver homeostasis and progression 
to HCC has yet to be elucidated.  
 Molecular profiling of cancer by high density microarray analysis is a powerful 
tool for identifying new biomarkers with diagnostic and predictive value as well as 
increasing our understanding of the mechanisms of carcinogenesis (132). Genomic 
studies of breast, lung, and colon cancers have identified unique gene networks and 
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regulatory pathways useful in classifying tumors into clinically relevant sub-types (133-
135). Furthermore, the corroboration of altered expression patterns with phenotypic 
endpoints such as histology, pathology, and clinical chemistry have provided the much 
needed validation of molecular profiling data (4).  
 HCC is the fifth leading cause of cancer death worldwide. Early diagnosis is 
difficult since most people are asymptomataic during the early stages of the disease and 
there are no diagnostic markers currently available, contributing to the high mortality 
rate. Moreover, the lack of appropriate and reproducible animal models for HCC 
impedes the development of diagnostic markers and therapies. Transcriptional profiling 
coupled with an appropriate animal model for HCC provides an opportunity to identify 
novel molecular markers with diagnostic and prognostic value. Here, we show that gene 
expression profiling of CD model of HCC can be phenotypically anchored to the well-
defined sequential emergence of histopathological changes and associated oxidative 
stress to DNA. The gene expression changes observed with this model are remarkably 
similar to human HCC expression data from diverse etiologies. Collectively, the 
expression patterns in advanced liver disease are strongly driven by pathology and not 
etiology.  Thus, understanding the early molecular events leading to such events is key 
for medical intervention. 
 
C. Experimental Procedures 
Animals and treatments 
 The studies detailed herein were performed using tissue samples (stored at -
80°C) from previously published report (136) where male Fisher 344 rats were 
administered with either a choline sufficient L-amino acid defined (CS) diet, or CD L-
amino acid defined diet and water ad libitum for 12, 30, or 80 weeks; or samples 
generated specifically for this study (3 days and 4 weeks) using the identical procedure.   
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RNA Isolation 
Total RNA was isolated using RNeasy kit (Qiagen, Valencia, CA). Samples were 
stored at -80°C until assayed. The quality of preparations was determined using Bio-
Analyzer (Agilent Technologies, Palo Alto, CA).   
Microarray Experiments 
Gene expression analysis of isolated RNA from liver tissue was performed using 
Affymetrix® Rat 230A microarrays (Affymetrix, Santa Clara, CA) at Functional Genomics 
Core at UNC-CH using standard procedures specified by the manufacturer 
(neuroscience.unc.edu/core_facilities/functional/).   
Microarray Data Analysis 
Preliminary analysis was performed using MAS 5.0 software (Affymetrix). Array 
quality was determined by examination of 3' to 5' intensity ratios of selected genes. Data 
was normalized to global probe intensity using a robust multi-array average (RMA) 
method (137) and expression data were log2-transformed and gene-median centered. 
Hierarchical clustering analysis was conducted using Cluster 
(rana.lbl.gov/EisenSoftware.htm) to perform gene-centered, average-linkage clustering 
(138); the data was visualized using Java TreeView (jtreeview.sourceforge.net).   
Two independent statistical tests were applied to identify the unique gene 
expression profiles of CD and CS. First, the method of Sorlie et al. (139) was utilized to 
define genes intrinsic to an experimental group versus control, where a group is defined 
as unique combination of the type of diet (CD or CS) and duration of treatment (4, 12, 80 
weeks and tumors). This method gives the best (lowest) scores to those genes whose 
variation is low within a group, but high across multiple groups. The resulting list is 
expected to encompass subsets of genes whose expression is common to all samples 
within each group. To establish a false discovery rate (FDR) for this computational 
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approach (i.e., to establish statistical significance), the group label for each sample was 
randomly permuted and the set of intrinsic scores was calculated from the resulting 
groupings. This process was repeated twenty times. A threshold of the intrinsic scores 
was determined by identifying the score that gave the greatest number of significant 
calls with less than 5% occurrence in the permuted results. In addition, a two-class, 
unpaired Significance Analysis of Microarrays [SAM; (140)] was performed as described 
for intrinsic gene identifier. The SAM algorithm differs from the intrinsic scores defined 
above since more weight is placed on differences in fold changes between the groups. 
Delta values were adjusted to obtain the gene list with a < 5% FDR. All microarray raw 
data tables are available at the UNC Microarray Database (genome.unc.edu). 
RNase Protection Assays 
Expression of base excision DNA repair genes was analyzed using RNase 
protection assay with rat multi-probe template set (rBER, BD PharMingen, San Diego, 
CA) as described elsewhere (84).  
Detection of Apurinic/Apyrimidinic (AP) Sites and Oxidized Purines 
Genomic DNA was extracted by a procedure slightly modified from the method 
reported previously (95). To minimize formation of oxidative artifacts during isolation, 
2,2,6,6-tetramethylpiperidinoxyl (TEMPO, 20 mM) was added to all solutions and all 
procedures were performed on ice. The AP and OGG1 slot blot assays were performed 
as previously described (83, 141).  
 
D. Results and Discussion 
 Hierarchical analysis of gene expression data distinguishes CS and CD 
treated groups. It has been well established that a CD diet causes HCC in rats and 
produces a well-defined temporal pattern of pathological changes involving steatosis, 
hepatocyte injury, fibrosis and cirrhosis (Figure 3.1). To assess whether expression 
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profiling temporally mirrors the altered pathological changes observed with the liver 
disease induced by this treatment, we applied a high-throughput Affymetrix Rat 230A 
array to liver tissues from control CS or CD diet-fed Fisher 344 rats. Liver tissues were 
chosen at 4, 12, and 80 weeks, as were tumors larger than 5 mm at 80 weeks, to reflect 
the various stages of liver injury. It should be noted; however, that the gene expression 
profiling was performed on whole liver making it difficult to discern the contribution of 
individual cell types. Furthermore, 30 and 80 week liver samples may not be devoid of 
tumors 5 mm or less and may contain necrotic and apoptotic hepatocytes in addition to 
other cell types associated with liver cirrhosis.  
  
 Identification of gene clusters temporally expressed in liver of CD treated 
rats.  Two independent statistical tests, intrinsic gene identifier (134) and SAM (140), 
were performed to identify genes whose expression profiles were unique to CD at any 
time point using the 6,045 fully annotated transcripts on the array. Intrinsic gene 
identifier analysis showed that expression levels of 3,102 genes segregated at least a 
single time point (e.g., 4, 12, 80 weeks, or tumors) compared to its corresponding control 
group. SAM identified 4,673 genes of which 88% (2,739 genes) were also detected by 
an intrinsic gene identifier analysis. Genes from both lists were assigned into functional 
categories using Gene Ontology (GO) and enriched KEGG pathways using Onto-
Pathway-Express (142). Considerable overlap between the two methods was observed 
as the enriched KEGG pathways identified by both analyses were identical (Appendix 5).  
The intrinsic gene list was subjected to clustering analysis using a centered, 
average-linkage hierarchical algorithm. The resulting dendrogram (Figure 3.2) revealed 
two major branches separating the experimental groups, CS and CD. Interestingly, 
heterogeneity between tumor samples was observed with T2 and T3 samples (two 
distinct tumors from the same animal) being similar to each other but somewhat different 
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from other tumors and 80 week CD samples. Data mining using GO annotations for 
intrinsic genes (NetAffx Analysis Center, affymetrix.com) was used to assign functional 
classes and to determine the cellular and molecular pathways defining treatment 
separation. Several clusters of highly up-regulated genes evoked by CD were 
associated with apoptosis, cell proliferation, protein synthesis, and tissue remodeling. 
Conversely, metabolism, lipid synthesis, and ion transport pathways were selectively 
down-regulated compared to CS.  
 To determine whether molecular profiling would model the temporal changes in 
histopathology observed with CD, genes with a functional assignment associated with 
lipid biosynthesis or metabolism (excluding ion transport pathways), apoptosis, cell 
proliferation, and tissue remodeling were compiled. Supervised hierarchical clustering 
was conducted to view temporal changes in expression of genes associated with 
abovementioned biological processes (Figure 3.3, Appendix 1). This result demonstrates 
that dramatic alterations in gene expression occur as early as 4 weeks in CD samples. 
 
 Gene expression patterns reveal CD attributes to altered lipid metabolism. 
Accumulation of lipid mostly comprised of triglycerides occurs in hepatocytes within days 
of administering a CD diet to rats (143). This has been attributed to the compromised 
ability to synthesize phosphatidylcholine (PC), a major constituent of lipoprotein 
envelopes, whereby secretion of triglycerides from the liver is inhibited. PC plays a major 
role as a structural component of cellular membranes and as a source of second 
messengers, it can influence both normal physiological and pathological processes 
including carcinogenesis.  
 Indeed, GO-assisted search identified 160 genes within the intrinsic gene list with 
a functional assignment to either lipid biosynthesis or metabolism (Figure 3.3A). After 4 
weeks of CD diet, an induction of genes for fatty acid (Cpt1a, Cte1, Fabp2, Fads1, and 
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Mte1) and cholesterol (Apoa1, Abcg1, and Vldlr) metabolism occurred most likely as a 
result of the accumulation of intracellular lipids.  At 12 weeks, there was an additional 
increase in expression of phospholipases (Pla2g4a, Plce1, Pspla1, and Dpep1) that 
release second messengers and metabolic precursors from membrane phospholipids. 
For example, activation of membrane receptors coupled to phospholipase C release 1,2-
sn-diacylglycerol (DAG) from intact membrane phospholipids which are potent activators 
of protein kinase C (PKC). PKC targets include proteins involved in the control of gene 
expression, cell division, and differentiation (144) and alterations in PKC signaling have 
been attributed to tumorigenesis (145). Interestingly, it has been demonstrated that CD 
rats accumulate high levels of DAG in cellular membranes and this coincides with 
increased PKC levels and activity (128). Phospholipase A2 releases arachidonic acid 
from cellular phospholipids, a precursor to the biologically potent eicosanoids, 
prostaglandins and thromboxanes of which several members were highly expressed 
(Ptgfrn, Ptgs1, Tbxas1, Ltc4s). At 80 weeks, there was an increase in expression of 
phospholipases (Plcg1 and Pla2g6) and phosphoesterases (Pde4b and Pter). Over the 
course of CD diet, there was a transient down-regulation of genes associated with 
steroid and fatty acid synthesis and lipid transport (Appendix 1).  
 
 Gene expression patterns reveal CD activates apoptotic pathways. There 
have been numerous reports of induction of apoptosis with CD diet through both p53-
dependent and -independent pathways. Supervised hierarchical clustering of genes 
associated with apoptosis revealed a strong induction of pro-apoptotic genes at 4 weeks 
of CD diet (Figure 3.3B) such as caspases, apoptosis activating factor 1 (APAF1), tissue 
necrosis factor, and p53. Tumor samples did not express p53 or mitochondrial mediated 
apoptotic genes such as APAF1 and caspases; however, there were a small number of 
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genes up-regulated in tumor samples associated with death receptor-mediated pathway 
including TNF and NGF receptor superfamilies and Cflar.  
In vitro studies with CWSV-1 rat hepatocytes have demonstrated that the rate of 
apoptosis is inversely correlated with cellular PC content (123).  Moreover, it has been 
shown that inhibition of PC biosynthesis by CD diet leads to apoptosis by an increase in 
intracellular ceramide levels in neurons (146); however, our data shows an increase in 
expression of genes related to ceramide metabolism including acid ceramidase (Asah) 
and UDP-glucose ceramide glucosyltransferase (Ugcg) suggesting that ceramide is not 
an important mediator of apoptosis in this model. Additionally, the induction of apoptotic 
genes coincided with a predominance of genes associated with positive regulators of the 
cell cycle (Figure 3.3C, Appendix 1) such as cyclins, oncogenes, and cyclin dependent 
kinases.  
 
 Gene expression patterns reveal CD mediates tissue repair through 
activation of hepatic stellate cells. Recurrent hepatocellular injury is a hallmark of the 
CD diet that chronically activates cellular and molecular mechanisms of tissue repair 
leading to fibrosis and cirrhosis of the liver. Analysis of gene expression patterns 
revealed a highly expressed cluster of genes related to the initiation and promotion of 
fibrosis at 4 and 12 weeks of CD treatment (Figure 3.3D), including transforming growth 
factor β, which promotes the proliferation of fibroblasts and hepatic stellate cells and the 
extracellular matrix components collagens, proteoglycans, fibronectin, laminins, and 
matrix metalloproteinases (147, 148).  Moreover, hepatic stellate cell-specific genes 
were up-regulated, including stellate activation associated cell protein, α-smooth muscle 
actin, vimentin, and tissue inhibitors of metalloproteinases, supporting their involvement 
in fibrosis (149, 150).  
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Gene expression reveals liver injury transition states in CD rats. Above, we 
identified gene clusters that temporally mirrored the histopathological alterations 
observed with the CD model in rat liver.  Here, we examined the genes associated with 
the initial transition from normal liver to a state of chronic liver injury and ultimately leads 
to the second transition to HCC. To define these two major transition states, we 
performed unpaired SAM analysis between CS samples versus CD non-tumor samples 
(i.e., transition state 1), and CD non-tumors versus CD tumors (i.e., transition state 2).  
Next, to cross-compare these genes lists we generated a Venn diagram (Figure 3.4) to 
identify genes that are shared or unique in these two liver injury transition events.  
Lastly, the gene lists were submitted to GoMiner (9) to identify significantly enriched 
biological processes (Appendix 2). 
SAM analysis of expression changes during transition state 1 identified 2,302 
and 5,882 genes to be significantly up- or down-regulated, respectively.  GO mapping 
found a significant enrichment in biological processes related to proliferation, cell death, 
and tissue remodeling.  In contrast, processes related to cell communication, in 
particular, G-protein coupled signal transduction and ion transport pathways, were 
significantly down-regulated, most likely a reflection of the loss of cell membrane 
structure due to the inability to synthesize phospholipids.  For transition state 2, SAM 
identified 581 and 212 genes to be significantly up- or down-regulated, respectively.  
Processes related to cell proliferation alongside with transcription-coupled nucleotide 
excision repair were significantly increased.  In contrast, processes related to oxidative 
DNA damage and repair and apoptosis were down-regulated potentially signifying 
increased genomic instability and survival of cells in liver tumors.  
Interestingly, there were 1,101 genes shared between the two transition states, 
but their expression changes were directionally opposite. Specifically, 518 and 583 
genes were significantly up- or down-regulated in transition state 1 and vice versa. There 
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were a number of processes related to cell motility, cytoskeleton reorganization, and 
immune response up-regulated in transition state 1, a reflection of the underlying 
molecular events that occur after extensive cellular injury.  In contrast, transition state 2 
showed a significant enrichment in metabolic processes that would be required to 
sustain tumor growth.  
 
 CD-induced hepatocarcinogenesis is preceded by oxidative stress to DNA. 
It has been shown that treatment of rodents with a CD diet causes oxidative stress to 
DNA that is predominantly removed and repaired by the base excision repair (BER) 
pathway. To confirm that oxidative stress to DNA is present in CD rats, changes in 
expression of DNA repair genes, a sensitive in vivo marker of oxidative stress to DNA 
(151), was evaluated. A significant increase in expression of proliferating–cell nuclear 
antigen, AP endonuclease 1, 8-oxoguanine DNA glycosylase 1 (Ogg1), and polymerase 
β was observed in CD-fed animals (Table 3.1). Additionally, expression of O6-
methylguanine-DNA methyl transferase, an enzyme involved in the direct repair of 
alkylated guanine residues, was enhanced. Previous reports have shown increases in 
DNA methyl transferase expression with preneoplastic and neoplastic livers of rodents 
fed a CD diet which is the result of a hypomethylated promoter (152).      
 In parallel, the intrinsic gene list for GO functional assignments associated with 
oxidative stress was examined and identified 92 genes. Hierarchical clustering of these 
genes revealed a temporal separation of genes that are over expressed in liver at 4 and 
12 weeks, 12 and 80 weeks, and tumor samples (Figure 3.5). The 4 and 12 week cluster 
reflects an up-regulation of cellular antioxidant defenses such as heat shock protein 
(Hspa1b, Hspcb, Hsp60, and Hspa1a) and glutathione peroxidase (Gpx2 and Gpx3) 
genes. At 12 and 80 weeks, an increase in genes linked to DNA damage including the 
DNA repair genes apurinic/apyrmidinic endonuclease 1, DNA polymerase delta, and the 
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DNA-damage-inducible transcript 4 was observed. Surprisingly, the expression of Ogg1 
was not increased in the microarray data; however, the concordant temporal 
upregulation of a number of DNA repair genes with CD is evidence of a biological 
response for oxidative DNA damage in this model. 
 In tumors, an up-regulation in DNA repair genes including mismatch repair 
protein, polymerase epsilon, and mediator of DNA damage checkpoint 1 was found. 
Additionally, a number of cellular antioxidants were up-regulated including thioredoxins 
and glutathione S-transferases. Interestingly, thioredoxins have been demonstrated to 
promote proliferation and growth of tumors through induction of growth factors and 
cytokine activity (153).  
 Although there have been previous reports documenting the accumulation of 8-
oxo-dG DNA adducts in liver of rats given a CD diet, the data must be interpreted with 
caution since previous reports may be erroneous due to ex vivo oxidation during DNA 
isolation, as reported by the European Standards Committee on Oxidative DNA Damage 
(ESCODD) (154). Thus, we measured oxidized purines in DNA using an isolation 
procedure that was shown to minimize artifactual ex vivo oxidation. Figure 3.6A 
illustrates that background level of oxidized purines was below 1 x 106 nucleotides, in 
agreement with ESCODD-reported values (100). Significant increases in oxidized 
purines were observed in animals given CD diet for 12 weeks and in tumor samples. 
Abasic sites in DNA are generated spontaneously by chemical depurination of labile 
oxidized bases and enzymatically by DNA glycosylases. To determine whether the 
number of mutagenic and clastogenic AP sites is increased following CD treatment, AP 
sites were measured. Significant increases (> 2.5 fold) in the number of AP sites were 
seen in 12 and 30 week CD treated rat liver (Figure 3.6B).  
 Generation of oxidants and the resulting state of oxidative stress in the cell 
induces both genotoxic and epigenetic events that can promote the process of 
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carcinogenesis. Oxidative stress to DNA is one of the earliest changes observed in 
rodent liver on a CD diet, with accumulations of 8-oxo-deoxyguanosine (8-oxo-dG), a 
mutagenic lesion capable of G:C to T:A transversions (155, 156). Additionally, end 
products of lipid peroxidation such as malondialdehyde and 4-hydroxy-2-nonenal have 
been reported to form in liver of CD-treated animals (122)  resulting in exocyclic DNA 
adducts that are known to be mutagenic and genotoxic, respectively (157). Here, we 
have demonstrated that gene expression profiling revealed differential expression of 
oxidative stress related genes for CD.  Specifically, microarray expression data showed 
an induction of several DNA repair genes involved in the BER pathway after 12 week 
CD treatment and beyond suggesting that DNA damage had occurred. This was 
confirmed with increases in AP and oxidized purines in liver DNA. The increase in 
expression of DNA repair genes and the accumulation of DNA lesions at 12 weeks 
corresponds to the development of fibrosis and cirrhosis of the liver. Recent studies 
demonstrated a correlation between increases in DNA repair expression and the 
histological stage of fibrosis in liver biopsies (158). Moreover, increases in 8-oxo-dG 
adducts and expression of DNA repair genes was reported in the surrounding tissue of 
liver tumors (159).  Thus, the fibrotic process may be a contributing factor to the 
transformation of hepatocytes towards a neoplastic phenotype. 
 
CD-induced rat HCC and human HCCs are similar at the level of gene 
expression. To determine how CD model of rat HCC recapitulates human HCC, gene 
expression patterns with data from a human HCC study (160) were compared.  This 
study encompassed 102 primary liver tumors and 74 non-tumor liver samples.  For this 
comparison, Ensembl genome browser (ensembl.org) was used to identify rat and 
human gene orthologs that were present on both microarray platforms. Of the 2,121 
genes that were identified as differentially expressed in CD-induced tumors (i.e., 
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transition state 2), 492 orthologous genes were selected.  Gene expression ratios were 
standardized to a mean ± s.d. of 0 ± 1 in each data set.  Hierarchical clustering analysis 
of the integrated data sets (Figure 3.7) showed two major clusters, one representing 
human and CD rat HCC samples, and the other, with a few exceptions, representing 
non-tumor human liver tissues.  Tumors from humans with HBV, HCV, as well as non-
infected individuals, were interspersed within the HCC cluster.  Furthermore, two 
distinctive nodes with highly expressed genes were evident in HCC samples as 
compared to non-tumor liver tissue.  Biological processes that were enriched in these 
nodes were identified using GO mapping. These included angiogenesis, cell-matrix 
adhesion, G-protein and tyrosine kinase signaling cascades, and protein metabolism. 
Thus, these data suggest that gene expression changes in CD-induced tumors in rats 
are similar to human HCC gene expression phenotype and may be potentially used to 
distinguish between human tumor and non-tumor samples.  
 
Gene expression distinguishes between causal and consecutive events in 
liver disease. While much is known about the cellular pathogenesis and etiologic 
agents leading to HCC; the molecular events that contribute to the disease are not well 
understood. Thus, the use of appropriate animal models coupled with global gene 
expression profiling can provide the opportunity to serially dissect the molecular events 
associated with liver injury and disease. Here, we have demonstrated that microarray 
gene expression data can be phenotypically anchored to the sequential pathological 
alterations observed during the development of rodent HCC induced by a CD diet. The 
hierarchical clustering analysis of this expression data set was strongly driven by the 
histopathological changes that are observed during the progression of HCC by CD diet. 
Thus, this data provides the opportunity to decipher the genomic changes required to 
elicit such phenotypic endpoints.   
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 Since the liver pathological changes observed in rodents on a CD diet are similar 
to that observed by agents (e.g., HBV, HCV and alcohol) causing chronic human liver 
injury, we suggest that similar expression patterns would be observed in advanced 
stages of human liver disease regardless of etiology. Indeed, gene expression patterns 
of CD-induced liver tumors are phenotypically similar to human HCC from diverse 
etiologies (i.e., HBV, HCV, and HBV/HCV negative individuals).  The fact that these liver 
tumors were interspersed among each other within the HCC branch demonstrates that 
regardless of the initial confounding etologic agent eventually these diseases converge 
onto a common and indistinguishable phenotype.  
 In conclusion, we have shown that gene expression profiling can temporally 
model the well-defined sequential emergence of pathology and oxidative stress 
observed with the CD model of rodent HCC. Moreover, the development of fibrosis and 
cirrhosis temporally coincided with the accumulation of oxidative DNA lesions; 
processes which may contribute to hepatocyte transformation. Molecular profiling of 
tumors will not identify the early molecular changes required for transformation; 
however, the CD model of HCC in the rat provides an opportunity to serially dissect the 
molecular events related to the onset of liver injury and carcinogenesis that is also 
relevant to progression of human HCC. 
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Table 3.1 
Expression of DNA repair genes in rat liver after treatment with a control choline 
sufficient (CS) or choline deficient (CD) diets 
 
  
1 week 
 
12 weeks 80 weeks 
DNA Repair Genes 
 
CS 
 
CD CS CD CS 
 
CD 
 
OGG1, 8-oxoguanine  DNA 
glycosylase 1 1.6 ± 0.1 1.9 ± 0.1* 1.9 ± 0.4 2.6 ± 0.5 0.9 ± 0.9 2.6 ±  0.4* 
MPG, N-methylpurine DNA 
glycosylase 3.2 ± 2.9 2.0 ± 0.2 2.0 ± 1.2 3.1 ± 0.8 1.0 ± 0.2 5.2 ±  3.4 
APE, apurinic/apyrimidinic 
endonuclease 1 6.6 ± 0.7 8.4 ± 1.0 7.5 ± 2.2 12.3 ± 5.1 4.3 ± 0.1 13.8 ±  3.6* 
Pol β, polymerase (DNA 
directed) β 5.6 ± 1.2 4.8 ± 0.7 4.5 ± 1.2 8.6 ± 2.1* 3.8 ± 0. 9 9.5 ±  5.2 
PCNA, proliferating cell 
nuclear antigen   4.4 ± 0.7 8.6 ± 3.2 4.4 ± 1.6 12.4 ± 5.1* 3.9 ± 1.7 8.1 ±  3.1 
PARP, poly (ADP-ribose) 
polymerase 10.6 ± 1.2 10.6 ± 0.1 10.4 ± 2.8 14.0 ± 3.5 7.8 ± 1.9 9.7 ±  2.6 
MGMT, O6-methylguanine 
DNA methyltransferase  
13.1 ± 1.5 17.3 ± 0.9* 14.0 ± 3.5 27.5 ± 8.7* 19.4 ± 1.2 33.5 ± 13.2* 
 
RNase protection assay was performed on total RNA isolated from liver samples.  
The results are mean ± standard deviation from 3 animals per group. The relative 
expression of each gene was normalized to the expression of the housekeeping 
gene L32. *Statistical difference (P < 0.05) from a corresponding CS group using 
student’s t-test.  
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Figure 3.1 
Pathological stages of liver disease progression in a rat model of HCC 
The choline deficient L-amino acid defined diet is a non-genotoxic model of rodent 
hepatocarcinogenesis. Choline deficiency produces a well-defined temporal pattern of 
histopathological changes beginning with a fatty liver (steatosis), hepatocellular injury, 
apoptosis with compensatory proliferation, fibrosis and cirrhosis. Pre-neoplastic foci with 
a glutathione S-transferase positive (GST-P) phenotype eventually give rise to the 
development of hepatocellular adenomas and carcinomas within a year of administering 
the diet. 
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Figure 3.2 
 
Hierarchial clustering of choline sufficient (CS) and choline deficient (CD) liver 
samples using “intrinsic” gene set 
 
Intrinsic analysis identified genes whose expression levels vary the least within a single 
treatment group but are highly variable between treatments (FDR < 5%). Hierarchial 
clustering analysis was conducted on a list of 3,100 non-redundant genes identified 
through such analysis. Functional classes were assigned to each gene using Gene 
Ontology (GO) and revealed that the highly up-regulated genes were related to cell 
proliferation, apoptosis, protein synthesis, and tissue remodeling where as down-
regulated genes were related to metabolism, lipid synthesis, and ion transport.  For 
unsupervised hierarchical clustering of entire rat array see Appendix 4. 
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Figure 3.3 
 
 
Supervised hierarchical clustering of altered cellular and molecular pathways 
associated with choline deficiency 
 
 
Gene Ontology (GO) was used to assign functional classes to “intrinsic” gene set to 
identify cellular pathways related to the histopathological events evoked by choline 
deficiency. These cellular pathways include lipid biosynthesis and metabolism (A), 
apoptosis (B), cell proliferation (C), and tissue remodeling (D). 
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Figure 3.4 
Venn diagram illustrating the distribution of gene alterations between liver injury 
transition states in choline deficient rats 
 
Significant gene lists were generated using SAM (FDR < 5%) for each transition state as 
described in text and cross-compared.  Values represent number of genes significantly 
induced (red) or repressed (green) that are either unique or shared by the two transition 
states. There were 1,101 genes shared between the two injury states but their 
expression changes were directionally oppositite. Gene lists were submitted to GoMiner 
(9) to identify significantly enriched biological processes (p < 0.05), of which a few are 
shown.  The number of genes associated with each process is given in parenthesis.  A 
complete listing of enriched biological processes is available in Appendix 2.   
 
 
  71 
 
Figure 3.5 
 
Temporal expression of oxidative stress genes in rat liver evoked by a choline 
deficient diet 
 
Gene Ontology (GO) identified 92 genes within the “intrinsic” gene set associated with 
oxidative stress from rat liver samples treated with a control choline sufficient (CS) or 
choline deficient (CD) diet for 4 to 80 weeks. Tumor (T) samples were collected from CD 
treated rats at 80 weeks. Supervised hierarchical clustering was conducted and is 
shown in Figure 5A. Colored bars on right side of A illustrate the location of clusters 
shown in B-D.  The clusters of temporally expressed genes expanded for 4 and 12 
weeks (B), 12 and 80 weeks (C), and tumor samples (D). 
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Figure 3.6 
 
Choline deficiency promotes the accumulation of oxidative DNA lesions in rat 
liver 
 
Genomic DNA was isolated from livers of control CS diet (□) and CD (■) treated rats, 
and tumors (■) and the number of (A) Ogg1-sensitive sites (B) or apurinic/apyrimidinic 
(AP) sites (B) determined as described in “Materials and Methods”.  Data are presented 
as means + standard deviation from 2-3 animals per group. *Statistical difference (P < 
0.05) from corresponding control group by Student’s t test. 
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Figure 3.7 
 
Clustering analysis of rat and human HCCs 
 
Unsupervised hierarchical cluster analysis of integrated rat (this study) and human (160) 
HCC datasets.  Ensembl genome browser was used to identify orthologous genes 
present on both arrays (492 genes) and expression ratios were standardized to a mean 
± standard deviation of 0 ± 1 prior to clustering. The two areas highlighted on the 
heatmap represent clusters of genes that are highly expressed in both rat and human 
HCC.  Biological processes associated with these gene clusters are shown.  A complete 
list of genes is available in Appendix 3.   
 
 
 
 
CHAPTER IV 
 
 
 
 
 
 
 
 
 
 
PPARα-REGULATED MOLECULAR NETWORKS ARE RESPONSIBLE FOR THE 
DIFFERENTIAL EFFECTS OF DIETARY FATTY ACIDS ON OXIDATIVE STRESS 
AND DNA DAMAGE IN MOUSE LIVER 
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A. ABSTRACT 
Epidemiological and animal model research shows that ω-3 and ω-6 
polyunsaturated fatty acids (PUFA) can have a profound effect on physiological 
processes linked to obesity and metabolic disorders. The mechanisms underlying the 
differential effects between these two PUFA are thought to include the ability to generate 
bioactive lipids, modulate gene expression through nuclear receptors, and increase 
cellular oxidant injury. To identify potential mechanistic differences between the two 
PUFA, male C57BL/6J mice were administered a high fat diet (23.5% from fat) 
containing corn (ω-6 PUFA) or fish oil (ω-3 PUFA) for up to 3 weeks and gene 
expression profiling was performed on liver. Pathway mapping of significantly altered 
genes showed that a diet rich in fish oil induced biological processes related to fatty acid 
oxidation, glutathione metabolism and oxidative stress; in contrast, corn oil significantly 
repressed these processes while inducing inflammatory response. These data 
suggested that PUFA can modulate the cellular redox state in liver. Thus, oxidative 
stress biomarkers in the liver were evaluated. It was determined that a corn oil-
containing diet leads to increases in expression of DNA repair genes (AP endonuclease 
1 and uracil DNA glycosylase) and the number of 8-OH-dG DNA adducts with 
concomitant decrease in reduced GSH content. Fish oil leads to reduction in 8-OH-dG 
DNA adducts while no induction of DNA repair genes was observed. Molecular and 
biochemical assays demonstrated that fish oil, but not corn oil, trans-activated PPARα. 
Moreover, comparison of gene expression data with known PPAR pan-agonist, WY-
14,643, determined that over 50% of the genes altered by fish oil treatment were driven 
by PPARα. Included within this gene list were many anti-oxidants such as glutathione-S-
transferases, heat shock and proteasome proteins. In summary, dietary fatty acids can 
modulate the cellular redox state and the direction may be dependent on their ability to 
trans-activate PPARα.  
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B. INTRODUCTION 
 
Metabolic syndrome has emerged as a public health issue worldwide as it is 
considered an important predictor for the development of chronic debilitating diseases 
such as type-II diabetes mellitus, cardiovascular disease, and certain types of cancer 
(161). It can be characterized as a group of metabolic abnormalities which include 
insulin resistance along with abdominal adiposity, dyslipidemia and a systemic pro-
inflammatory state (162). Its prevalence coincides with the rapidly growing obesity 
epidemic (163) which has arisen due to the prevailing sedentary lifestyles and unhealthy 
dietary habits in industrialized societies. Obesity, considered as a central component in 
this syndrome, is a chronic metabolic and nutritional disorder with multi-factorial etiology, 
involving genetic and environmental factors. Increased dietary fat intake is considered to 
be causal but more substantial evidence now indicates that the type, not the amount, of 
fat is important in the risk of chronic disease (164). As such, it is imperative to 
understand the mechanistic differences in biological effects of different types of fats in 
relation to the development of obesity and related co-morbidities. 
As obesity rates rose over the past half century the intake ratio of the essential 
dietary fatty acids, ω-6 and ω-3 polyunsaturated fatty acids (PUFA), has also changed 
dramatically to between 10:1 to 20:1 (92, 165). These two types of fatty acids compete 
directly with one another for enzymes and for incorporation into the cell, where they can 
influence cell signaling pathways and receptor function. As well, the metabolic 
derivatives of these two fatty acids have diverse biological functions, typically 
antagonistic to each other, and can modulate a variety of physiological and 
pathophysiological processes. PUFA can alter plasma lipid levels, cardiovascular 
function, insulin action, neuronal development, and the function and regulation of the 
immune system. PUFA have shown therapeutic efficacy in chronic diseases such as 
arthritis (166), cardiovascular disease (167), diabetes (168), and carcinogenesis (169).  
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Obesity and related metabolic disorders have been associated with several 
important common pathogenic mechanisms of disease including hyperlipidemia, 
systemic inflammation (170), and oxidative stress (171). Numerous epidemiological 
studies as well as animal models have shown that ω-3 and ω-6 PUFA affect these 
pathogenic processes (172). The dietary intake of PUFA and most importantly, the 
dietary PUFA ratio can directly or indirectly modulate the accumulation of visceral and 
intracellular lipid content by stimulating adipogenesis, activating transcription factors, 
and altering intracellular signaling events (173). PUFA are considered important 
modulators of the immune system as they are used to synthesize eicosanoids, short-
lived hormone-like lipids that include prostaglandins and leukotrienes, with potent 
inflammatory and chemotactic functions. The conjugated double bonds in PUFA are 
highly susceptible to free radical-mediated lipid peroxidation. Since these reactions are 
self-propagating, the initial oxidation of only a few lipid molecules can result in significant 
tissue damage. The by-products of this chain reaction, such as malondialdehyde (MDA) 
and 4-hydroxynonenal (HNE), can readily diffuse from the site of production and 
covalently bind to DNA and proteins potentially disrupting or altering vital cellular 
functions. Moreover, these by-products are potent chemoattractants promoting 
macrophage infiltration and inflammation (174).  
In the present study, it was determined that ω-3 and ω-6 PUFA differentially 
modulate the cellular redox state in mouse liver which may be dependent on their ability 
to trans-activate PPARα. As oxidative stress is an important common mechanism in the 
development of human diseases, it further emphasizes the importance of understanding 
the role of dietary intervention in the prevention of human disease. 
 
C. MATERIALS AND METHODS 
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Animals and treatments.  Adult (aged 6-8 weeks) male wild-type C57Bl/6J mice 
were purchased from Jackson Laboratories (Bar Harbor, ME). Mice were fed with a 
commercial AIN-76A diet [control, 5% fat (Harlan TEKLAD, Madison, WI)] or modified 
AIN-76A diet (Table 4.1) where 23.5% of fat was provided as either corn oil (Mazola® 
Corn Oil, Cordova, TN) or fish oil (OmegaPure™ Refined Menhaden Fish Oil, kindly 
donated  by OmegaProtein, Houston, TX) for 1 or 3 weeks. Diets were supplemented by 
the manufacturer with 1000 ppm mixed-tocopherols and 200 ppm tertiary butyl 
hydroquinone to prevent oxidation. To assure quality and consistency of oils, diets were 
prepared fresh daily and all leftovers removed. Fatty acid hydroperoxide values were 
monitored (175) and determined to be < 3 mEq/kg. All mice were maintained in a 
temperature- and light-controlled facility, and permitted ad libitum consumption of food 
and water. At the end of the study, liver and body weight measurements were collected. 
A portion of liver tissue was preserved in formalin for histological sections and the 
remaining tissue was snapped frozen in liquid nitrogen and stored at –80°C for later 
analyses. All animals were given humane care in compliance with NIH and institutional 
guidelines and studies were performed according to protocols approved by the 
appropriate institutional review board. 
Extraction and measurement of fatty acids:   Lipids were extracted using the 
method of Bligh and Dyer (176). The lower (chloroform) phase was transferred to a 
clean tube and evaporated to dryness under nitrogen. The residual lipids were 
saponified and the fatty acids trans-methylated by sequential 1 ml addition of 4.25 % 
NaOH in CHCl3:MeOH (2:1, v/v) and 1N HCl in saline (177). The samples were mixed 
vigorously then centrifuged at 1500 x g for 5 min. The lower phase containing the fatty 
acid methyl esters was carefully transferred to a clean, dry tube and evaporated to 
dryness under nitrogen. Fatty acid methyl esters were then resuspended in 50 µl 
undecane, and analyzed using capillary gas chromatography (GC). Fatty acid methyl 
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esters were analyzed by Fast GC on a Perkin Elmer AutoSystem XL Gas 
Chromatograph (Shelton, CT), split injection, with helium as the carrier gas. The methyl 
esters were separated on a capillary column coated with 70% cyanopropyl 
polysilphenylene – siloxane (10 m x 0.1 mm ID- BPX70 0.2 µm; SGE, Austin, TX); 
injector 240ºC and detector 280ºC.  Data were analyzed with the Perkin Elmer 
Totalchrom Chromatography Software, version 6.2. Heptadecanoic acid (17:0) was 
added to the samples as an internal standard to correct for recovery and quantitation. 
Individual fatty acids were identified by comparing their retention to authentic standards 
(Nu Chek Prep, Elysian, MN). 
RNA Isolation:  Total RNA was isolated using RNeasy kit (Quiagen, Valencia, 
CA) and dissolved in RNase-free water.  Samples were stored at -80°C until assayed for 
no more than 2 months to minimize degradation. The quality of preparations was 
determined using an Agilent Bio-Analyzer (Agilent Technologies, Palo Alto, CA). 
Microarrays: Total RNA was isolated from mouse liver and gene expression 
analysis performed using Agilent 22K mouse arrays (G4121B, Agilent) following 
standard protocols specified by the manufacturer. A mouse standard RNA [(Icoria, 
Research Triangle Park, NC); (94)] was used as an internal reference to normalize 
expression ratios across all arrays. Images were obtained from an Agilent microarray 
scanner, features extracted by Agilent image analysis software, and the data was 
deposited into the UNC microarray database (https://genome.unc.edu). Data was then 
batch extracted, Lowess normalized (178) and subjected to cluster analysis (138). 
Genes were omitted from further analysis if they were either absent or flagged for poor 
feature quality in at least two of the three biological replicates in each experimental 
group. About 17,400 genes were selected for further analyses based on these quality 
metrics. Missing data were imputed using the SAM add-in for Excel (Microsoft Corp., 
Redmond, WA) plug-in with 100 permutations and k-nearest neighbors (KNN) with k = 5. 
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Unpaired SAM analysis of control liver samples at 1 and 3 weeks demonstrated no 
significant difference in expression as the lowest false discovery rate obtained was 60% 
(82 genes). As such, all subsequent statistical analyses were performed with 1 and 3 
week control samples grouped as a single entity. Significant gene lists were subjected to 
average-linkage hierarchical clustering analysis using Pearson correlation and the data 
visualized in Java Treeview (138). 
RNase Protection Assays: Expression of base excision DNA repair genes was 
analyzed with an RNase protection assay using mouse multi-probe template set (mBER, 
BD PharMingen, San Diego, CA) essentially as described in (84). Riboprobes were 
synthesized in the presence of [32P]dUTP to yield labeled antisense RNA probes. The 
RNase protection assays were performed on 30 µg total RNA samples using a 
RiboQuantTM multi-probe RNase protection assay kit (BD PharMingen). Protected 
fragments were separated on 5% polyacrylamide nucleic acid separation gels, dried and 
exposed to x-ray film. The intensity of protected bands was quantified using Kodak 1D 
Image Analysis Software (New Haven, CT) and normalized to the intensity of 
housekeeping gene L32.  
Determination of Liver Tissue Glutathione Levels: Frozen liver tissue (~ 
50mg) was homogenized in 5% sulfosalicyclic acid, centrifuged at 8k x g for 10 min, and 
the supernatant assayed for total or reduced glutathione content following specified 
protocol supplied by the manufacture (BioVision, Mountain View, CA).  
Immunohistochemistry: Formalin-fixed, paraffin-embedded liver sections (6 
µm) were mounted on glass slides. Sections were deparaffinized in xylene, rehydrated in 
a series of graded alcohol concentrations, and placed in PBS with 1% Tween 20. 
Immunostaining was performed using DAKO EnVision System HRP (Dako Cytomation, 
Carpinteria, CA) with primary antibody [1:100 PCNA (Dako Cytomation; 1:200 8-
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hydroxyguanosine (Research Diagnostics; Flanders, NJ)] diluted in PBS containing 1% 
bovine serum albumin and incubated overnight at 4°C. Slides were counterstained with 
hematoxylin. In order to ensure the quantitative measurement of each immunoreaction, 
all sections from each animal and group to be compared were processed in parallel. 
Antibody specificity was determined by incubating each antibody with its respective 
antigen before immunostaining. Quantitative analysis of immunostained liver sections 
was performed using BIOQUANT software (BIOQUANT Image Analysis, Nashville, TN) 
by averaging percent positively stained nuclei to total nuclei within 10 random fields at 
200×. 
DNA Isolation: DNA was extracted by a procedure slightly modified from the 
method reported previously (95). To minimize formation of oxidative artifacts during 
isolation, 2,2,6,6-tetramethylpiperidinoxyl (TEMPO, 20 mM final concentration) was 
added to all solutions and all procedures were performed on ice. Briefly, frozen tissues 
were thawed and homogenized in PBS. After centrifugation at 2,000 x g for 10 min, the 
nuclear pellets were incubated in lysis buffer (Applied Biosystems, Foster City, CA) 
overnight at 4°C with proteinase K (500 mg/ml; Applied Biosystems). DNA was extracted 
twice with a mixture of phenol/chloroform/water followed by ethanol precipitation. The 
extracted DNA was incubated in PBS (pH 7.4) with RNase A followed by DNA 
precipitation with cold ethanol. Then, the DNA pellet was resuspended in sterilized 
double distilled water. The DNA solution was stored at -80°C until assayed.  
Detection and Quantification of 8-OH-dG by Capillary LC-MS/MS: The 
measurement of 8-OH-dG by LC-MS/MS was performed essentially as described in 
(179). Briefly, DNA (50 µg) was digested into individual nucleosides and 8-OH-dG 
purified by reverse phase HPLC using Beckman Ultrasphere ODS C18 column (5 um, 
4.6 x 250 mm, Beckman, Fullerton, CA).  Quantitative analysis of 8-OH-dG was 
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performed with an 1100 capillary high-performance liquid chromatograph (Agilent, 
Wilmington, DE) coupled to a TSQ-Quantum triple quad mass analyzer 
(ThermoFinnigan, San Jose, CA). Both analyte and internal standard were detected by 
single reaction monitoring of the transition of nucleoside to base adduct m/z 284.2 to 
168.2 and m/z 289.2 to 173.2, respectively.  
Electrophoretic mobility shift assay (EMSA) for PPARα: Nuclear protein 
extracts were prepared using the method described by Dignam et al., (180) and EMSA 
was performed using a DNA-protein binding detection kit [Panomics Electromobility Gel-
Shift Kits (Redwood City, CA)] according to manufacture’s protocol. Briefly, the 10 µl 
reaction mixture contained 1X binding buffer, 10 µg nuclear extract, and 1 µg Poly d(I-C) 
and was pre-incubated for 5 min on ice prior to adding 10 ng PPARα biotin-labeled 
probe (5’-AAAAACTGGGCCAAAGGTCT-3’). Specificity of the binding was determined 
by competition experiments, which were carried out by adding a 20-fold molar excess of 
unlabelled PPARα to the reaction mixture before labeled probe was added. Samples 
were electrophoresed through 6% non-denaturing TBE polyacrylamide gel and 
transferred to nylon membrane. The membrane was incubated with streptavidin-HRP 
conjugate at 1:1000 for 15 min. Protein-DNA complexes were visualized by exposing to 
x-ray film.  
Acyl-CoA oxidase activity: Activity of the peroxisomal enzyme acyl-CoA 
oxidase was measured as described in (181). The activity was measured from the 
amount of formaldehyde formed by the peroxidation of methanol by hydrogen peroxide, 
a product of peroxisomal β-oxidation. Protein concentration was determined using a 
BCA assay (Pierce Biotechnology Inc, Rockford, IL).  
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D. RESULTS 
Dietary fatty acid treatment effects on liver morphology and biochemistry. 
Male C57Bl/6J mice, in groups of 5, were given either a control low fat diet (5%) or high 
fat diets (23.5%) of either corn oil (ω-6 PUFA) or fish oil (ω-3 PUFA) for 1 or 3 weeks. 
Diets were prepared fresh daily to prevent rancidity and in vitro fatty acid peroxidation of 
diets after 24 hours of preparation were < 3 mEq/kg. Food intake and body weights of 
the mice were not affected by the type of dietary lipid (data not shown). Liver to body 
weight ratio (Table 4.2) significantly increased in mice administered high-fat diets of corn 
oil or fish oil. This was most pronounced with a high-fat diet of fish oil with a 1.5-fold 
increase over control was observed at both 1 and 3 weeks. To determine the role of 
proliferation and cellular hypertrophy on the observed increased liver weight, the % 
PCNA positively stained nuclei and number of nuclei per field, respectively, was 
measured. Proliferation as compared to control low-fat diet was unaffected by dietary 
treatments. The significant decrease in nuclei per field following fish oil treatment 
compared to controls at both 1 and 3 weeks would infer that the observed gain in liver 
weight was attributable to an increase in parenchymal cell size. 
To determine the changes in fatty acid composition following dietary treatment, 
total liver lipids were analyzed by gas chromatography, Table 4.3. Temporal differences 
were not observed between 1 and 3 weeks for the various dietary treatments and for 
clarity, the data dicussed here reflects the values from the 3 week time point. It was 
surprising to observe only modest changes in fatty acid conent between a control low-fat 
and high-fat diet of corn oil even though the diet composition was formulated with a 4.7-
fold increase in % fat. The ω-6:ω-3 PUFA ratios were 4.7 and 7.0 for control and corn 
oil, respectively, attributable to the 82.5% increase in hepatic linoleic acid (18:2n-6) 
content from corn oil diet. In contrast, a high-fat diet of fish oil significantly altered the 
fatty acid composition in the liver compared to control. The ω-6:ω-3 PUFA ratio was 
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dramatically reduced from 7.0 to 0.94. As expected hepatic linoleic acid (18:2n-6) 
content was diminished to almost half along with significant increases in the long-
chained PUFA docosahexaenoic acid (186%) and the monounsaturated fatty acid 13-
docosenoic acid (1,535%).  
Temporal and treatment-dependent changes in gene expression. Gene 
expression profiling was performed on liver tissue collected at 1 or 3 weeks following 
dietary treatments.  A multi-class Significant Analysis of Microarrays [SAM; (140)] test 
was performed to identify genes whose expression levels were significantly differentially 
changed within at least one treatment group (i.e., control, corn oil, or fish oil) and within 
a single time point (i.e., 1 week or 3 weeks). The list of significantly altered genes with a 
false discovery rate (FDR) of less than 5% and 1.5 fold change consists of 4,537 genes. 
Clustering analysis was performed on this gene set, Figure 4.1A. The dendrogram 
shows that the samples segregated based on dietary treatment with one exception and 
within those clusters further separation was based on duration of treatment. To identify 
temporal changes in gene expression, SAM analysis was performed on 1 and 3 week 
liver samples from control, corn oil, or fish oil treated mice. The analysis revealed that 
the expression phenotypes for livers from mice administered a control-low fat diet or a 
high-fat diet of fish oil at 1 and 3 weeks were not significantly different. The lowest 
obtainable FDR was 60% (82 genes) and 7% (14 genes) for control and fish oil, 
respectively. A total of 824 genes were differentially expressed for corn oil between 1 
and 3 weeks. The majority of these genes, 768, were induced at 3 weeks of corn oil 
treatment. GoMiner (9) analysis was performed on the entire gene list to identify 
significantly enriched Gene Ontology (GO) biological processes (P < 0.05; minimum of 3 
gene transcripts per category). From this, it was observed that intracellular movement 
via endocytosis and exocytosis were up-regulated along with one-carbon metabolism 
(Figure 4.1B).  
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To identify treatment-dependent changes in gene expression in livers from mice 
given high-fat diets of corn oil or fish oil at 1 and 3 weeks, SAM analysis was performed. 
Comparison of expression data at 1 week showed that 1,339 genes were differentially 
expressed between the two treatment groups (Figure 4.1C). Within this gene set, GO 
analysis revealed that fish oil induced biological categories related to fatty acid oxidation, 
apoptosis, epigenetic gene regulation, and glutathione and xenobiotic metabolism. In 
contrast, corn oil induced categories related to responses to stress, wounding, and 
unfolded proteins as well as innate immune response. Comparison of expression data at 
3 weeks showed that 436 genes, a 3-fold reduction compared to 1 week, were 
differentially expressed between the two treatment groups.  The biologically processes 
described at 1 week are similar at 3 weeks with the exception of epigenetic gene 
regulation, apoptosis, and glutathione metabolism which no longer appear on the list.  
Gene expression analysis reveals discordant effect on anti-oxidant defense 
genes by ω-3 and ω-6 PUFA. Analysis of the biological pathways evoked by corn oil 
and fish oil within the liver revealed dissimilar responses to oxidative stress, and 
glutathione and xenobiotic metabolism. To further examine the treatment responses on 
oxidative stress-related pathways, GO was used to identify genes within the microarray 
that have an association with oxidative stress. A total of 163 genes were identified of 
which 81 were found to be significantly differentially expressed among the different 
treatment groups. Supervised hierarchical clustering of this gene set was performed and 
two major gene clusters were identified that were specific to fish oil or corn oil and are 
shown in Figures 4.2A-B. Several enzymatic and non-enzymatic antioxidant defenses 
were induced by a diet rich in fish oil. These genes fall into several categories including 
phase II detoxification enzymes (i.e. glutathione S-transferases), anti-oxidants (i.e., 
catalase, GSH peroxidase, and GSH reductase), molecular chaperones/proteasome 
systems (i.e. heat shock proteins and proteosomal protein sub-units). Furthermore, DNA 
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repair enzymes (i.e., Tdg, Ung, and Ape) and anti-inflammatory response proteins (i.e., 
heme oxygenase) were induced in the liver in mice given a high-fat diet of corn oil. Also, 
several genes related to metal metabolism, metallothioneins, thioredoxins, and heme 
oxygenase, were induced as well.  
High-fat diets rich in ω-6 PUFA cause pro-oxidant state in mouse liver. 
Analysis of the oxidative stress-related gene set revealed that corn oil and fish oil based 
diets lead to discordant responses in antioxidant defense systems within the liver 
suggesting alterations in the cellular redox state. Total and reduced GSH content were 
measured in liver tissue from mice fed a control low-fat diet or diets rich in corn oil or fish 
oil (Table 4.4). Total GSH levels across all dietary treatments and time points were not 
significantly different and ranged between 6.8 and 7.4 µmoles GSH equivalents/g tissue. 
Reduced GSH content in the liver; however, was found to be significantly reduced by 
corn oil by 3- and 2-fold at 1 and 3 weeks, respectively, compared to corresponding 
time-matched controls.  
As shown in Figure 4.2B, a high-fat diet of corn oil induced several DNA repair 
genes in liver of which several belong to the base excision repair (BER) pathway. BER is 
the predominant mechanism used for the removal of oxidized bases from DNA. A diet 
rich in corn oil but not fish oil significantly induced the expression of two BER genes, 
uracil DNA glycosylase (UNG) and AP endonuclease 1 (APE), as compared to 
corresponding time-matched controls at both 1 and 3 weeks, Table 4.5. These two 
genes were also observed to be significantly induced by corn oil in microarray analysis. 
Expression of O6-methylguanine DNA methyltransferase (Mgmt), an enzyme involved in 
the direct repair of alkylated guanine residues and not involved in repair of oxidative 
DNA lesions, was found to be induced by fish oil at 3 weeks. This would be consistent 
with previous report (182) whereby induction of antioxidant gene expression modulated 
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Mgmt activity levels at least, in part, by augmented mRNA levels. 
Next, a widely-used marker of oxidative DNA damage is 8-hydroxy-
deoxyguanosine (8-OH-dG) which was measured using immunohistochemical detection 
(Figure 4.3A-B). Microscopic examination of liver sections from all dietary treatments 
showed sporadic distribution of positively stained nuclei with no lobular localization. 
Quantitative analysis of 8-OH-dG DNA adducts in livers of mice administered a control 
low-fat diet had 50-60% positively stained nuclei. These levels were significantly 
increased by a high-fat corn oil diet to almost 80% by 3 weeks. Most surprisingly, a diet 
rich in fish oil significantly reduced the percentage of positively stained nuclei compared 
to controls by almost 2-fold. As immunohistochemical detection is considered semi-
quantitative and susceptible to non-specific reactions, 8-OH-dG adducts were also 
measured using capillary LC-MS/MS. The number of 8-OH-dG in livers from control mice 
were ~ 1 adduct per 106 dG (Figure 4.3B), in agreement with consensus reports from 
European Standards Committee on Oxidative DNA Damage (100). Analysis of liver 
tissues from mice following a high-fat diet of corn oil found a significant increase in these 
DNA adducts, approximately 2-fold over controls. There was no significant difference in 
adducts in livers from mice given control or fish oil based diets.  
Activation of PPARα plays a role in the differential effects of ω-3 or ω-6 
PUFA. Analysis of microarray data suggested that fish oil, but not corn oil, activated 
peroxisome proliferator-activated receptor alpha (PPARα) as GO processes related to 
fatty acid oxidation and peroxisome organization and biogenesis were significantly 
enriched by fish oil. It has been shown that fatty acids and their eicosanoid derivatives 
can regulate gene transcription through PPARs (183). To determine the degree of 
involvement of PPARα in regulating gene expression by high fat diets of ω-3 or ω-6 
PUFA, expression data from livers of mice treated with a potent PPARα pan-agonist, 
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WY-14,643 (WY; 50 mg/kg) for 1 or 4 weeks (Woods et al., unpublished data), was 
compared to the expression data generated in this study. SAM analysis of control and 
WY treated samples identified 1,275 gene transcripts to be differentially expressed. 
Since the study described herein and the WY study were performed using the same 
microarray platform, probe set ids were used to intersect the two significant gene lists to 
generate a single non-redundant shared gene list. A total of 845 genes were identified. 
Unsupervised hierarchical clustering was conducted on this gene set and is shown in 
Figure 4.4A. The dendrogram shows that the expression phenotypes from livers of mice 
given fish oil or WY are similar. To cross-compare the gene alterations between fish oil 
and WY, a venn diagram (Figure 4.4B) was constructed from the significant gene lists 
generated using SAM analysis (FDR <5%, 1.5 fold-change). Of the 719 genes that were 
differentially expressed by fish oil, 68% of those were shared with WY. GO analysis of 
the PPARα-regulated gene set shared between fish oil and WY showed induction of 
biological processes related to fatty acid metabolism, cofactor metabolism, and oxygen 
and reactive oxygen species (ROS) metabolism while responses to stress and immune 
response were repressed. Fish oil, however, did not induce processes related to cell 
proliferation or apoptosis in the liver as was demonstrated with WY treatment.  
There are conflicting reports on the potency of ω-3 and ω-6 PUFA to 
transactivate PPARα (184-186). Thus, the effects of high-fat diets rich in ω-3 and ω-6 
PUFA on DNA binding activity of PPARα in liver of mice are shown in Figure 4.5A. Gel 
shift assays demonstrated that fish oil considerably increased PPARα binding activity 
compared to control and corn oil diet treated mice. Competition assay using excess 
unlabeled DNA oligo blunted PPARα binding activity confirming the translocation and 
activation of PPARα following fish oil treatment in mice. These data correlated with the 
5-fold increase in activity of the classical PPARα–regulated gene acyl-CoA oxidase, 
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Figure 4.5B. There was no significant difference in DNA binding activity or acyl-CoA 
activity with a high-fat diet of corn oil.  
 
E. DISCUSSION 
Nutrient-gene interactions have become a key issue in the modulation and 
prevention of human disease. It has been suggested that a temporal shift in ω-6:ω-3 
PUFA intake ratios over the past half century have contributed to the growing obesity 
epidemic; however, the mechanisms by which different dietary fatty acids affect the 
molecular processes of human disease have not been fully elucidated. In the present 
study, molecular profiling was performed on liver tissue of mice treated with either high-
fat diets of corn oil or fish oil to identify the molecular processes modulated by PUFA 
treatment. It was determined that three key GO categories affected included fatty acid 
oxidation, cofactor metabolism, and immune response. As obesity has been linked to 
pathogenic mechanisms including hyperlipidemia, oxidative stress, and systemic 
inflammation these data would suggest that dietary fatty acids can influence key cellular 
and molecular events that underlie this disease.  
Oxidative stress is a common mechanism of liver disease and it can evolve from 
fatty acid oxidation and inflammation while the level of oxidants is modulated by the 
antioxidant capacity and cofactor supply of the cell. Analysis of expression data for 
oxidative stress-related genes revealed that fish oil, to a significantly greater extent than 
corn oil, induced a number of antioxidant and stress-inducible genes capable of 
inactivating ROS and protecting or removing oxidized macromolecules in the cell. 
Included were various isoforms of GSH S-transferases and thiol reductases, enzymes 
required for recycling GSH and reducing oxidized proteins and lipid hydroperoxides. 
Also, secondary defenses to restore cellular homeostasis by stabilizing or excising 
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damaged proteins (i.e., heat shock chaperone proteins and proteasomal pathways) were 
increased. In contrast, corn oil resulted in the induction of 6 DNA repair genes, all 
members of the BER pathway, the predominant pathway to excise and repair oxidative 
DNA lesions. As many of these cellular defense systems are known to be induced under 
conditions of physiological or chemical stress including oxidative stress, it would suggest 
that both types of dietary fatty acids result in an increase in oxidants. However, these 
data would imply that only fish oil evokes changes in gene expression profiles to defend 
against excess ROS production and potentially detrimental shifts in cellular redox state.  
The induction of phase II detoxification and antioxidant enzymes is a major 
protective mechanism against increased production of ROS. The transcriptional 
activation of these stress response genes has been linked to the cis-acting 
transcriptional enhancer called the ARE which, in turn, is positively regulated by the 
transcription factor Nrf2. The mouse strain used in these studies, C57Bl/6J, has been 
shown to carry a single nucleotide polymorphism within the Nrf2 promoter that results in 
reduced constitutive and induced expression compared to C3H/HeJ (187). Examination 
of nuclear Nrf2 protein levels and protein-DNA binding activity in livers from mice given 
high-fat diets of corn oil or fish oil were either undetectable or unchanged among 
treatment groups (data not shown), which is consistent with previous report with 7-day 
WY treatment (188). This would suggest an alternative mechanism involved in the 
regulation of antioxidant defense system in this mouse model. A potential candidate is 
PPARα, as it is preferentially activated by ω-3 PUFA and has been shown to regulate 
genes in common with the stress-inducible transcription factors, Nrf2 and HSF (188). 
Moreover, studies using PPARα-null mice have shown decreased resistance to oxidant-
induced liver injury (188, 189) suggesting that the hepatoprotective effects of PPARα 
may be under transcriptional regulation. 
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The PPARα regulatory network largely encompasses lipid metabolism and 
glucose homeostasis pathways, Figure 4.6. Microarray and biochemical analysis 
showed that high-fat diets of fish oil but not corn oil lead to increased fatty acid oxidation 
through trans-activation of PPARα. This process results in the proliferation of 
peroxisomes and the coordinate induction of hepatic genes involved in the β-oxidation of 
fatty acids in peroxisomes, mitochondria, and other cellular components. The main gene 
targets of PPARα include acyl-coA oxidase (Aco), carnitine palmitoyltransferase 1 
(Cpt1), which are in involved in β-oxidation and Cyp4a1, which is involved in ω-oxidation 
of fatty acids. It has been shown using peroxisome proliferators such as WY that fatty 
acid oxidation results in disproportionate increase in oxidant production through several 
H2O2 generating enzymes (i.e., Acox1 and Cpt1a) and H2O2 degrading enzymes (Cat) 
with disruption of GSH peroxidase leading to increased oxidative stress. To defend 
against PPARα activation and ROS production several defense mechanisms appear to 
concomitantly up-regulated. These include increases in glutathione-S-transferases, ROS 
metabolizing enzymes (Cat, Gpx), heat shock proteins (Hspca, Hspb2) including 
proteasome maintenance proteins, and uncoupling proteins (UCP1, UCP2, UCP3). The 
hepatoprotective effects against oxidant-induced liver injury by PPARα may be mediated 
by augmenting anti-oxidant expression levels. Furthermore, as WY and fish oil induce 
this same gene set, it would suggest that PPARα is the driving force behind the 
transcriptional changes responsible for up-regulation of cellular anti-oxidant defense 
mechanisms in mouse liver. There may be some concern with dietary intervention with 
fish oil as the positive effects appear to be mediated through PPARα, the same pathway 
used by peroxisome proliferators (PP) to induce liver growth and carcinogenesis in 
rodents (190). However, fish oil did not promote proliferation or oxidative stress in the 
liver which has been presented with more typical PP.  
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In addition to regulating lipid homeostasis, PPARα has been shown to possess 
anti-inflammatory properties. It is important in controlling the duration of inflammation 
induced by arachidonic acid, an eicosanoid derivative of ω-6 PUFA, as PPARα knock-
out mice displayed a prolonged response to inflammatory stimuli (191). Studies have 
shown that administration of PPARα ligands, including WY, augment IL-4 expression 
(192) along with blunting c-Jun activation (193) which abrogates the expression of pro-
inflammatory cytokines such as IL-6, TNFα, IFN-γ and NO synthase. Moreover, they 
diminish NF-kB levels (194) and DNA binding activity by increasing the expression of 
IκBα (195). The PPARα regulatory network (Figures 4.6A-C) clearly demonstrates that 
PPARα ligands, such as fish oil and WY, repress the expression of pro-inflammatory 
cytokines. These data would support GO analysis of PUFA expression data and would 
suggest that corn oil treatment results in a pro-inflammatory state. Inflammation 
activates a variety of immune cells, which induce a number of oxidant-generating 
enzymes such as NADPH oxidase, inducible nitric oxide synthase, and 
myleoperoxidase. These enzymes are capable of producing high concentrations of ROS 
which include superoxide anion, hydrogen peroxide, nitric oxide, and peroxynitrite. Thus, 
the increase in inflammatory mediators may be a considerable source of ROS 
accounting for the pro-oxidant state established in the liver following corn oil treatment. 
The production of ROS in excess of the antioxicant capacity of the cell can shift 
the cellular redox state. It is known that decreases in GSH content, a useful indicator of 
oxidative stress, can result in tissue damage as cellular macromolecules would be 
vulnerable to free radical attack. Moreover, changes in the redox state of intracellular 
thiols, especially GSH, influence the actions of redox sensitive transcription factors 
contributing to alterations in gene transcription. Indeed, depletion of reduced GSH by 
corn oil treatment at both 1 and 3 weeks generated a protracted pro-oxidant state in the 
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liver. This condition most likely contributed to the elevated levels of 8-OH-dG DNA 
adducts. Surprisingly, this was not accompanied by an increase in 8-oxoguanine DNA 
glycosylase 1 (Ogg1) expression, an enzyme responsible for excising oxidized guanines 
from DNA.  It has been demonstrated that shifts in the cellular redox state can reduce 
transcriptional activity of Ogg1 by decreased binding of Sp1 transcription factor to its 
promoter (196) in addition to abolishing Ogg1 protein activity (197). This enzyme is 
particularly sensitive to thiol modifying agents as 8 cysteine residues reside within the 
active site. The shift in the cellular redox state by corn oil treatment would account for 
the inability to induce Ogg1 expression and the resultant accumulation of 8-OH-dG 
adducts. A most intriguing observation was the reduction in 8-OH-dG adducts following 
fish oil treatment in comparison to a low-fat control diet. It can be speculated that this is 
the result of a steady-state in anti-oxidant capacity as reduced GSH content was 
unaffected. This, in part, was contributed to by the increase in expression of genes 
responsible for regulating GSH levels such as glutamate-cysteine ligase, the rate-limiting 
enzyme in GSH synthesis, and GSH reductase which recycles GSH from its oxidized 
form.   
The accumulation of oxidative DNA lesions, if unrestrained, can contribute to 
disease development. As such, the cell has developed an elaborate system known as 
DNA repair to reduce the yield of mutations and chromosomal aberrations. This includes 
BER which functions as a tightly coordinated sequence of events where oxidative DNA 
damage is removed and repaired. It has been shown to be DNA-damage inducible (198) 
and a sensitive biomarker of oxidative DNA damage (151, 199). During the process of 
BER, a glycosylase such as Ogg1 or Ung excises an incorrect base from DNA creating 
a transient abasic site. Ape1 cleaves the DNA backbone leaving behind a single strand 
break to allow incorporation of the correct nucleotide. Pol β, the rate-limiting step in BER 
(200), replaces the nucleotide and DNA ligase seals the gap. In this study, the 
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expression levels of Ung, which is responsible for excising misincorporated uracil from 
DNA, were increased in the livers of mice given a high-fat diet of corn oil. It has been 
demonstrated that folate deficient diets result in increased rates of uracil 
misincorporation into DNA and DNA hypomethylation (201) by disrupting one-carbon 
compound metabolism. Dysregulation of this metabolic pathway can negatively affect 
DNA metabolism and integrity as it serves two critical cellular functions, de novo 
synthesis of deoxynucleotides and SAM-dependent DNA methylation. Two genes within 
this pathway required for thymidine synthesis, 5,6-dihydrofolate reductase (Dhfr) and 
thymidylate synthetase (Tyms) were transcriptionally repressed in the liver of mice 
administered high-fat diet of corn oil. It is unknown at this time as to how corn oil 
treatment disrupts one-carbon metabolism but it could be speculated that changes in 
cofactor supply and/or sensitivity to cellular redox state may play a role.  
It could be inferred from the DNA repair expression data that corn oil alters the 
balance and coordination of BER by stimulating the initiation of BER (Ung and Ape1) 
without subsequent stimulation of the rate limiting step (Pol β). The inability to detect AP 
sites in the liver (data not shown) of these mice demonstrates that Ape1 activity was 
adequate to process the abasic site and, in the process, generate a single strand break.  
Thus, a state of altered BER would generate an environment conducive to the 
accumulation of genotoxic and clastogenic lesions. As Pol β expression and activity are 
dependent on cellular deoxynucleotide triphosphate levels, the resultant imbalance in 
BER may be due to a dysregulation in thymidine synthesis. An imbalance in DNA repair 
has serious implications as it is associated with increased genomic instability, a hallmark 
of carcinogenesis. These data provide evidence for gene-nutrient interactions that could 
potentially be harmful by increasing rate of DNA mutations.  
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Recent epidemiological studies on obesity have shown that body mass index 
(202, 203) and fat accumulation (171) closely correlate with markers of systemic 
oxidative stress.  Moreover, increased oxidative stress in accumulated fat is, in part, 
responsible for the dysregulation of adipocytokines which participate in the pathogenesis 
of obesity-associated metabolic syndrome (171). Herein this study, we propose that 
increased oxidative stress and DNA damage in liver of mice treated with high-fat diet of 
ω-6 PUFA may serve as an early instigator in molecular and cellular processes leading 
to obesity and obesity-related co-morbidities. These effects may be ameliorated through 
increased dietary intake of ω-3 PUFA as they have an adaptive reaction against 
increased oxidative stress by inducing antioxidant genes.  
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Table 4.1 
Diet formulations 
 Low Fat Diet 
5% Corn Oil 
High Fat Diet 
23.5% Corn or Fish Oil 
Diet Ingredient g/kg g/kg 
Casein 200 250 
DL-methionine 3 3.75 
Corn Starch 520 312 
Dextrose, monohydrate 130 78 
Cellulose 50 62.5 
Corn Oil 50 30 
Various Fat Source 0 205 
Mineral Mix 35 43.75 
Vitamin Mix 10 12.5 
Choline Bitartrate 2 2.5 
Total 1000 1000 
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Table 4.2 
Effect of high-fat ω-3 and ω-6 PUFA diets on hepatic morphology 
 
Control Corn Oil Fish Oil 
  1 wk 3 wk  1 wk 3 wk  1 wk 3 wk 
% Liver to Body Wt  4.0 ± 0.31 4.0 ± 0.21  4.2 ± 0.36 4.7 ± 0.22b  5.9 ± 0.65b 5.9 ± 0.63b 
nuclei per field 
(cellular 
hypertrophy) 
 
 
274 ± 28 285 ± 17  308 ± 19 241 ± 28  210 ± 28a 242 ± 18a 
% PCNA nuclei  
 
 
1.2 ± 0.20 1.3 ± 0.33  1.4 ± 0.26 1.3 ± 0.22  1.4 ± 0.40 1.3 ± 0.27 
 
C57Bl/6 male mice were given AIN-76A diet (5% fat; control diet) or diets 
supplemented with either corn or fish oil (23.5% fat) for 1 to 3 weeks. Body and 
liver weights were determined at end of 1 or 3 weeks.  Hemotoxylin-eosin stained 
liver sections were used to assess hepatocyte hypertrophy by counting the 
number of nuclei per random field at 200×.  Proliferation was measured as an 
index of percent PCNA positively stained nuclei to total nuclei. Data are 
represented as means + standard deviation from 5 animals per group. Statistical 
difference (aP < 0.05; bP < 0.01) compared to corresponding control group using 
one-way ANOVA. 
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Table 4.3 
 
Fatty acid composition of liver total lipids following treatment with high fat diets of 
either corn oil or fish oil 
 
 1 week  3 weeks 
Fatty Acid Control Corn Oil Fish Oil  Control Corn Oil Fish Oil 
14:0 321 ± 69 179 ± 37 415 ± 149  426 ± 132 195 ± 78 341 ± 58 
14:1 20 ± 9 ND 19 ± 10  28 ± 10 ND 19 ± 3a 
16:0 14802 ± 1348 13807 ± 1327 13580 ± 1199  17359 ± 3517 13860 ± 2942 13265 ± 739 
16:1 n-7 1549 ± 649 577 ± 101 592 ± 398  1450 ± 780 371 ± 167 1195 ± 189 
18:0 6317 ± 460 7695 ± 129a 5468 ± 483d  7175 ± 1030 8154 ± 445 5227 ± 343a,e 
18:1 n-9 8690 ± 2085 7355 ± 400 5145 ± 914a  13275 ± 6105 7603 ± 2375 4621 ± 330 
18:2 n-6 10752 ± 815 20693 ± 670c 6839 ± 558c,d  10760 ± 1390 19639 ± 3908a 6401 ± 549a,e 
18:3 n-3 200 ± 16 199 ± 22 146 ± 95  226 ± 37 259 ± 54 124 ± 51d 
20:0 184 ± 26 261 ± 35 241 ± 54  193 ± 14 172 ± 72 223 ± 24 
20:1n-9 265 ± 35 245 ± 17 136 ± 48a,d  316 ± 54 276 ± 58 88 ± 22b,e 
20:2n-6 232 ± 13 295 ± 35a 82 ± 10c,f  305 ± 118 369 ± 49 89 ± 20a,e 
20:3cis n-6 774 ± 90 530 ± 60a 381 ± 89b  964 ± 267 832 ± 243 330 ± 61a 
20:3transn-6 ND 28 ± 48 ND  120 ± 29 50 ± 86 36 ± 62 
20:4n-6 4486 ± 610 8788 ± 572 3218 ± 127c,f  6026 ± 2059 9883 ± 1090 2279 ± 190b,e 
20:5n-3 102 ± 10 106 ± 5 25 ± 39a,d  82 ± 41 57 ± 19 ND 
22:0 76 ± 66 61 ± 6 358 ± 113b,e  116 ± 10 78 ± 4 391 ± 98b,e 
22:1n-9 128 ± 86 115 ± 4 2194 ± 761b,e  158 ± 36 127 ± 11 2584 ± 358c,f 
22:5 53 ± 15 17 ± 1 32 ± 8  52 ± 17 23 ± 5 42 ± 31 
22:6n-3 3284 ± 917 4138 ± 151 10404 ± 1611b,e  3551 ± 1147 4032 ± 178 10186 ± 84 
24:0 852 ± 1178 133 ± 10a 633 ± 89  860 ± 1172 144 ± 20 661 ± 75 
24:1n-9 ND ND 56 ± 26a  20 ± 35 31 ± 6 ND 
Total n-6 16244  ± 5731 30171 ± 8414 11071 ± 2879a  18175 ± 6307 30547 ± 8623 8681 ± 3245a,d 
Total n-3 3585 ± 1593 4442 ± 2019 10575 ± 5957  3858 ± 1962 4348 ± 2239 10310 ± 5845 
n-6/n-3 ratio 4.5 6.7 1.0  4.7 7.0 0.94 
 
Values represent means ± standard deviation (nmoles fatty acid/g liver), n =3. 
Saturated fatty acids (14:0, 16:0, 18:0, 20:0, 22:0); monounsaturated fatty acids 
(14:1n-7, 16:1n-7, 18:1n-9, 20:1n-9, 22:1n-9, 24:1n-9); polyunsaturated fatty acids 
[PUFA (18:2n-6, 18:3n-3, 20:2n-6, 20:3n-6, 20:4n-6, 20:5n-3, 22:6n-3)]; n-6 long-
chain PUFA (20:4n-6); n-3 long-chain PUFA (20:5n-3, 22:6n-3). The significance of 
the differences between mean values was assessed by one-way ANOVA and 
Tukey’s post-hoc test: ap< 0.05, bp < 0.01, cp < 0.001 vs controls or dp < 0.05, ep < 
0.01, fp < 0.001 vs corn oil treatment. ND = not detected. 
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Table 4.4 
Effects of high-fat ω-3 and ω-6 PUFA diets on liver glutathione content 
 Glutathione Eqv 
(µmoles/g tissue) Control Corn Oil Fish Oil 
Total 7.3 ± 0.94 7.4 ± 0.74 6.2 ± 0.93 1 week Reduced 5.2 ± 0.53 1.6 ± 0.86* 5.8 ± 1.14 
     
Total 6.8 ± 1.20 7.0 ± 0.98 6.8 ± 1.23 3 weeks Reduced 6.4 ± 1.45 2.9 ± 0.75* 5.4 ± 1.09 
 
Total and reduced glutathione content (µmoles/g tissue) was measured in mouse 
liver tissue following treatment with high fat diets of corn oil (ω-6) or fish oil (ω-3) 
for 1 or 3 weeks. Results are expressed as means ± standard deviation from 5 
animals per group. *Statistical difference (P < 0.05) compared to corresponding 
control group using one-way ANOVA followed by Tukey’s multiple-comparison 
post-hoc test.  
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Table 4.5 
Expression of base excision DNA repair genes are induced by high-fat diets rich 
in ω-6 PUFA  
 
 
 
1 week 
 
3 weeks 
DNA Repair Genes 
  
Control 
 
Corn Oil Fish Oil 
 
Control Corn Oil Fish Oil 
 
OGG1, 8-oxoguanine  
   DNA glycosylase 1 
 
  6.7 ± 0.2   6.5 ± 0.5   4.7 ± 2.1 
 
  4.8 ± 1.8  5.0 ± 1.1  7.1 ± 0.51 
MPG, N-methylpurine  
   DNA glycosylase 
 
  4.9 ± 1.6   2.9 ± 0.6   4.1 ± 1.0 
 
  4.1 ± 1.2  3.7 ± 1.1  5.0 ± 0.7 
TDG, thymine DNA       
glycosylase 
 
  9.7 ± 1.0 11.6 ± 1.2   6.1 ± 2.0 
 
  7.8 ± 1.6  8.6 ± 1.6  7.4 ± 5.6 
UNG, uracil DNA    
glycosylase 
 
  3.3 ± 0.6  13.0 ± 1.4b   2.5 ± 0.9 
 
  2.8 ± 0.7   6.8 ± 1.2b  2.5 ± 1.2 
APE, apurinic/apyrimidinic    
endonuclease 1 
 
10.0 ± 3.2 20.1 ± 1.5b   6.8 ± 1.8 
 
10.5 ± 3.6  18.7 ± 4.4a   10.9 ± 4.6 
Nthl1, E. coli endonuclease 
III-like 1 
 
  4.1 ± 0.5  3.4 ± 0.8   3.6 ± 0.7 
 
  3.3 ± 0.4  2.6 ± 1.0  3.5 ± 0.2 
Pol β, polymerase (DNA 
directed) β 
 
16.4 ± 3.1 19.7 ± 1.9 18.9 ± 0.5 
 
16.7 ± 5.7 16.9 ± 2.7 14.2 ± 1.3 
PCNA, proliferating cell 
nuclear antigen 
 
19.6 ± 4.2 14.8 ± 1.8 18.5 ± 5.7 
 
16.1 ± 2.7 16.8 ± 2.1 15.3 ± 0.41 
MGMT, O6-methylguanine 
DNA methyltransferase  
 
14.2 ± 1.3  8.0 ± 3.7 16.8 ± 4.0 
 
10.4 ± 2.0  9.1 ± 1.7 19.1 ± 3.4a 
 
RNase protection assay was performed on total RNA isolated from liver samples 
The results are mean ± standard deviation from 3 animals per group. The relative 
expression of each gene was normalized to the expression of the housekeeping 
gene L32. *Statistical difference (aP < 0.05; bP < 0.001) from corresponding control 
group using one-way ANOVA followed by Tukey’s multiple comparison post-hoc 
test.
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Figure 4.1 
 
Temporal and treatment-dependent changes in gene expression in mouse liver 
following treatment with high-fat diets of ω-3 and ω-6 PUFA 
 
(A) Unsupervised hierarchical clustering of significantly differentially expressed genes in 
liver from mice fed a control low-fat diet (5% corn oil) or high fat diets of either corn oil 
(ω-6) or fish oil (ω-3) for 1 or 3 weeks. Significant Analysis of Microarrays (SAM) (140) 
was performed to identify genes whose expression levels were significantly different 
(FDR < 5% with 1.5 fold change) among any treatment group compared to 
corresponding control. The color of each gene is proportional to the mean expression 
level (in log2 units, see color bar) of the gene across the entire set of samples (red - 
median, black – no change, and green - below median value). The dendrogram shows 
that samples clustered into three groups based on dietary treatment. To identify 
temporal (B) and treatment-dependent (C) changes in gene expression among and 
between high-fat diets, SAM two-class unpaired analysis was performed. These gene 
lists were submitted to GoMiner (9) to identify significantly enriched biological processes 
(P<0.05). A few of these processes are shown within color coded circles (red – 
upregulated; green – down-regulated) to its respective treatment as indicated. The 
number of genes associated with each process is given in parentheses.  SAM analysis 
found no temporal difference in gene expression for fish oil where the lowest obtainable 
FDR was 6.3% (14 genes). 
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Figure 4.2 
 
A high-fat diet of ω-3 PUFA leads to an induction of anti-oxidant defense genes in 
mouse liver 
 
Gene ontology (GO) identified 163 genes on the microarray with an association with 
oxidative stress. SAM multi-class analysis identified 81 of those genes to be significantly 
differentially expressed (FDR < 5% with 1.5 fold change) within at least one treatment 
group. Supervised hierarchical clustering was performed using this gene list. The 
dendrogram showed that genes segregated into two main clusters based on dietary 
treatment. The gene clusters induced by fish oil (A) or corn oil (B) treatment are shown. 
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Figure 4.3 
 
The type of PUFA influences the degree of accumulation of 8-OH-dG DNA adducts 
in liver compared to control low-fat diet 
 
Representative micrographs (200×) of 8-OH-dG stained liver sections (A) from mice fed 
for 3 weeks with low-fat control diet, or high fat diets of either corn oil (ω-6), or fish oil 
(ω-3). Quantification of 8-OH-dG DNA adducts from immunostained liver sections using 
Bioquant image analysis software by averaging percent nuclei stained to total nuclei at 
200x (bar graph) or number of adducts in genomic liver DNA determined by capillary LC-
MS/MS analysis (line graph) are shown (B). Results are expressed as mean ± standard 
deviation from 5 animals per group. *Statistical difference (P < 0.05) compared to 
corresponding control group using one-way ANOVA followed by Tukey’s multiple 
comparison post-hoc test.  
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Figure 4.4 
 
Gene expression phenotypes in livers from mice given a high-fat diet of ω-3 PUFA 
or PPARα agonist, WY-14,643, are similar 
 
(A) Unsuperivsed hierarchical clustering of integrated gene expression data sets from 
this study and data from livers of mice treated with PPARα pan agonist, WY-14,643 (50 
mg/kg) for 1 or 4 weeks. Dendrogram shows two major sample clusters demonstrating 
that liver gene expression phenotypes are most similar between fish oil and WY-14,643. 
(B) Venn diagram illustrating the distribution of gene alterations between fish oil and 
WY-14,643. Significant gene lists were generated using SAM (FDR < 5%) for each 
treatment and cross-compared. Values represent the number of genes significantly 
induced (red) or repressed (green) that are either unique or shared between the two 
treatment groups. Gene lists were submitted to GoMiner (9) to identify significantly 
enriched biological processes (P < 0.05 and a minimum of 3 gene transcripts), of which 
a few are shown. The number of genes within a given process is shown in parentheses. 
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Figure 4.5 
 
Activation of PPARα in liver with ω-3 PUFA dietary treatment 
 
(A) Mice were administered a control low-fat diet or high-fat diets of either corn oil (ω-6) 
or fish oil (ω-3) for 1 or 3 weeks. Liver nuclear protein extracts were prepared and 
PPARα activity was determined by EMSA using biotin-labeled consensus sequence 
oligonucleotide as described in Materials and Methods. For unlabeled probe 
competition, nuclear extracts from mice administered a fish oil diet were used, denoted 
by arrows. Results are representative of two biological replicates. (B) Activity of acyl-
CoA oxidase (ACO), a PPARα-regulated gene, measured biochemically in livers from 
mice fed control low fat diet or high fat diets of corn oil or fish oil for 1 or 3 weeks. 
Results are expressed as mean ± standard deviation from 3 animals per group. 
*Statistical difference (P < 0.05) compared to corresponding control group using one-
way ANOVA followed by Tukey’s multiple comparison post-hoc test.  
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Figure 4.6 
 
Gene expression modulation of PPARα-regulated networks by PUFA 
 
Gene expression modulation of PPARα regulated networks by high-fat diets of corn oil 
or fish oil and a PPARα pan-agonist, WY-14,643. Gene expression data from liver of 
mice fed with high-fat diets of either corn oil (A) or fish oil (B) for 3 weeks and from mice 
treated with Wy-14,643 for 4 weeks (C) were averaged and genes within network 
scheme color-coded according to level of expression (red – induced, green – repressed, 
gray – unchanged, and yellow – gene absent from array). Genes within the inner blue 
circle are known to either directly or indirectly promote or attenuate oxidative stress. 
Those encircled in orange are lipid metabolism genes while those encircled in red are 
modulators of inflammation. Network scheme was prepared using Pathway Studio® 4.0 
software (204) based on PubMed and other public datasources.  
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A. Conclusion and Perspectives 
Considerable mechanistic gaps exist in our ability to characterize the complex 
associations among environmental exposures, genetics, and adverse health outcomes. 
Toxicity and disease is most frequently not the product of a singly perturbed gene or 
protein but instead is the result of complex interweaving networks of biological 
processes involving genes, proteins, and metabolites. Thus, establishing direct linkages 
between exposure and adverse health outcomes requires a comprehensive 
understanding of the diverse and complex responses leading to pathogenesis. The 
results obtained from microarray profiling experiments can provide a molecular 
framework of toxicity upon which phenotypic endpoints of toxicity can assist to derive the 
mechanism of action. The research studies detailed herein are distinct in their own right 
but were designed to demonstrate the power and versatility of toxicogenomic studies to 
assist in understanding the evolution and progression of oxidant-induced liver toxicity 
and disease. Incorporating the results from microarray profiling experiments with 
phenotypic markers for oxidative stress and DNA damage allowed us to improve the 
linkages between oxidant-induced hepatic toxicity and pathology and most importantly, 
provide insight into the molecular networks involved in eliciting observed pathologies.  
 
1. Predictive Markers of Early Effect  
The sensitivity afforded by toxicogenomic studies provides an unprecedented 
window into the early events preceding toxicity that can serve as predictive markers of 
exposure or early effect. For instance, previous studies using APAP-induced 
hepatotoxicity in the rat demonstrated that cellular pathways perturbed at low doses of 
APAP may be indicative of overt toxicity occurring at higher doses (91). Indeed, in our 
work the gene signature indicative for oxidative stress was successfully phenotypically 
anchored to markers of oxidative stress for both low and overtly toxic doses of APAP 
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(179). Taken together, these studies demonstrate that gene expression profiling can 
assess toxicity more comprehensively by detecting subtle indicators of potential adverse 
effects in the absence of overt toxicity. From a risk assessment point of view, the ability 
of microarray studies to detect subtle changes with ever lower doses should lead to 
improved extrapolation methods as toxicity studies to evaluate chemical safety can be 
conducted using more relevant human exposure levels.  
Although, a disconnect between traditional measures of observable toxicity with 
alterations in gene expression supported by unconventional phenotypic endpoints will 
bring forth a critical reassessment for how we define toxicity. In our study, the observed 
state of oxidative stress was short-lived subsiding within 24h of exposure along with the 
reversal of altered expression changes. A major challenge is to determine which 
molecular events that change with low doses are necessary for pathological outcomes, 
versus those that are adaptive, beneficial, and/or unrelated to the development of 
pathologies (205). Discriminating between these lines will require an extensive dose-
response study upon which the data can then be used to determine points of departure, 
establish thresholds of toxicity, and predict exposure levels required to initiate the 
cascade of molecular responses leading to an adverse outcome. There are still many 
challenges ahead for how we interpret alterations in gene expression but we must be 
especially careful to refrain from classifying every expression change as an adverse 
event.  
 
2. Assessing Degree of Conservation for Mechanisms of Toxicity 
 A surprising revelation from our toxicogenomic study on APAP-induced 
hepatotoxicity was the dose- and species-dependent discord in detecting 3-nitrotyrosine 
protein adducts, an indirect measure of peroxynitrite formation. The detection of 3-
nitrotyrosine has been repeatedly measured in the livers of mice administered a toxic 
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dose of APAP and is considered a critical mediator for liver injury (206). Surprisingly, in 
our study using the rat, nitrated protein residues were only detected following a sub-toxic 
dose which, in turn, would infer that the oxidant species formed in the presence of sub-
toxic and overtly toxic doses of APAP are not identical. The culmination of these studies 
would suggest that there are mechanistic differences in APAP metabolism that are both 
dose- and species-dependent. Assessing the degree of conservation for the mechanism 
of APAP-induced hepatotoxicity would facilitate the implementation of mechanistically 
based uncertainty factors that account for both within- and across-species variability. If 
repeated studies demonstrate that the mechanism of APAP-toxicity is not conserved 
across rodent species then it can be speculated that neither species would serve well to 
accurately access human health hazards. These types of discrepancies have fostered 
the search for new tools to identify best-fit models for evaluating potential adverse 
outcomes in humans.  A similarity in gene expression patterns could be used to select 
the most appropriate animal model prior to the conduct of toxicity studies based on the 
premise that shared expression often implies shared function (7).  
 
3. Identification of Best-fit Animal Models through Comparative Genomics  
To date, very few studies in toxicology exploit comparative genomic approaches 
to identify best-fit animal models to study toxicity or disease. Comparative expression 
analysis was performed on CD-induced rat HCC (207) with data from human HCC study 
(160) which included 102 primary tumors and 74 non-tumor liver samples. Clustering 
analysis of orthologous genes revealed that CD-induced rat HCC and human HCC 
share similar expression phenotypes. Moreover, functional analysis of similarly 
expressed genes revealed biological processes consistent with known cancer biology. A 
particular hallmark of rat HCC was the up-regulation of tyrosine kinase signaling 
pathways which recently has been linked to a sub-class of human HCC patients with 
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poor survival (208). Similar studies have also been performed using genetically-modified 
(transgenic and knock-outs) and chemically-induced models of mouse HCC (209). The 
results from these studies discriminated the mouse models into three classes of which 
two of them closely recapitulated the molecular patterns for two sub-classes of human 
HCC. Taken together, these results support the concept that best-fit models for human 
cancer studies can be identified by applying genome-scale comparison of gene 
expression patterns. The clear gain to be realized from such an approach is to connect 
molecular pathogenic features of human cancer to rodent models with increased 
confidence.  
 
4. Improving the Linkage Between Oxidant-induced Hepatic Toxicity and HCC 
 The similarity in gene expression changes between rat and human HCC would 
indicate that the underlying transcriptional regulation in gene expression changes is 
conserved and therefore, the CD-induced rat HCC is a suitable model for studying the 
biology of hepatocarcinogenesis. It is well established that regardless of etiology (i.e., 
HBV, HCV, and alcohol), the progression to HCC proceeds through a series of 
pathological changes including fatty liver, repeated cycles of cellular injury and repair, 
fibrosis, and cirrhosis. The gene expression patterns for the CD-model of HCC were 
strongly driven by the histopathological changes, as described above, accompanied by 
progressional shifts in antioxidant defenses, specifically DNA repair genes, suggesting 
progressively increasing genomic instability. Increases in AP sites and oxidized purines 
confirmed these results and established a temporal link between fibrosis and the 
accumulation of DNA lesions. Recent studies have demonstrated a correlation between 
increases in DNA repair expression and histological stage of fibrosis in liver biopsies 
(158). Thus, we would propose that the fibrotic process may be a contributing factor to 
the transformation of hepatocytes towards a neoplastic phenotype. It would be 
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particularly interesting to follow-up these studies to determine if a correlation exists 
between grade of fibrosis and the number of oxidative DNA lesions.  
 
5. Role of Dietary Oils as Vehicles to Conduct Toxicological Studies  
Nutritional modulation of toxicity or disease has become an emerging issue in 
toxicology. The growing obesity epidemic (163) is of particular concern as it is 
associated with increased systemic oxidative stress (171), a condition that may 
predispose individuals to increased susceptibility to environmental toxicity or disease. A 
contributory factor to the rise in obesity rates has been the disproportionate intake ratios 
of ω-6:ω-3 PUFA. Molecular profiling supported by measures of oxidative stress 
demonstrated that ω-6 PUFA results in a pro-oxidant state in mouse liver most likely 
established by increased production of pro-inflammatory mediators. Pathway mapping of 
expression data suggested that the differential effects on oxidative stress by the two 
dietary fatty acids were mediated by PPARα. Using a comparative genomics approach 
with a known PPARα agonist, we were able to demonstrate that ω-3 but not ω-6 PUFA 
shared similar expression patterns and biological functions which included an up-
regulation of anti-oxidant defense mechanisms. These data would then infer that the 
observed differential effects on oxidative stress are mediated by their ability to trans-
activate PPARα. As oxidative-stress signaling pathways are a common mechanism for 
human toxicity and disease, it would be expected that the composition of dietary fatty 
acids in tissues would impart some inherit resistance or susceptibility to disease. Indeed, 
several in vivo animal models have shown that increased intake of ω-6 PUFA is 
associated with increased risk for cyclosporine-mediated nephrotoxicity (210) and 
potentiates PCB-induced vascular toxicity (211) and aliphatic nitrile toxicity (212). This 
potentiation of drug and environmental toxicity by corn oil brings into question whether it 
is an appropriate vehicle to conduct toxicology studies. It has been a mainstay for 
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decades as the vehicle of choice to administer unpalatable or volatile chemicals. 
However, this practice is unlikely to change due to the difficulty in identifying suitable 
vehicles for administering lipophilic compounds which lack any observable side effects.  
 
B. Challenges and Limitations 
1. Study Limitations 
One of the promises of toxicogenomics is to predict toxicity at earlier times and 
doses than currently employed methods. In our work with APAP, the phenotypic 
anchoring of a gene signature for oxidative stress at a sub-toxic dose builds support for 
gene expression profiling as a sensitive indicator to detect potentially adverse effects in 
the absence of overt toxicity (179). The conclusions drawn from this study were limited in 
scope due to the fact that an appropriate dose-response was not conducted. This is of 
particular importance as we demonstrated a discrepancy in the accumulation of 3-
nitrotyrosine protein adducts suggesting that the mechanism of toxicity may not be 
conserved among sub-toxic to moderate to overtly toxic doses of APAP.  Establishing 
predictive markers of early effect requires the ability to determine which molecular 
events are needed to initiate the cascade of events leading to pathology. Delineating 
these points of departure require temporal and dose-response studies that are linked 
with the appropriate phenotypic markers of toxicity. Such information would provide us 
with the ability to determine which gene expression changes are required to initiate 
toxicity and provide a foundation to build potential biomarkers of APAP exposure. 
Cancer research requires the use of animal models that most accurately 
reproduce the human condition. The CD diet is an extensively studied non-genotoxic, 
non-chemical induced model of rodent HCC that recapitulates the sequelae of 
pathological events observed in human HCC associated with viral infection and alcohol 
abuse. This diet is administered over the course of a year and may be considered a 
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particular harsh treatment as one-carbon metabolism and fatty acid oxidation pathways 
are severely impaired. Although the histopathology between this model and progression 
of human HCC may appear similar, the mechanisms that bring about such changes may 
not.  The comparative expression analysis between CD-induced rat HCC and human 
HCC was severely limited in statistical power as this study included only 4 rat tumors, 2 
of those being distinct tumors from the same animal. Secondly, annotation of the rat 
genome has lagged behind the human and mouse and this most likely limited our ability 
in identifying all gene orthologs between rat and human HCC data sets.  
The major focus of Aim 3 was identifying and understanding how ω-3 and ω-6 
PUFA mediate their differential effects on oxidative stress in the mouse liver. In the 
C57Bl/6J mouse strain it was discovered that PPARα was activated by fish oil but not 
corn oil treatment and suggested that it was the driving force behind the transcriptional 
changes responsible for the up-regulation of cellular anti-oxidant defense mechanisms.  
Although, this observation may be limited to this mouse model and others that have 
deficiencies in the transcriptional activation of Nrf2, a transcription factor which is 
responsible for the activation of stress response genes. Previous studies have shown 
that PPARα and Nrf2 transcriptional regulate similar genes (188). Thus, repeating these 
studies in an Nrf2 competent mouse line, in addition to PPARα null, would assist in 
determining the degree of involvement of PPARα in mediating the hepatoprotective 
effects against oxidative stress.  It should also be considered that the amount of dietary 
fat provided to these mice was considerably high in relation to daily human consumption. 
This was particular true for fish oil as n-6/n-3 ratios were reduced to 1 and may have 
contributed to the degree of PPARα activation observed in this study.  As 
epidemiological studies are showing that n-6/n-3 ratios are more important in 
determining disease risk, it would be pertinent to determine the ratio that delivers the 
best health benefits.  
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2. Current Challenges and Limitations of Toxicogenomic Studies 
2.1 Standardization of Toxicogenomic Protocols and Data Analysis 
Since the inception of DNA microarrays in the early 1990s, several thousand 
papers describing data from microarrays are published each year. Yet, after 15 years of 
research and development a major criticism of microarray data that still lingers has been 
the lack of consensus on the reproducibility and accuracy of the derived data. The 
repeatability and reproducibility of microarray experiments, comparability across 
platforms, and best practices for not only experimental design and sample preparation 
but also for data acquisition, statistical analysis, and interpretation remain inadequately 
characterized (213). A lack of resolution of these issues has hampered translation of 
microarray technologies into the regulatory and clinical settings (214).  
Consortiums of academic institutions, regulatory and governmental agencies, 
and the private sector have begun to address these fundamental issues. The Microarray 
Quality Control Project (MAQC), External RNA Controls Consortium (ERCC) and the 
Toxicogenomics Research Consortium (TRC) have all launched initiatives aimed to 
establish a set of quality assurance and quality control criteria to assess and assure data 
quality, to identify critical factors affecting data quality, and to optimize and standardize 
microarray procedures (213). To date, several large cross-format studies have already 
been published (94, 215, 216) which have set out to evaluate the performance for up to 
12 different microarray platforms in profiling the expression of identical RNA samples 
within and across different laboratories. Each of these studies concluded that with 
careful experimental design using standardized protocols for sample preparation, data 
acquisition and data normalization that microarray data can indeed be reproducible and 
comparable among different formats and laboratories. Commercial platforms 
demonstrated the highest level of reproducibility between laboratories when used 
together with standardized protocols (94, 216). Initiatives for reference RNA materials 
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which can be incorporated into the microarray workflow process are currently in progress 
(217). These materials can then be used by microarray facilities to monitor the technical 
performance and comparability of data sets generated over time. It is anticipated that the 
results from these studies will establish universal quality control standards that will 
provide improved confidence in the consistency and reliability of gene expression data 
sets.   
The validity of microarray studies are generally measured as the concordance 
and discordance of the data with quantitative real-time PCR (qRT-PCR), a method 
commonly accepted as the “gold standard” of relative gene expression measurements 
(218). Studies performed by MAQC revealed an excellent fold-change correlation for 
differentially expressed genes with medium-to-high expression levels with qRT-PCR 
(216). Moreover, it was determined that discordant responses in differential gene 
expression among the various microarray platforms were largely attributable to 
differences in probe hybridization and platform detection thresholds (219). The detection 
of genes with low expression levels varied considerably across microarray platforms 
which was largely dependent on the ability to reliably detect expression. Despite the use 
of standardized protocols across platforms, there were still considerable differences in 
significant gene lists. Thus, many issues remain open for investigation in the processing 
and analysis of microarray data.   
One of the fundamental goals of gene expression profiling experiments is to 
identify those genes that are differentially expressed within the system being studied. 
Microarray studies are uniquely characterized by small sample sizes, multiple hypothesis 
testing, and high-dimensional biological data which presented important new challenges 
to statisticians as traditional statistical approaches were ill-suited. Fold-change was the 
first method used to evaluate whether genes were differentially expressed and was 
popular for many years primarily due to its simplicity. Today, it is now widely accepted to 
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be an inadequate test statistic as it does not incorporate variance and offers no 
associated level of confidence (220). The preference of statistical significance metric (P 
value) has frequently been used as a gene selection method although, it is biased to 
random noise and platform-dependent systematic errors (214). The reliance of P value 
alone has resulted in the apparent lack of agreement in expression data between 
laboratories and microarray platforms (214, 221). Results from the MAQC human data 
sets (215, 216) and TRC rat toxicogenomic data set (221) indicate that fold-change 
ranking with a non-stringent P value cutoff can be successful in identifying reproducible 
gene lists. Unfortunately, reproducibility of gene lists does not necessarily equate to 
accuracy. The lack of reference data sets impedes the independent validation of data 
analysis methods for their merits and limitations.  
The outcome of microarray studies can be affected by many technical, 
instrumental and computational factors and it is imperative to understand these 
limitations and variables. Recent concerted efforts have demonstrated that microarray 
results are comparable across laboratories when standardized protocols are followed. 
Clearly, microarrays have a long way to go before they can be used to support 
regulatory decision-making but the contributions made thus far by the MAQC and TRC 
have provided a solid foundation from which to build.  
 
2.2 Gene Expression is a Limited Biological Measurement 
Gene expression data captures only a snapshot in time the changes in mRNA 
expression levels that occur in response to a given stimulus under study. It is unknown 
as to whether the observed changes occurred as a result of fluctuations in transcriptional 
activity, changes in mRNA stability, or changes in cell populations within a given tissue. 
Moreover, the information gathered from microarray studies does not provide insight into 
whether or how these changes in expression levels impact cellular functions. An indirect 
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understanding of global and molecular trends in gene expression data can be made 
through Gene Ontology (GO) vocabularies which describe gene products as a function 
of their biological processes, their cellular components, and their molecular/biochemical 
function provide. This information of gene functionality can then be used to uncover how 
sets of genes and their products work together in health and disease. As the emerging 
fields of proteomics and metabolomics catch up with genomics, the integration of such 
data sets will provide an unprecedented systems biology approach to elucidate complex 
disease pathways.  
 
2.3 Interpretation of Toxicogenomic Data Requires Phenotypic Anchoring  
Toxicology studies are quite complex with sources of variability resulting from the 
dose and delivery of the chemical under study, the choice of animal species and 
differences in biological and pathological responses of various tissues (93).  The 
combination of this with the known technical variability in genomic studies (94) 
underscores the importance of careful validation of alterations in gene expression 
patterns. A recent toxicogenomic study (TRC, unpublished data) using a well 
characterized and studied hepatotoxicant, APAP, conducted across seven different 
centers within the US determined that animal-to-animal variability accounted for one of 
the largest sources of variability in microarray studies, despite the use of standardized 
protocols to minimize experimental and technical variables. The extent of liver injury 
induced by APAP as measured by necrosis and ALT activity varied appreciably across 
centers and animals. Yet, applying correlation-based analysis to associate liver toxicity 
to gene expression was demonstrated to be a powerful tool in identifying a selection of 
genes that respond to APAP treatment. This type of statistical approach of linking 
expression data with pathology was critical for extracting biological meaningful data with 
confidence.  
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The gene signature itself provides little information for understanding the 
underlying mechanism of toxicity or disease. Linking differentially expressed genes with 
phenotypic markers of toxicity is required to understand how sets of genes and their 
products work together in generating adverse health outcomes. Moreover, expression 
changes are dynamic and subject to reversible temporal changes that can be displaced 
in time relative to toxicity. This is further complicated when only a subpopulation of the 
treatment group experiences the toxic effect, as in the case of carcinogenesis. The 
interpretation of toxicogenomic data will continue to be a difficult task but when put in 
context with phenotypic endpoints of toxicity can facilitate the development of potential 
biomarkers of exposure and effect, elucidate molecular mechanisms, and classify new 
chemical entities. 
 
C. Future Directions 
Toxicogenomics continues to evolve especially as advances are made in the 
fields of bioinformatics and computational biology which develop the powerful tools 
required to integrate disparate data sets across time, dose, and phenotypic markers. 
Such methods are now making it possible to provide a systematic evaluation of the 
effects of variant genetic sequences on responses to toxicants. Genetic linkage and 
association studies between individuals with and without disease has been used to 
identify a number of disease susceptibility genes (222, 223), as well as polymorphisms 
that determine individual diversity in drug responses (224). Toxicologists are now 
realizing the potential of genetically controlled inbred mouse populations as a surrogate 
for studying genetic variation in the human population. It is anticipated that the results 
from toxicogenetic studies involving chemical exposures to large panels of inbred mouse 
strains will identify polymorphisms responsible for sensitivity to toxicity to particular 
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agents and identification of chemical-induced genetic changes associated with particular 
diseases (205).  
 
D. Summary 
In summary, toxicogenomics moves the field of toxicology beyond traditional 
approaches by linking the critical molecular events caused by exposure to environmental 
factors with the sequelae of events leading to toxicity. This mechanistic information for 
toxicant action is crucial for understanding adverse health effects in humans and for 
making more informed regulatory decisions regarding exposure levels. This field is 
rapidly maturing as regulatory agencies such as Food and Drug Administration (FDA) 
and Environmental Protection Agency (EPA) are now encouraging the submission of 
complementary toxicogenomic data (8). Nevertheless, there is still considerable unease 
with some stakeholders on the use of toxicogenomic data in risk assessment and will 
bring forth continued scrutiny on the interpretation and incorporation of toxicogenomic 
data sets into regulatory decision making (8). One thing we can be confident about is 
that the tools of the genomic era are here to stay.  
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APPENDIX 1 
 
Gene lists of cellular pathways evoked by choline deficiency in rat liver 
Data mining using Gene Ontology (GO) from NetAffx Analysis Center was used to assign 
functional classes to each gene to determine the cellular and molecular pathways. To 
determine whether molecular profiling would model the temporal changes in histopathology 
observed with choline deficiency, genes with a functional assignment associated with lipid 
biosynthesis or metabolism, apoptosis, cell proliferation, and tissue remodeling were 
compiled into a single non-redundant list.  Supervised hierarchical clustering was conducted 
to view temporal changes in expression of genes associated with abovementioned biological 
processes (see Figure 3.4). Average gene expression ratios (log2-transformed) between 
choline deficient (CD) and choline sufficient (CS) for each corresponding time point and 
tumors are shown. 
 
   Log Ratio (CD/CS) 
Unigene ID Gene Symbol Description 4 wks 12 wks 80 wks Tumors 
Lipid Biosynthesis & Metabolism 
Rn.2854 Decr1 2,4-Dienoyl Coa Reductase 1, Mitochondrial -0.05 -0.20 -0.27 -0.87 
Rn.7879 Decr2 2-4-Dienoyl-Coenzyme A Reductase 2, Peroxisomal -0.58 -0.34 -0.59 -1.11 
Rn.29594 Hmgcs2 3-Hydroxy-3-Methylglutaryl-Coenzyme A Synthase 2 -0.25 -0.22 -0.18 -0.66 
Rn.9215 Aacs Acetoacetyl-Coa Synthetase -0.06 -0.24 0.04 0.53 
Rn.56980 Slc33a1 Acetyl-Coa Transporter 0.13 -0.32 -0.06 -0.33 
Rn.4054 Acat1 Acetyl-Coenzyme A Acetyltransferase 1 -0.03 -0.09 0.17 -0.40 
Rn.3786 Acaa2 Acetyl-Coenzyme A Acyltransferase 2 (Mitochondrial 3-Oxoacyl-Coenzyme A Thiolase) 0.14 0.39 0.00 -0.57 
Rn.44372 Acac Acetyl-Coenzyme A Carboxylase -0.86 -1.58 0.17 0.12 
Rn.44372 Acac Acetyl-Coenzyme A Carboxylase -0.77 -2.00 -0.39 -0.32 
Rn.44359 Acacb Acetyl-Coenzyme A Carboxylase Beta -0.48 -0.46 -0.05 -0.40 
Rn.6302 Acadm Acetyl-Coenzyme A Dehydrogenase, Medium Chain 0.22 0.17 -0.72 -0.36 
Rn.6215 Acsl1 Acyl-Coa Synthetase Long-Chain Family Member 1 -0.60 -0.46 -0.64 -0.77 
Rn.6215 Acsl1 Acyl-Coa Synthetase Long-Chain Family Member 1 -0.80 -0.74 -0.79 -1.00 
Rn.54820 Acsl3 Acyl-Coa Synthetase Long-Chain Family Member 3 1.12 1.95 0.18 1.24 
Rn.33697 Acsl6 Acyl-Coa Synthetase Long-Chain Family Member 6 -0.02 -0.30 -0.30 -0.02 
Rn.13649 Acad9 Acyl-Coenzyme A Dehydrogenase Family, Member 9 0.01 0.06 -0.16 -0.29 
Rn.31796 Acox1 Acyl-Coenzyme A Oxidase 1, Palmitoyl 0.11 -0.02 -0.25 -0.21 
Rn.10622 Acox2 Acyl-Coenzyme A Oxidase 2, Branched Chain -1.13 -0.94 -1.12 -0.40 
Rn.10546 Acox3 Acyl-Coenzyme A Oxidase 3, Pristanoyl -0.47 -0.79 -0.49 -0.64 
Rn.104556 LOC289036 Adiponectin Receptor 1 -0.20 0.25 -0.61 -0.45 
Rn.101807 LOC312670 Adiponectin Receptor 2 -0.46 -0.25 -0.20 -0.26 
Rn.101967 ADRP Adipose Differentiation-Related Protein 0.23 0.64 -1.42 -1.36 
Rn.101967 ADRP Adipose Differentiation-Related Protein -0.03 0.18 -0.24 -0.62 
Rn.10308 Apoa1 Apolipoprotein A-I 0.60 1.03 0.51 0.58 
Rn.89304 Apoa2 Apolipoprotein A-Ii -0.39 -0.35 -1.16 -1.25 
Rn.15739 Apoa4 Apolipoprotein A-Iv -1.46 -2.82 -0.47 -0.29 
Rn.48763 Apoa5 Apolipoprotein A-V -0.27 -0.55 -0.52 -0.44 
Rn.8887 Apoc1 Apolipoprotein C-I -0.45 -0.38 -0.54 -0.33 
Rn.262 Apom Apolipoprotein M -0.66 -0.93 -0.97 -0.36 
Rn.11318 Alox15 Arachidonate 12-Lipoxygenase -0.36 -0.30 0.08 -0.07 
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   Log Ratio (CD/CS) 
Unigene ID Gene Symbol Description 4 wks 12 wks 80 wks Tumors 
Rn.9662 Alox5 Arachidonate 5-Lipoxygenase -0.12 -0.23 -0.30 -0.25 
Rn.2184 Cyp2c23 Arachidonic Acid Epoxygenase -1.26 -0.88 -0.78 -0.42 
Rn.29771 Acly Atp Citrate Lyase -1.05 -1.37 -0.28 -0.57 
Rn.7024 Abcd3 Atp-Binding Cassette, Sub-Family D (Ald), Member 3 -0.49 0.56 -0.28 0.38 
Rn.8398 Abcg1 Atp-Binding Cassette, Sub-Family G (White), Member 1 1.26 1.10 0.67 0.23 
Rn.74258 Abcg5 Atp-Binding Cassette, Sub-Family G (White), Member 5 (Sterolin 1) -0.05 0.03 -0.29 0.92 
Rn.4896 Crot Carnitine O-Octanoyltransferase 0.15 0.19 -0.90 -1.50 
Rn.4896 Crot Carnitine O-Octanoyltransferase 0.03 -0.30 -1.11 -2.75 
Rn.2856 Cpt1a Carnitine Palmitoyltransferase 1, Liver 0.34 0.25 0.03 0.47 
Rn.6028 Cpt1b Carnitine Palmitoyltransferase 1B 0.37 -0.09 -0.15 -0.04 
Rn.11326 Cte1 Cytosolic Acyl-Coa Thioesterase 1 3.12 3.89 2.13 0.99 
Rn.11208 Dgkz Diacylglycerol Kinase Zeta -0.20 0.28 0.26 0.30 
Rn.1840 Dgka Diacylglycerol Kinase, Alpha (80 Kda) -0.53 -0.24 0.12 -0.05 
Rn.11413 Dgkb Diacylglycerol Kinase, Beta -0.25 -0.25 -0.04 0.01 
Rn.3285 Dbi Diazepam Binding Inhibitor 0.02 -0.09 -1.21 -1.04 
Rn.6051 Dpep1 Dipeptidase 1 (Renal) 0.04 0.07 -0.13 -0.17 
Rn.80835 Dci Dodecenoyl-Coenzyme A Delta Isomerase 0.64 0.80 -0.61 -0.51 
Rn.80835 Dci Dodecenoyl-Coenzyme A Delta Isomerase 0.02 -0.24 -0.13 0.02 
Rn.6847 Echs1 Enoyl Coenzyme A Hydratase, Short Chain, 1, Mitochondrial -0.57 -0.69 -1.00 -0.53 
Rn.3671 Ehhadh Enoyl-Coenzyme A, Hydratase/3-Hydroxyacyl Coenzyme A Dehydrogenase 0.22 1.20 -0.61 -1.23 
Rn.3252 Fdft1 Farnesyl Diphosphate Farnesyl Transferase 1 -0.86 -0.39 0.01 -0.09 
Rn.89119 Faah Fatty Acid Amide Hydrolase -0.64 -0.63 -0.51 -0.07 
Rn.91358 Fabp2 Fatty Acid Binding Protein 2, Intestinal 1.74 1.81 0.83 0.25 
Rn.4258 Fabp4 Fatty Acid Binding Protein 4, Adipocyte 3.26 3.71 2.18 1.21 
Rn.10008 Fabp6 Fatty Acid Binding Protein 6, Ileal (Gastrotropin) -0.25 -0.36 -0.04 0.03 
Rn.28161 Fads1 Fatty Acid Desaturase 1 0.16 0.74 -0.51 -0.60 
Rn.32872 Fads2 Fatty Acid Desaturase 2 -0.11 0.30 -0.49 -0.94 
Rn.4243 rELO1 Fatty Acid Elongase 1 -0.78 -1.14 -1.39 -1.34 
Rn.46942 rELO2 Fatty Acid Elongase 2 -2.03 -1.24 0.66 -0.14 
Rn.5820 Grn Granulin 1.19 1.48 0.83 0.56 
Rn.11253 Hadhb 
Hydroxyacyl-Coenzyme A Dehydrogenase/3-Ketoacyl-
Coenzyme A Thiolase/Enoyl-Coenzyme A Hydratase 
(Trifunctional Protein), Beta Subunit 
0.27 0.14 0.15 -0.51 
Rn.2700 Hsd17b10 Hydroxysteroid (17-Beta) Dehydrogenase 10 -0.50 -0.40 -0.76 -0.28 
Rn.10515 Hsd17b2 Hydroxysteroid (17-Beta) Dehydrogenase 2 0.21 -1.03 0.72 -0.51 
Rn.10895 Hsd17b3 Hydroxysteroid (17-Beta) Dehydrogenase 3 -0.11 -0.31 -0.17 -0.29 
Rn.2082 Hsd17b4 Hydroxysteroid (17-Beta) Dehydrogenase 4 -0.13 -0.07 -0.39 -0.42 
Rn.7040 Hsd17b7 Hydroxysteroid (17-Beta) Dehydrogenase 7 -0.46 -0.48 -0.45 -0.21 
Rn.98478 Hsd17b8 Hydroxysteroid (17-Beta) Dehydrogenase 8 -0.52 -0.09 -0.27 0.04 
Rn.10857 Hsd17b9 Hydroxysteroid (17-Beta) Dehydrogenase 9 -0.56 -1.43 -1.44 -0.71 
Rn.10780 Idi1 Isopentenyl-Diphosphate Delta Isomerase 0.37 0.40 0.41 0.76 
Rn.92789 Hadhsc L-3-Hydroxyacyl-Coenzyme A Dehydrogenase, Short Chain 0.05 -0.22 -0.41 -0.67 
Rn.10481 Lcat Lecithin Cholesterol Acyltransferase -0.73 -0.45 -0.29 0.01 
Rn.38594 Ltc4s Leukotriene C4 Synthase 0.07 0.37 -0.95 -1.17 
Rn.48656 Lipa Lipase A, Lysosomal Acid 0.32 0.27 0.25 0.31 
Rn.1195 Lipc Lipase, Hepatic -0.55 -0.70 -0.74 -0.45 
Rn.1256 Lcn7 Lipocalin 7 -0.18 0.02 -0.05 -0.32 
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   Log Ratio (CD/CS) 
Unigene ID Gene Symbol Description 4 wks 12 wks 80 wks Tumors 
Rn.48863 Lbp Lipopolysaccharide Binding Protein 2.41 1.87 0.94 0.94 
Rn.3834 Lpl Lipoprotein Lipase 2.73 3.44 1.83 0.94 
Rn.48696 Lisch7 Liver-Specific Bhlh-Zip Transcription Factor 7 0.72 0.85 0.00 0.07 
Rn.26430 Lrp2 Low Density Lipoprotein Receptor-Related Protein 2 0.06 0.03 -0.06 0.94 
Rn.23204 Lrp3 Low Density Lipoprotein Receptor-Related Protein 3 -0.32 -0.48 -0.39 0.29 
Rn.21381 Lrp4 Low Density Lipoprotein Receptor-Related Protein 4 0.21 0.25 0.36 0.52 
Rn.10293 Lrpap1 Low Density Lipoprotein Receptor-Related Protein Associated Protein 1 0.17 -0.09 -0.32 -0.26 
Rn.10293 Lrpap1 Low Density Lipoprotein Receptor-Related Protein Associated Protein 1 -0.02 -0.29 0.03 -0.10 
Rn.10293 Lrpap1 Low Density Lipoprotein Receptor-Related Protein Associated Protein 1 -0.11 -0.21 -0.06 -0.52 
Rn.37524 Mte1 Mitochondrial Acyl-Coa Thioesterase 1 0.98 1.02 0.33 -0.53 
Rn.37524 Mte1 /// Cte1 Mitochondrial Acyl-Coa Thioesterase 1 /// Cytosolic Acyl-Coa Thioesterase 1 1.69 1.98 0.72 -0.35 
Rn.14519 Pex11a Peroxisomal Biogenesis Factor 11A 0.08 0.31 -0.48 -1.04 
Rn.14519 Pex11a Peroxisomal Biogenesis Factor 11A 0.11 -0.02 -0.23 -0.65 
Rn.29982 Pex12 Peroxisomal Biogenesis Factor 12 -0.36 -0.47 -0.19 -0.05 
Rn.7844 Pex14 Peroxisomal Biogenesis Factor 14 -0.22 -0.39 -0.23 -0.18 
Rn.11773 Pex3 Peroxisomal Biogenesis Factor 3 -0.25 -0.36 -0.23 -0.30 
Rn.17644 Pcscl Peroxisomal Ca-Dependent Solute Carrier-Like Protein -0.36 0.25 -1.49 0.71 
Rn.10292 Pxmp2 Peroxisomal Membrane Protein 2 -1.02 -0.96 -0.72 -0.84 
Rn.4065 Pxmp3 Peroxisomal Membrane Protein 3 0.09 0.03 -0.20 -0.26 
Rn.19267 Pecr Peroxisomal Trans-2-Enoyl-Coa Reductase -0.41 -0.70 -0.65 -0.36 
Rn.96181 Ppard Peroxisome Proliferator Activated Receptor Delta -0.22 -0.15 0.01 -0.16 
Rn.19436 Ebp Phenylalkylamine Ca2+ Antagonist (Emopamil) Binding Protein -1.17 -0.59 -0.66 0.40 
Rn.22158 Pten Phosphatase And Tensin Homolog -0.02 0.12 -0.28 -0.01 
Rn.61687 Ppap2a Phosphatidate Phosphohydrolase Type 2A -0.43 0.14 -0.35 -0.46 
Rn.3301 Ppap2c Phosphatidic Acid Phosphatase Type 2C 0.12 0.27 0.02 0.26 
Rn.23872 Pib5pa Phosphatidylinositol (4,5) Bisphosphate 5-Phosphatase, A 0.16 -0.05 0.05 0.01 
Rn.44448 Pik3r3 Phosphatidylinositol 3-Kinase P55 Subunit 0.06 -0.08 0.08 -0.01 
Rn.11015 Pik4ca Phosphatidylinositol 4-Kinase, Catalytic, Alpha Polypeptide 0.00 0.31 -0.10 -0.20 
Rn.51538 Pigm Phosphatidylinositol Glycan, Class M 0.13 0.05 -0.03 0.01 
Rn.59136 Pigs Phosphatidylinositol Glycan, Class S -0.12 0.04 -0.08 -0.01 
Rn.9771 Pitpn Phosphatidylinositol Transfer Protein 0.03 0.22 -0.42 -0.50 
Rn.2399 Pitpnb Phosphatidylinositol Transfer Protein, Beta 0.45 0.16 0.08 0.20 
Rn.30025 Pip5k2b Phosphatidylinositol-4-Phosphate 5-Kinase, Type Ii, Beta 0.06 -0.08 -0.02 0.00 
Rn.94783 Pip5k2c Phosphatidylinositol-4-Phosphate 5-Kinase, Type Ii, Gamma -0.27 0.10 0.04 0.30 
Rn.10696 Pspla1 Phosphatidylserine-Specific Phospholipase A1 0.00 0.47 -0.26 -0.88 
Rn.37733 Pde4b Phosphodiesterase 4B 0.02 0.10 -0.47 0.43 
Rn.915 Pgd Phosphogluconate Dehydrogenase -1.09 0.09 0.25 -0.03 
Rn.9738 Pgam2 Phosphoglycerate Mutase 2 0.14 -0.08 0.14 0.04 
Rn.46424 Pla2g2c Phospholipase A2, Group 2C -0.18 -0.37 -0.07 -0.11 
Rn.11346 Pla2g2a Phospholipase A2, Group Iia (Platelets, Synovial Fluid) -0.34 -0.62 -0.07 -0.38 
Rn.10162 Pla2g4a Phospholipase A2, Group Iva (Cytosolic, Calcium-Dependent) 1.05 1.81 0.51 0.18 
Rn.20244 Pla2g5 Phospholipase A2, Group V -0.19 -0.34 -0.12 0.11 
Rn.44692 Pla2g6 Phospholipase A2, Group Vi -0.06 -0.03 0.28 0.41 
Rn.6828 Pla2g10 Phospholipase A2, Group X 0.00 -0.37 -0.24 -0.29 
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Rn.45523 Plcb1 Phospholipase C, Beta 1 0.45 -0.28 0.41 0.35 
Rn.64650 Plce1 Phospholipase C, Epsilon 1 -0.11 0.32 -0.63 -0.70 
Rn.11243 Plcg1 Phospholipase C, Gamma 1 -0.01 0.04 0.21 0.35 
Rn.44484 Pter Phosphotriesterase Related 0.27 0.29 -0.55 1.40 
Rn.7279 Phyh Phytanoyl-Coa Hydroxylase (Refsum Disease) -0.19 -0.40 -0.59 0.54 
Rn.24751 Pafah1b2 Platelet-Activating Factor Acetylhydrolase Alpha 2 Subunit (Paf-Ah Alpha 2) 0.19 -0.07 -0.22 -0.37 
Rn.17971 Pafah1b3 Platelet-Activating Factor Acetylhydrolase, Isoform 1B, Alpha1 Subunit 0.19 0.44 0.25 0.48 
Rn.48685 Ptgdr2 Prostaglandin D2 Receptor 0.06 -0.15 -0.07 0.06 
Rn.11400 Ptgds Prostaglandin D2 Synthase -0.15 -0.07 0.45 0.21 
Rn.7730 Ptges Prostaglandin E Synthase 0.06 -0.23 0.40 0.08 
Rn.6332 Ptgfrn Prostaglandin F2 Receptor Negative Regulator 0.05 0.34 -0.95 -1.22 
Rn.73051 Ptgis Prostaglandin I2 (Prostacyclin) Synthase 0.09 -0.06 0.04 -0.22 
Rn.44404 Ptgs1 Prostaglandin-Endoperoxide Synthase 1 -0.20 0.50 -0.78 -0.89 
Rn.64583 Prkaa2 Protein Kinase, Amp-Activated, Alpha 2 Catalytic Subunit -0.76 -0.83 -0.22 0.09 
Rn.3619 Prkab1 Protein Kinase, Amp-Activated, Beta 1 Non-Catalytic Subunit -0.61 -0.52 0.13 0.58 
Rn.48744 Prkab2 Protein Kinase, Amp-Activated, Beta 2 Non-Catalytic Subunit -0.10 -0.24 0.04 -0.04 
Rn.40816 Rxrg Retinoid X Receptor Gamma -0.45 -0.46 0.27 0.12 
Rn.22142 Rdh10 Retinol Dehydrogenase 10 (All-Trans) -0.01 -0.45 0.00 -0.24 
Rn.94108 RoDHII Retinol Dehydrogenase Type Ii (Rodh Ii) 1.00 0.03 -0.69 0.20 
Rn.46850 Sec14l2 Sec14-Like 2 (S. Cerevisiae) -0.53 -0.87 -0.54 -0.82 
Rn.1167 Acads Short Chain Acyl-Coenzyme A Dehydrogenase 0.01 -0.14 -0.20 0.09 
Rn.3289 Slc25a20 Solute Carrier Family 25 (Carnitine/Acylcarnitine Translocase), Member 20 -0.24 -0.15 -0.39 -0.46 
Rn.8368 Slc25a1 Solute Carrier Family 25, Member 1 -0.13 -0.22 -0.46 -0.35 
Rn.1047 Slc27a1 Solute Carrier Family 27 (Fatty Acid Transporter), Member 1 -0.14 0.07 -0.07 -0.10 
Rn.3608 Slc27a2 Solute Carrier Family 27 (Fatty Acid Transporter), Member 2 0.12 -0.06 -0.21 -0.20 
Rn.33239 Sqle Squalene Epoxidase 0.30 0.32 0.41 0.75 
Rn.1023 Scd1 Stearoyl-Coenzyme A Desaturase 1 -0.71 -1.29 -0.71 -0.57 
Rn.83595 Scd2 Stearoyl-Coenzyme A Desaturase 2 1.72 2.46 1.66 0.00 
Rn.4620 Srd5a1 Steroid 5 Alpha-Reductase 1 -2.06 -1.36 -0.65 -1.27 
Rn.2193 Ssg1 Steroid Sensitive Gene 1 1.02 2.23 0.13 -0.74 
Rn.6312 Sts Steroid Sulfatase -0.84 -0.94 -0.65 1.12 
Rn.11399 Star Steroidogenic Acute Regulatory Protein -0.06 -0.32 -0.05 -0.07 
Rn.31887 Scp2 Sterol Carrier Protein 2 -0.11 -0.32 -0.44 -0.27 
Rn.31887 Scp2 Sterol Carrier Protein 2 -0.09 -0.28 -0.57 -0.03 
Rn.95306 Srebf1 Sterol Regulatory Element Binding Factor 1 0.14 -0.64 -0.78 -0.73 
Rn.95306 Srebf1 Sterol Regulatory Element Binding Factor 1 0.07 -0.08 -0.44 -0.24 
Rn.41474 Sult4a1 Sulfotransferase Family 4A, Member 1 -0.49 -0.25 -0.34 -0.24 
Rn.16283 Tbxas1 Thromboxane A Synthase 1 0.33 0.31 0.05 -0.17 
Rn.9975 Vldlr Very Low Density Lipoprotein Receptor 0.66 0.49 0.92 0.33 
Rn.9975 Vldlr Very Low Density Lipoprotein Receptor 0.45 0.67 0.65 0.26 
Apoptosis 
Rn.2104 App amyloid beta (A4) precursor protein -0.09 -0.03 0.20 -0.10 
Rn.64522 Apaf1 apoptotic protease activating factor 1 1.30 0.99 0.28 -0.34 
Rn.4279 Appbp1 APP-binding protein 1 -0.34 -0.29 0.08 -0.11 
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Rn.91239 Birc4 baculoviral IAP repeat-containing 4 0.41 0.54 0.10 0.98 
Rn.13007 Bcl10 B-cell CLL/lymphoma 10 0.49 0.81 0.68 0.23 
Rn.9996 Bcl2 B-cell leukemia/lymphoma 2 0.91 0.14 -0.65 -0.56 
Rn.27923 Btg2 B-cell translocation gene 2, anti-proliferative -0.17 -0.38 -0.06 0.04 
Rn.27923 Btg2 B-cell translocation gene 2, anti-proliferative 0.84 1.30 0.60 1.83 
Rn.8897 Btg3 B-cell translocation gene 3 -0.21 -0.22 0.03 0.02 
Rn.83607 Bmf Bcl2 modifying factor -0.17 -0.27 -0.05 -0.28 
Rn.2060 Bnip3 BCL2/adenovirus E1B 19 kDa-interacting protein 3 0.04 -0.06 -0.33 -0.18 
Rn.827 Bnip3l BCL2/adenovirus E1B 19 kDa-interacting protein 3-like -0.04 -0.14 0.14 -0.16 
Rn.14598 Bak1 BCL2-antagonist/killer 1 0.62 0.57 0.07 -0.01 
Rn.10323 Bcl2l1 Bcl2-like 1 0.52 0.17 0.34 0.22 
Rn.10323 Bcl2l1 Bcl2-like 1 -0.15 -0.19 -0.10 -0.10 
Rn.44267 Bcl2l2 Bcl2-like 2 0.50 0.91 0.64 0.47 
Rn.44461 Bok Bcl-2-related ovarian killer protein 0.42 0.35 -0.04 -0.23 
Rn.44461 Bok Bcl-2-related ovarian killer protein 0.06 -0.05 -0.25 -0.17 
Rn.19770 Bcl2a1 BCL2-related protein A1 0.26 -0.25 -0.18 -0.57 
Rn.10119 Galgt1 beta-4N-acetylgalactosaminyltransferase 0.54 -0.23 -0.43 -0.67 
Rn.89639 Bid3 BH3 interacting (with BCL2 family) domain, apoptosis agonist -0.08 -0.21 -0.07 -0.18 
Rn.108186 Btbd14b BTB (POZ) domain containing 14B 0.31 -0.01 -0.35 -0.50 
Rn.28010 Cflar CASP8 and FADD-like apoptosis regulator 0.57 -0.06 0.28 0.44 
Rn.37508 Casp1 caspase 1 1.55 1.79 0.89 0.20 
Rn.81078 Casp12 caspase 12 0.52 1.06 0.35 0.17 
Rn.1438 Casp2 caspase 2 0.65 0.72 0.18 -0.02 
Rn.10562 Casp3 caspase 3 1.42 1.09 0.34 1.77 
Rn.10562 Casp3 caspase 3 1.69 1.39 0.52 1.99 
Rn.88160 Casp6 caspase 6 1.00 0.66 0.58 1.07 
Rn.32199 Casp9 caspase 9 -0.67 -0.50 -0.76 -0.79 
Rn.32199 Casp9 caspase 9 -0.12 -0.53 0.71 0.46 
Rn.53995 Casp7 caspase-7 0.31 0.29 0.17 0.21 
Rn.6479 Cebpb CCAAT/enhancer binding protein (C/EBP), beta -0.18 -0.26 0.12 0.35 
Rn.60353 Dapkl Death-associated like kinase 1.04 0.68 0.19 -0.29 
Rn.1531 Dap death-associated protein -0.03 0.08 -0.02 0.41 
Rn.7262 Dad1 defender against cell death 1 0.06 0.35 -0.20 -1.02 
Rn.67077 Dffb DNA fragmentation factor, 40 kD, beta polypeptide (caspase-activated DNase) -0.06 0.13 -0.31 0.00 
Rn.48799 Dffa DNA fragmentation factor, alpha subunit -0.40 0.08 -0.17 -0.12 
Rn.45601 Edg8 endothelial differentiation, sphingolipid G-protein-coupled receptor, 8 0.46 1.18 0.73 -0.64 
Rn.22800 Faim Fas apoptotic inhibitory molecule 0.96 0.47 -0.03 -0.49 
Rn.59459 Gnrh1 gonadotropin-releasing hormone 1 1.07 0.90 0.81 0.26 
Rn.64578 Birc3 inhibitor of apoptosis protein 1 0.80 0.19 0.50 -0.17 
Rn.9911 Mapk10 mitogen activated protein kinase 10 0.48 -0.53 0.85 0.40 
Rn.44266 Mapk8ip mitogen activated protein kinase 8 interacting protein 0.07 0.07 -0.02 -0.16 
Rn.11081 Map3k1 mitogen activated protein kinase kinase kinase 1 0.64 0.33 0.23 0.30 
Rn.4158 Asah N-acylsphingosine amidohydrolase (acid ceramidase) -0.07 -0.03 -0.22 -0.14 
Rn.4158 Asah N-acylsphingosine amidohydrolase (acid ceramidase) 1.38 0.82 0.65 0.44 
Rn.127149 Asah2 N-acylsphingosine amidohydrolase 2 0.91 0.98 1.30 1.44 
Rn.3126 Ngfrap1 nerve growth factor receptor associated protein 1 0.33 0.28 0.00 0.10 
Rn.18572 Smpd2 neutral sphingomyelinase 0.19 -0.18 -0.12 -0.16 
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Rn.32919 Nsmaf neutral sphingomyelinase (N-SMase) activation associated factor 0.34 0.18 0.31 0.40 
Rn.2411 Nfkb1 Nuclear factor kappa B p105 subunit -0.26 -0.32 -0.03 -0.13 
Rn.40242 LOC246143 p75-like apoptosis-inducing death domain protein PLAIDD 0.02 0.41 0.24 -0.02 
Rn.40242 LOC246143 p75-like apoptosis-inducing death domain protein PLAIDD 0.37 0.49 0.14 -0.09 
Rn.6959 Pdcd2 Programmed cell death 2 0.12 0.28 0.24 0.36 
Rn.90142 Pdcd4 programmed cell death 4 0.80 0.91 0.28 -0.17 
Rn.8124 Pdcd8 programmed cell death 8 (apoptosis-inducing factor) -0.41 0.06 -0.50 -0.32 
Rn.98279 Prkcd protein kinase C, delta -0.10 -0.18 -0.16 -0.06 
Rn.1495 Ppp1cc protein phosphatase 1, catalytic subunit, gamma isoform -0.22 -0.19 -0.03 -0.10 
Rn.73852 Ppp1r14a protein phosphatase 1, regulatory (inhibitor) subunit 14A 1.44 1.91 0.87 1.64 
Rn.2773 Ppp1r14b protein phosphatase 1, regulatory (inhibitor) subunit 14B -0.01 -0.13 -0.17 0.02 
Rn.87667 Ppp1r14c protein phosphatase 1, regulatory (inhibitor) subunit 14c 0.02 -0.21 -0.15 -0.11 
Rn.8898 Ppp2r2d protein phosphatase 2, regulatory subunit B, delta isoform -0.26 -0.23 -0.28 -0.10 
Rn.817 Ptma prothymosin alpha 0.63 0.68 0.59 0.56 
Rn.91176 P2rx1 purinergic receptor P2X, ligand-gated ion channel, 1 0.29 0.35 0.15 0.12 
Rn.92406 Smp2a rat senescence marker protein 2A gene, exons 1 and 2 -0.07 0.12 -0.29 -0.03 
Rn.91057 Rara retinoic acid receptor, alpha 0.77 0.99 0.65 0.76 
Rn.1300 Stk17b serine/threonine kinase 17b (apoptosis-inducing) -0.02 -0.04 0.00 -0.06 
Rn.107226 Sh3kbp1 SH3-domain kinase binding protein 1 -0.08 -0.24 0.16 -0.10 
Rn.22706 Siat9 sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 synthase) -0.12 -0.21 -0.07 -0.04 
Rn.18522 Sphk1 sphingosine kinase 1 -0.03 -0.12 -0.09 -0.10 
Rn.2398 Tieg TGFB inducible early growth response -0.07 -0.40 -0.18 -0.05 
Rn.10 Tgm2 tissue-type transglutaminase 0.99 1.16 0.97 0.36 
Rn.10 Tgm2 tissue-type transglutaminase 0.01 0.05 -0.04 -0.08 
Rn.9792 Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) 0.07 0.16 -0.04 0.25 
Rn.11119 Tnfrsf1a tumor necrosis factor receptor superfamily, member 1a 0.02 0.33 0.13 0.25 
Rn.54443 Tp53 tumor protein p53 0.80 1.05 0.93 0.73 
Rn.24091 Ugcg UDP-glucose ceramide glucosyltransferase 0.56 0.28 0.36 0.23 
Rn.9744 Ugt8 UDP-glucuronosyltransferase 8 0.57 0.38 0.33 0.34 
Rn.9744 Ugt8 UDP-glucuronosyltransferase 8 0.89 0.44 0.45 0.63 
Rn.88756 Ets1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) -0.32 -0.08 0.22 0.29 
Proliferation 
Rn.11204 Bmyc Avian Myelocytomatosis Viral (V-Myc) Related Oncogene 0.50 0.65 0.34 0.58 
Rn.103225 Brca2 Breast Cancer 2 0.98 1.16 0.62 0.45 
Rn.1303 Cdh1 Cadherin 1 0.30 0.13 0.14 0.30 
Rn.8046 Csnk1d Casein Kinase 1, Delta 1.17 1.13 0.07 0.30 
Rn.12365 Csnk1e Casein Kinase 1, Epsilon 1.02 0.82 0.16 0.39 
Rn.11380 Hsd3b7 Cca2 Protein 0.21 1.61 0.26 -0.24 
Rn.64487 Arhgef9 Cdc42 Guanine Nucleotide Exchange Factor (Gef) 9 0.34 0.60 0.17 0.08 
Rn.105815 Cdc42bpb Cdc42-Binding Protein Kinase Beta 0.71 1.27 0.76 1.30 
Rn.7070 --- Cdk104 Mrna 1.35 2.22 1.07 1.67 
Rn.15195 Cdk105 Cdk105 Protein 1.72 2.61 1.49 2.00 
Rn.25368 Cdk5rap2 Cdk5 Activator-Binding Protein 0.46 0.11 0.33 0.28 
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Rn.9262 Cdc20 Cell Cycle Protein P55Cdc 0.34 0.55 0.31 0.04 
Rn.9262 Cdc20 Cell Cycle Protein P55Cdc -0.06 -0.23 -0.11 -0.13 
Rn.6934 Cdc2a Cell Division Cycle 2 Homolog A (S. Pombe) 0.09 -0.04 -0.17 0.02 
Rn.54977 Cdc5l Cell Division Cycle 5-Like (S. Pombe) 1.36 1.39 0.65 0.11 
Rn.31842 Cgref1 Cell Growth Regulator With Ef Hand Domain 1 0.17 0.26 0.51 0.56 
Rn.87514 Cgrrf1 Cell Growth Regulator With Ring Finger Domain 1 -0.13 0.20 -0.09 -0.19 
Rn.9232 Ccnb1 Cyclin B1 0.74 0.95 0.45 0.54 
Rn.9232 Ccnb1 Cyclin B1 0.44 0.41 0.07 0.20 
Rn.106758 Ccnc Cyclin C -0.04 0.21 -0.04 0.38 
Rn.22279 Ccnd1 Cyclin D1 0.16 0.44 0.40 0.72 
Rn.22279 Ccnd1 Cyclin D1 0.21 0.32 -0.17 1.22 
Rn.22279 Ccnd1 Cyclin D1 0.07 -0.14 -0.18 -0.14 
Rn.96083 Ccnd2 Cyclin D2 0.21 0.26 0.10 0.25 
Rn.3483 Ccnd3 Cyclin D3 0.95 0.34 -0.50 -0.15 
Rn.11012 Gak Cyclin G Associated Kinase 0.12 0.32 -0.38 -0.66 
Rn.5834 Ccng1 Cyclin G1 0.02 -0.11 0.17 -0.04 
Rn.6115 Cdk4 Cyclin-Dependent Kinase 4 0.22 0.51 0.32 0.32 
Rn.10089 Cdkn1a Cyclin-Dependent Kinase Inhibitor 1A -0.31 -0.18 0.15 0.42 
Rn.29897 Cdkn1b Cyclin-Dependent Kinase Inhibitor 1B -0.14 0.01 -0.06 -0.25 
Rn.29897 Cdkn1b Cyclin-Dependent Kinase Inhibitor 1B 0.39 0.33 0.67 0.45 
Rn.92509 Cdkn1c Cyclin-Dependent Kinase Inhibitor 1C, P57 0.15 0.26 0.08 0.15 
Rn.105626 Cdkn2b Cyclin-Dependent Kinase Inhibitor 2B (P15, Inhibits Cdk4) -0.11 0.23 0.38 0.11 
Rn.63865 Cdkn2c Cyclin-Dependent Kinase Inhibitor 2C (P18, Inhibits Cdk4) 0.56 0.48 0.60 0.57 
Rn.11274 Dbp D Site Albumin Promoter Binding Protein 0.14 0.03 0.00 -0.32 
Rn.27546 Dek Dek Oncogene (Dna Binding) -0.14 -0.11 0.11 0.18 
Rn.20467 Lig1 Dna Ligase I -0.20 -0.37 0.06 -0.15 
Rn.88690 Pold1 Dna Polymerase Delta, Catalytic Subunit 0.06 0.40 0.39 0.53 
Rn.92497 Prim1 Dna Primase, P49 Subunit 0.09 0.17 0.18 0.33 
Rn.11027 Dnch1 Dynein, Cytoplasmic, Heavy Chain 1 1.56 1.02 0.47 0.59 
Rn.44896 Dnch2 Dynein, Cytoplasmic, Heavy Polypeptide 2 1.86 0.76 0.43 0.27 
Rn.11273 Dncic1 Dynein, Cytoplasmic, Intermediate Chain 1 2.48 1.55 0.42 0.46 
Rn.35769 Pin Dynein, Cytoplasmic, Light Chain 1 -1.50 -0.14 -0.88 -0.94 
Rn.2064 Dncli1 Dynein, Cytoplasmic, Light Intermediate Chain 1 0.48 0.48 0.19 0.32 
Rn.4223 Dkc1 Dyskeratosis Congenita 1, Dyskerin -0.04 0.11 0.07 0.04 
Rn.52317 E2f5 E2F Transcription Factor 5 0.02 0.00 0.12 0.31 
Rn.37227 Egfr Epidermal Growth Factor Receptor -0.16 -0.12 -0.20 -0.38 
Rn.42897 Ereg Epiregulin 0.11 0.74 1.39 0.63 
Rn.36412 Fabp1 Fatty Acid Binding Protein 1, Liver 0.30 0.46 -0.05 0.06 
Rn.1699 Fbln5 Fibulin 5 0.17 0.16 0.25 0.09 
Rn.11008 Frap1 Fk506 Binding Protein 12-Rapamycin Associated Protein 1 -0.16 0.06 -0.14 0.24 
Rn.22304 Bat3 Hla-B-Associated Transcript 3 -0.22 -0.18 -0.01 0.11 
Rn.22304 Bat3 Hla-B-Associated Transcript 3 0.48 -0.16 0.08 -0.02 
Rn.964 Igf2 Insulin-Like Growth Factor 2 0.10 0.10 0.27 0.16 
Rn.34026 Igfbp1 Insulin-Like Growth Factor Binding Protein 1 -0.12 -0.20 0.00 -0.08 
Rn.26369 Igfbp3 Insulin-Like Growth Factor Binding Protein 3 0.04 -0.25 0.01 0.09 
Rn.1593 Igfbp5 Insulin-Like Growth Factor Binding Protein 5 0.31 0.27 0.01 0.17 
Rn.6446 Ilkap Integrin-Linked Kinase-Associated Serine/Threonine 1.94 1.55 0.59 0.80 
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Phosphatase 2C 
Rn.7990 LOC246046 Liver Regeneration P-53 Related Protein 0.41 0.21 0.26 0.40 
Rn.7990 LOC246046 Liver Regeneration P-53 Related Protein 0.66 0.74 0.53 0.48 
Rn.4338 Lyn Lyn Protein Non-Receptor Kinase 0.30 0.13 0.09 0.27 
Rn.81062 Mcf2l Mcf.2 Cell Line Derived Transforming Sequence-Like 0.31 -0.13 -0.08 0.66 
Rn.5850 Map2k1 Mitogen Activated Protein Kinase Kinase 1 0.33 0.42 0.05 0.20 
Rn.82693 Map2k2 Mitogen Activated Protein Kinase Kinase 2 -0.13 -0.26 -0.06 -0.08 
Rn.40328 Map3k12 Mitogen Activated Protein Kinase Kinase Kinase 12 0.68 0.38 0.13 0.44 
Rn.42944 Mapk12 Mitogen-Activated Protein Kinase 12 0.81 0.47 0.65 0.37 
Rn.33262 Raf1 Murine Leukemia Viral (V-Raf-1) Oncogene Homolog 1 (3611-Msv) -0.18 -0.20 -0.08 -0.27 
Rn.88821 Fbxo2 Neural F Box Protein Nfb42 0.25 0.45 0.37 0.25 
Rn.4073 Nbl1 Neuroblastoma, Suppression Of Tumorigenicity 1 0.52 0.60 1.72 0.92 
Rn.8395 Nfkbib Nuclear Factor Of Kappa Light Chain Gene Enhancer In B-Cells Inhibitor, Beta 0.56 0.53 0.76 0.46 
Rn.66392 Numa1 Nuclear Mitotic Apparatus Protein 1 0.56 0.53 0.76 0.46 
Rn.4110 Ns Nucleostemin -0.05 -0.19 -0.17 -0.18 
Rn.25935 Per2 Period Homolog 2 (Drosophila) -0.19 -0.42 -0.07 2.20 
Rn.1476 Pmp22 Peripheral Myelin Protein 22 0.07 -0.17 -0.02 -0.37 
Rn.10999 Pdgfa Platelet Derived Growth Factor, Alpha 0.43 0.74 0.18 0.20 
Rn.64626 Pdgfc Platelet-Derived Growth Factor, C Polypeptide 0.47 0.92 0.26 0.05 
Rn.9346 Polb Polymerase (Dna Directed), Beta 0.13 -0.03 0.81 0.77 
Rn.40977 Pole Polymerase (Dna Directed), Epsilon 0.17 0.05 -0.16 0.24 
Rn.19327 Polg Polymerase (Dna Directed), Gamma 0.00 0.24 0.32 0.34 
Rn.106248 Polr2g Polymerase (Rna) Ii (Dna Directed) Polypeptide G 0.05 -0.43 0.01 0.03 
Rn.28212 Polr2f Polymerase Ii -0.23 -0.41 -0.52 -0.01 
Rn.48808 Porf1 Preoptic Regulatory Factor-1 -0.20 -0.56 -0.62 -0.15 
Rn.82757 Prok1 Prokineticin 1 Precursor -0.07 0.06 0.08 0.60 
Rn.223 Pcna Proliferating Cell Nuclear Antigen -0.02 0.95 2.18 2.16 
Rn.20465 PAL31 Proliferation Related Acidic Leucine Rich Protein Pal31 0.45 1.20 0.27 0.40 
Rn.20465 PAL31 Proliferation Related Acidic Leucine Rich Protein Pal31 0.38 0.27 0.25 0.26 
Rn.12281 Prkcdbp Protein Kinase C, Delta Binding Protein 0.03 -0.24 -0.03 -0.03 
Rn.2024 Ppp1ca Protein Phosphatase 1, Catalytic Subunit, Alpha Isoform -0.17 -0.45 -0.17 -0.18 
Rn.34888 Pim1 Proviral Integration Site 1 0.21 0.36 0.25 0.45 
Rn.107698 Ran Ran, Member Ras Oncogene Family -0.27 0.20 0.19 0.42 
Rn.108215 Stk6 Serine/Threonine Kinase 6 0.28 0.18 -0.20 -0.21 
Rn.14527 Sycp2 Synaptonemal Complex Protein 2 -0.19 -0.26 -0.27 -0.43 
Rn.5890 Tep1 Telomerase Associated Protein 1 -0.44 -0.39 -0.18 -0.22 
Rn.10576 Thpo Thrombopoietin -0.34 -0.35 -0.25 -0.17 
Rn.90996 Top2a Topoisomerase (Dna) 2 Alpha -0.15 0.37 0.43 0.63 
Rn.90996 Top2a Topoisomerase (Dna) 2 Alpha 0.47 0.79 0.62 0.81 
Rn.91572 Top1 Topoisomerase (Dna) I 0.17 0.15 -0.07 0.10 
Rn.13425 Tm4sf4 Transmembrane 4 Superfamily Member 4 -0.04 -0.44 0.02 -0.01 
Rn.64517 Tnfsf11 Tumor Necrosis Factor (Ligand) Superfamily, Member 11 0.81 0.81 0.89 0.09 
Rn.30043 Tnfsf4 Tumor Necrosis Factor (Ligand) Superfamily, Member 4 -0.20 -0.44 -0.11 -0.22 
Rn.31075 --- Tumor Necrosis Factor Alpha-Induced Protein 1-Like Protein 0.23 0.40 0.22 0.44 
Rn.105040 Tnfrsf12a Tumor Necrosis Factor Receptor Superfamily, Member 12A 0.17 0.09 -0.18 0.14 
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Rn.36610 Tpt1 Tumor Protein, Translationally-Controlled 1 -0.26 -0.13 -0.01 -0.28 
Rn.2758 Txnip Upregulated By 1,25-Dihydroxyvitamin D-3 -0.29 0.04 0.20 -0.41 
Rn.93714 Jun V-Jun Sarcoma Virus 17 Oncogene Homolog (Avian) 0.35 0.08 -0.39 -0.40 
Rn.93714 Jun V-Jun Sarcoma Virus 17 Oncogene Homolog (Avian) -0.43 -0.17 -0.15 -0.23 
Rn.93714 Jun V-Jun Sarcoma Virus 17 Oncogene Homolog (Avian) -0.13 -0.02 0.21 0.46 
Rn.10725 Mafb V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Family, Protein B (Avian) 0.24 0.01 -0.02 -0.12 
Rn.3818 Mafk V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Family, Protein K (Avian) 0.38 0.18 -0.56 -0.32 
Rn.3193 Wfdc1 Wap Four-Disulfide Core Domain 1 0.35 0.23 -0.12 -0.46 
Rn.11908 Zrf2 Zuotin Related Factor 2 -0.13 -0.32 0.09 -0.02 
Tissue Remodeling 
Rn.54393 Adam23 A Disintegrin And Metalloprotease Domain 23 -0.05 -0.09 -0.13 -0.08 
Rn.42918 Adam3 A Disintegrin And Metalloprotease Domain 3 (Cyritestin) -0.34 -0.24 0.01 0.09 
Rn.10357 Adam7 A Disintegrin And Metalloprotease Domain 7 -0.24 -0.27 0.07 0.08 
Rn.42919 Adam1 A Disintegrin And Metalloproteinase Domain 1 (Fertilin Alpha) -0.09 -0.25 -0.04 -0.03 
Rn.98788 Adam15 A Disintegrin And Metalloproteinase Domain 15 (Metargidin) -0.14 0.18 0.22 0.02 
Rn.24102 Adam17 A Disintegrin And Metalloproteinase Domain 17 (Tumor Necrosis Factor, Alpha, Converting Enzyme) 0.53 0.56 0.10 0.15 
Rn.42923 Adam18 A Disintegrin And Metalloproteinase Domain 18 0.01 -0.41 -0.09 -0.03 
Rn.24189 Adam6 A Disintegrin And Metalloproteinase Domain 6 -0.12 -0.25 -0.23 -0.23 
Rn.25221 Adam9 A Disintegrin And Metalloproteinase Domain 9 (Meltrin Gamma) -0.16 -0.14 -0.16 -0.22 
Rn.2090 Arpc1b Actin Related Protein 2/3 Complex, Subunit 1B 1.25 1.68 0.91 0.34 
Rn.94978 Actb Actin, Beta 0.44 0.60 0.15 -0.13 
Rn.94978 Actb Actin, Beta 0.34 0.73 0.15 -0.51 
Rn.11353 Add2 Adducin 2 (Beta) -0.14 -0.19 -0.07 -0.08 
Rn.76589 Add3 Adducin 3 (Gamma) 0.03 0.21 0.23 0.03 
Rn.6993 Arf6 Adp-Ribosylation Factor 6 0.68 0.37 0.06 -0.08 
Rn.54503 Agc1 Aggrecan 1 -0.03 -0.52 0.04 0.05 
Rn.5812 Spna2 Alpha-Spectrin 2 -0.46 0.53 -0.36 -0.19 
Rn.11149 Abtb2 Ankyrin Repeat And Btb (Poz) Domain Containing 2 -0.18 -0.29 0.06 -0.14 
Rn.10624 Atp1b2 Atpase, Na+/K+ Transporting, Beta 2 Polypeptide -0.01 -0.20 -0.16 -0.08 
Rn.2269 Bsg Basigin 0.27 0.37 -0.17 -0.44 
Rn.48895 Bace Beta-Site App Cleaving Enzyme -0.08 -0.26 -0.13 -0.33 
Rn.783 Bgn Biglycan 1.24 1.80 0.43 -0.44 
Rn.40101 Bcar1 Breast Cancer Anti-Estrogen Resistance 1 -0.17 -0.13 -0.49 1.09 
Rn.10315 Bcan Brevican -0.18 -0.33 -0.09 -0.01 
Rn.76726 Cdh17 Cadherin 17 1.26 0.66 0.10 0.48 
Rn.10390 Cdh6 Cadherin 6 -0.05 -0.14 -0.15 -0.21 
Rn.6822 Capn2 Calpain 2 0.65 1.21 0.59 -0.28 
Rn.9726 Capn3 Calpain 3 -0.24 -0.32 0.03 -0.06 
Rn.3430 Capns1 Calpain, Small Subunit 1 0.39 0.46 -0.17 -0.33 
Rn.57635 Cnn3 Calponin 3, Acidic 0.65 1.17 0.22 -0.87 
Rn.112585 Cap1 Cap, Adenylate Cyclase-Associated Protein 1 (Yeast) 0.94 1.16 0.74 0.43 
Rn.10229 Cap2 Cap, Adenylate Cyclase-Associated Protein, 2 (Yeast) -0.12 -0.12 -0.02 -0.03 
Rn.42865 Capza3 Capping Protein (Actin Filament) Muscle Z-Line, Alpha 3 -0.32 -0.31 -0.04 0.02 
Rn.12572 Cpb2 Carboxypeptidase B2 (Plasma) -0.18 -0.36 -0.23 -0.39 
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Rn.41757 Cpn1 Carboxypeptidase N, Polypeptide 1, 50Kd 0.14 0.27 0.40 0.42 
Rn.11056 Cpz Carboxypeptidase Z 0.04 0.32 -0.06 -0.40 
Rn.10343 Comp Cartilage Oligomeric Matrix Protein -0.70 -0.34 0.01 -0.18 
Rn.107912 Ctsc Cathepsin C 0.20 -0.16 -0.25 -0.97 
Rn.11085 Ctsd Cathepsin D 0.80 0.96 0.33 0.06 
Rn.1997 Ctsh Cathepsin H -0.10 0.17 -0.29 -0.27 
Rn.1294 Ctsl Cathepsin L 0.35 0.63 0.49 0.60 
Rn.1294 Ctsl Cathepsin L 0.30 0.92 0.28 0.70 
Rn.98382 Ctsql2 Cathepsin Q-Like 2 0.04 -0.15 -0.18 -0.11 
Rn.1475 LOC252929 Cathepsin Y 0.83 0.97 1.24 0.12 
Rn.98191 Cav3 Caveolin 3 -0.10 -0.25 -0.24 -0.29 
Rn.60067 Cdc42 Cell Division Cycle 42 Homolog (S. Cerevisiae) 0.23 0.71 0.16 0.24 
Rn.60067 Cdc42 Cell Division Cycle 42 Homolog (S. Cerevisiae) 0.40 0.62 0.19 0.17 
Rn.63352 Ctrl Chymotrypsin-Like -0.09 -0.26 -0.01 0.03 
Rn.105845 Ctrb Chymotrypsinogen B -0.25 -0.20 -0.03 -0.13 
Rn.19943 Clasp2 Clip-Associating Protein 2 0.08 0.48 0.06 0.18 
Rn.1780 Clu Clusterin 0.88 0.62 -0.02 -0.43 
Rn.2953 COLIA1 Collagen, Type 1, Alpha 1 0.53 0.90 0.13 -0.06 
Rn.2953 COLIA1 Collagen, Type 1, Alpha 1 2.92 3.76 0.66 0.19 
Rn.3247 Col3a1 Collagen, Type Iii, Alpha 1 1.50 1.91 0.13 -0.12 
Rn.2875 Col5a2 Collagen, Type V, Alpha 2 0.45 0.62 0.18 0.25 
Rn.2819 Coro1b Coronin, Actin-Binding Protein, 1B -0.16 -0.53 -0.09 -0.02 
Rn.18514 Cst8 Cystatin 8 0.67 1.13 0.94 0.11 
Rn.106351 Cst3 Cystatin C -0.21 -0.13 -0.19 -0.24 
Rn.86411 LOC257643 Cystatin Sc -0.07 -0.08 -0.15 -0.06 
Rn.58124 LOC266776 Cystatin Te-1 0.27 0.65 -0.67 -1.07 
Rn.108075 Csrp1 Cysteine And Glycine-Rich Protein 1 0.65 0.64 0.45 0.26 
Rn.22129 Cyr61 Cysteine Rich Protein 61 -0.05 0.34 0.40 0.21 
Rn.9887 Krt21 Cytokeratin 21 1.40 2.55 0.87 -0.30 
Rn.106103 Dcn Decorin -0.01 -0.06 -0.50 -1.24 
Rn.91364 Dpp4 Dipeptidylpeptidase 4 -0.12 0.01 -0.29 -0.24 
Rn.91364 Dpp4 Dipeptidylpeptidase 4 -0.11 -0.37 -0.09 -0.16 
Rn.10076 Dpp6 Dipeptidylpeptidase 6 1.91 1.96 1.17 2.52 
Rn.3363 Dpp7 Dipeptidylpeptidase 7 0.12 0.36 0.49 0.27 
Rn.7807 Ddr1 Discoidin Domain Receptor Family, Member 1 -0.13 -0.22 -0.10 -0.26 
Rn.74705 Dcbld2 Discoidin, Cub And Lccl Domain Containing 2 0.33 0.28 0.25 0.05 
Rn.11247 Dbn1 Drebrin 1 0.39 0.49 0.12 0.05 
Rn.4115 Dbnl Drebrin-Like 0.45 0.65 0.04 0.18 
Rn.11284 Dctn1 Dynactin 1 -0.17 -0.19 -0.09 -0.28 
Rn.10307 Dmd Dystrophin 0.20 0.28 1.80 3.39 
Rn.6044 Ela1 Elastase 1, Pancreatic 0.25 0.42 0.22 0.21 
Rn.16221 Emb Embigin 1.42 1.51 -0.01 -1.64 
Rn.3603 Ephx1 Epoxide Hydrolase 1 -0.09 -0.30 0.03 0.81 
Rn.91373 Espn Espin 1.11 1.54 0.29 -0.05 
Rn.12759 Fbn1 Fibrillin-1 0.73 1.23 0.13 -0.17 
Rn.12759 Fbn1 Fibrillin-1 -0.26 -0.22 0.06 -0.11 
Rn.22906 Fbn2 Fibrillin-2 -0.14 -0.28 0.10 0.07 
Rn.82756 Fap Fibroblast Activation Protein 0.49 1.04 -0.06 -0.16 
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Rn.15709 Fgf13 Fibroblast Growth Factor 13 -0.12 -0.21 -0.03 0.03 
Rn.44476 Fgf14 Fibroblast Growth Factor 14 2.54 -0.60 3.26 2.45 
Rn.81231 Fgf21 Fibroblast Growth Factor 21 -0.27 -0.25 -0.05 -0.06 
Rn.81232 Fgf22 Fibroblast Growth Factor 22 -0.12 -0.25 -0.12 -0.13 
Rn.81229 Fgf23 Fibroblast Growth Factor 23 -0.23 -0.22 -0.09 -0.10 
Rn.81236 Fgf3 Fibroblast Growth Factor 3 -0.11 -0.55 0.22 0.02 
Rn.98842 Fgf7 Fibroblast Growth Factor 7 -0.15 -0.28 0.01 -0.12 
Rn.73565 Fgf8 Fibroblast Growth Factor 8 -0.17 -0.33 -0.06 -0.09 
Rn.25174 Fgf9 Fibroblast Growth Factor 9 -0.01 0.47 0.40 0.20 
Rn.9797 Fgfr1 Fibroblast Growth Factor Receptor 1 0.01 0.20 0.24 0.13 
Rn.9797 Fgfr1 Fibroblast Growth Factor Receptor 1 0.36 0.15 -0.13 -0.27 
Rn.12732 Fgfr2 Fibroblast Growth Factor Receptor 2 0.15 0.49 1.16 0.38 
Rn.23671 Fgfr3 Fibroblast Growth Factor Receptor 3 -0.31 -0.32 -0.24 -0.13 
Rn.89278 Folh1 Folate Hydrolase -1.09 -1.61 -0.96 -0.45 
Rn.20140 Ftcd Formiminotransferase Cyclodeaminase 0.23 0.28 -0.06 0.13 
Rn.8411 Gabarap Gamma-Aminobutyric Acid Receptor Associated Protein 0.29 -0.22 -0.40 -0.24 
Rn.1437 Gc Group Specific Component -0.35 -0.37 -0.45 -0.43 
Rn.11139 Hpn Hepsin -0.18 -0.24 -0.10 -0.08 
Rn.50531 Hapln1 Hyaluronan And Proteoglycan Link Protein 1 -0.33 -0.29 -0.12 -0.19 
Rn.76545 Hapln2 Hyaluronan And Proteoglycan Link Protein 2 -0.44 -0.60 -0.59 -1.04 
Rn.7327 Igfals Insulin-Like Growth Factor Binding Protein, Acid Labile Subunit -0.15 -0.26 -0.23 -0.34 
Rn.54492 Itga7 Integrin Alpha 7 -0.03 -0.41 -0.07 -0.33 
Rn.54492 Itga7 Integrin Alpha 7 -0.20 -0.11 0.03 -0.17 
Rn.54465 Itgam Integrin Alpha M 0.93 1.12 0.56 0.09 
Rn.25733 Itgb1 Integrin Beta 1 1.16 1.35 0.23 -0.49 
Rn.25733 Itgb1 Integrin Beta 1 0.00 0.78 0.24 0.18 
Rn.10727 Itgb4 Integrin Beta 4 -0.07 -0.18 -0.15 -0.06 
Rn.9721 Ibsp Integrin Binding Sialoprotein 0.83 0.59 -0.30 -1.00 
Rn.12 Icam1 Intercellular Adhesion Molecule 1 -0.02 -0.10 -0.16 -0.06 
Rn.64488 Impg1 Interphotoreceptor Matrix Proteoglycan 1 -0.31 -0.43 0.11 -0.20 
Rn.41153 Ka14 Keratin Complex 1, Acidic, Gene 14 -0.09 1.80 1.86 1.05 
Rn.9359 Krt1-19 Keratin Complex 1, Acidic, Gene 19 0.76 2.09 0.21 0.24 
Rn.11083 Krt2-8 Keratin Complex 2, Basic, Gene 8 -0.24 -0.46 -0.26 -0.43 
Rn.6526 Kif1b Kinesin Family Member 1B 0.67 1.01 -0.01 0.30 
Rn.89698 Kif1c Kinesin Family Member 1C 0.01 0.04 0.08 -0.20 
Rn.47400 Kif3a Kinesin Family Member 3A -0.06 -0.21 -0.20 -0.38 
Rn.10894 Kif3c Kinesin Family Member 3C -0.27 -0.26 0.12 -0.04 
Rn.41871 Klc3 Kinesin Light Chain 3 0.14 -0.02 0.32 0.21 
Rn.45205 Knsl7 Kinesin-Like 7 0.46 0.61 -0.09 0.16 
Rn.44161 Lmna Lamin A 0.72 1.16 0.02 0.24 
Rn.44161 Lmna Lamin A 0.01 -0.06 0.03 -0.06 
Rn.11362 Lmnb1 Lamin B1 0.20 -0.16 0.63 -0.07 
Rn.10597 Lama3 Laminin, Alpha 3 1.52 2.28 2.43 -0.08 
Rn.57 Lgals1 Lectin, Galactose Binding, Soluble 1 2.16 2.90 1.09 0.37 
Rn.764 Lgals3 Lectin, Galactose Binding, Soluble 3 0.06 -0.04 0.16 0.72 
Rn.64588 Lgals5 /// Lgals9 Lectin, Galactose Binding, Soluble 5 /// Lectin, Galactose Binding, Soluble 9 -0.09 -0.41 -0.26 -0.13 
Rn.6336 Lgals7 Lectin, Galactose Binding, Soluble 7 1.56 1.84 1.37 1.11 
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Rn.2982 Lgals2 Lectin, Galactoside-Binding, Soluble, 2 (Galectin 2) 1.35 2.10 1.23 0.40 
Rn.3251 Lgals3bp Lectin, Galactoside-Binding, Soluble, 3 Binding Protein -0.14 -0.21 -0.16 -0.17 
Rn.9656 Lgals4 Lectin, Galactoside-Binding, Soluble, 4 (Galectin 4) -0.18 -0.21 -0.03 0.05 
Rn.47037 Lman2 Lectin, Mannose-Binding 2 1.36 3.42 1.55 0.49 
Rn.2379 Mgp Matrix Gla Protein -0.27 -0.72 -0.10 -0.20 
Rn.9946 Mmp10 Matrix Metalloproteinase 10 0.17 -0.09 -0.13 -0.14 
Rn.11123 Mmp11 Matrix Metalloproteinase 11 3.28 3.39 0.86 0.62 
Rn.33193 Mmp12 Matrix Metalloproteinase 12 0.05 0.26 -0.17 -0.35 
Rn.74064 Mmp16 Matrix Metalloproteinase 16 -0.10 -0.34 -0.14 -0.22 
Rn.6422 Mmp2 Matrix Metalloproteinase 2 (72 Kda Type Iv Collagenase) 1.46 2.40 0.45 0.00 
Rn.6422 Mmp2 Matrix Metalloproteinase 2 (72 Kda Type Iv Collagenase) 0.20 0.69 0.33 0.00 
Rn.22562 Mmp23 Matrix Metalloproteinase 23 0.00 -0.15 -0.20 -0.01 
Rn.10282 Mmp7 Matrix Metalloproteinase 7 -0.06 -0.09 0.05 -0.19 
Rn.10209 Mmp9 Matrix Metalloproteinase 9 (Gelatinase B, 92-Kda Type Iv Collagenase) -1.39 -0.79 -0.03 1.06 
Rn.33598 Mme Membrane Metallo Endopeptidase -0.04 -0.27 -0.15 -0.09 
Rn.102300 LOC361170 Metalloprotease/Disintegrin -0.21 -0.22 0.07 0.10 
Rn.11402 Mtap1a Microtubule-Associated Protein 1 A 0.78 1.20 0.26 0.65 
Rn.3135 Map1lc3a Microtubule-Associated Protein 1 Light Chain 3 Alpha -0.15 -0.34 -0.09 -0.01 
Rn.98152 Map1b Microtubule-Associated Protein 1B 0.53 0.59 0.07 0.14 
Rn.91417 LOC367171 Microtubule-Associated Protein 4 -0.01 -0.24 -0.11 -0.02 
Rn.2455 Mapt Microtubule-Associated Protein Tau 1.06 0.25 -0.24 -0.05 
Rn.7652 Mapre1 Microtubule-Associated Protein, Rp/Eb Family, Member 1 0.87 0.99 0.54 0.29 
Rn.3742 Mfge8 Milk Fat Globule-Egf Factor 8 Protein -0.44 -0.13 0.04 0.24 
Rn.17256 Map2k6 Mitogen-Activated Protein Kinase Kinase 6 -0.09 0.75 0.84 0.42 
Rn.10779 Muc1 Mucin 1, Transmembrane -0.25 -0.24 -0.04 -0.11 
Rn.24930 Muc4 Mucin 4 -0.18 -0.47 0.03 -0.16 
Rn.10789 Muc5ac Mucin 5, Subtypes A And C, Tracheobronchial/Gastric -0.06 1.11 0.04 1.31 
Rn.18860 Mucdhl Mucin And Cadherin-Like -0.14 -0.21 0.02 -0.10 
Rn.87175 Madcam1 Mucosal Vascular Addressin Cell Adhesion Molecule 1 -0.35 -0.20 -0.14 -0.25 
Rn.8997 Mpz Myelin Protein Zero -0.07 -0.29 -0.22 -0.02 
Rn.87331 Mag Myelin-Associated Glycoprotein 0.85 0.90 0.72 0.28 
Rn.98166 Myh10 Myosin Heavy Chain 10, Non-Muscle -0.16 -0.36 -0.14 -0.05 
Rn.94969 Myh11 Myosin Heavy Chain 11 -0.21 -0.07 0.11 -0.05 
Rn.48756 Loc192253 Myosin Heavy Chain Myr 8 -0.21 -0.04 -0.15 -0.17 
Rn.54399 Myh6 Myosin Heavy Chain, Polypeptide 6 -0.55 -0.24 0.11 -0.05 
Rn.54399 Myh6 /// Myh7 Myosin Heavy Chain, Polypeptide 6 /// Myosin, Heavy Polypeptide 7, Cardiac Muscle, Beta 0.47 0.45 0.10 0.33 
Rn.33782 Myo9b Myosin Ixb -0.04 -0.34 -0.07 -0.10 
Rn.81191 Mylk2 Myosin Light Chain Kinase 2, Skeletal Muscle 0.59 0.57 0.13 0.59 
Rn.6021 Mrlcb Myosin Regulatory Light Chain 0.75 1.32 0.44 0.52 
Rn.103179 Mrlcb Myosin Regulatory Light Chain -0.16 -0.32 -0.24 -0.13 
Rn.34319 Myh13 Myosin, Heavy Polypeptide 13, Skeletal Muscle -0.05 -0.17 -0.28 -0.11 
Rn.10092 Myh4 Myosin, Heavy Polypeptide 4 0.78 0.87 0.20 -0.10 
Rn.11385 Myh9 Myosin, Heavy Polypeptide 9 1.54 1.94 0.55 -0.45 
Rn.9560 Marcks Myristoylated Alanine Rich Protein Kinase C Substrate 0.84 1.16 0.39 -0.13 
Rn.9560 Marcks Myristoylated Alanine Rich Protein Kinase C Substrate 1.27 2.20 0.90 0.00 
Rn.9560 Marcks Myristoylated Alanine Rich Protein Kinase C Substrate 0.17 0.51 0.40 -0.25 
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Rn.17097 Napsa Napsin A Aspartic Peptidase -0.08 -0.14 0.00 0.03 
Rn.11331 Ngfg Nerve Growth Factor, Gamma -0.08 -0.32 -0.09 -0.08 
Rn.10926 Nrxn3 Neurexin 3 -0.10 -0.36 -0.18 0.00 
Rn.3048 Nfasc Neurofascin -0.19 -0.27 -0.10 -0.19 
Rn.10263 Nlgn3 Neuroligin 3 -0.17 -0.33 0.16 0.06 
Rn.10263 Nlgn3 Neuroligin 3 -0.37 -0.51 -0.38 -0.95 
Rn.11029 Nln Neurolysin (Metallopeptidase M3 Family) -0.18 -0.13 -0.22 -0.13 
Rn.10691 Nrcam Neuron-Glia-Cam-Related Cell Adhesion Molecule -0.22 -0.29 -0.11 -0.01 
Rn.44474 Mmp8 Neutrophil Collagenease -0.08 0.10 -0.24 0.06 
Rn.105658 Nid Nidogen (Entactin) 0.60 0.46 -0.13 -0.16 
Rn.11245 Ninj1 Ninjurin 1 -0.30 0.13 -0.38 0.86 
Rn.31429 Ocln Occludin 0.11 0.49 -0.14 -0.48 
Rn.31429 Ocln Occludin 0.08 0.04 -0.35 -0.59 
Rn.31429 Ocln Occludin -0.10 -0.36 -0.18 -0.13 
Rn.11366 Opcml Opioid-Binding Protein/Cell Adhesion Molecule-Like 0.06 0.05 0.11 0.37 
Rn.9149 Pak1 P21 (Cdkn1A)-Activated Kinase 1 0.24 -0.17 -0.19 -0.11 
Rn.3840 Pak2 P21 (Cdkn1A)-Activated Kinase 2 -0.14 -0.22 -0.14 -0.31 
Rn.43875 Pga5 Pepsinogen 5, Group I (Pepsinogen A) -0.16 -0.16 0.05 -0.01 
Rn.11086 Prph1 Peripherin 1 -0.85 -1.07 -1.10 -1.19 
Rn.17112 Pgcp Plasma Glutamate Carboxypeptidase -0.02 -0.47 -0.55 -0.99 
Rn.32103 Pls3 Plastin 3 (T-Isoform) 0.08 0.33 0.59 0.23 
Rn.1085 Plec1 Plectin 0.06 0.20 0.39 0.42 
Rn.13805 Podxl Podocalyxin-Like -0.38 -0.23 -0.15 -0.04 
Rn.13805 Podxl Podocalyxin-Like 0.45 0.55 0.30 0.06 
Rn.2910 Pcolce Procollagen C-Proteinase Enhancer Protein 1.00 1.66 0.47 0.16 
Rn.12945 Plod2 Procollagen Lysine, 2-Oxoglutarate 5-Dioxygenase 2 0.02 -0.09 -0.05 0.03 
Rn.107239 Col1a2 Procollagen, Type I, Alpha 2 -0.14 -0.13 0.08 0.02 
Rn.107239 Col1a2 Procollagen, Type I, Alpha 2 0.52 0.56 0.20 0.52 
Rn.23928 Col11a1 Procollagen, Type Xi, Alpha 1 0.23 0.14 0.08 0.11 
Rn.11218 Col12a1 Procollagen, Type Xii, Alpha 1 0.93 1.06 0.12 0.04 
Rn.4445 Plod 
Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 
(Lysine Hydroxylase, Ehlers-Danlos Syndrome Type 
Vi) 
0.32 0.23 0.10 0.14 
Rn.90152 Plod3 Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 3 0.59 0.14 0.48 0.47 
Rn.1152 Pfn1 Profilin 1 0.78 0.61 0.55 -0.02 
Rn.3515 Pfn2 Profilin 2 -0.05 -0.27 0.00 -0.11 
Rn.11310 Ptpn21 Protein Tyrosine Phosphatase 2E 0.02 1.15 1.08 -0.43 
Rn.53971 Ptpns1 Protein Tyrosine Phosphatase, Non-Receptor Type Substrate 1 0.82 0.70 0.49 0.18 
Rn.10674 Prg2 Proteoglycan 2, Bone Marrow 0.69 0.63 -0.24 -0.81 
Rn.40122 Pgsg Proteoglycan Peptide Core Protein 0.90 1.04 -0.11 -0.85 
Rn.95071 Rap1b Rap1B, Member Of Ras Oncogene Family -0.18 -0.11 -0.09 -0.05 
Rn.98353 Reln Reelin 0.74 1.45 1.21 1.03 
Rn.98353 Reln Reelin -0.05 0.00 0.28 0.19 
Rn.93200 Ret Ret Proto-Oncogene -0.16 -0.18 -0.21 -0.25 
Rn.2108 Risc Retinoid-Inducible Serine Caroboxypetidase 0.46 0.59 0.72 0.02 
Rn.34221 Ril Reversion Induced Lim Gene 1.78 2.04 0.51 0.36 
Rn.89756 Rock1 Rho-Associated Kinase Beta 0.29 1.01 0.05 -0.14 
Rn.28912 Evl Rnb6 0.00 0.11 -0.06 -0.19 
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   Log Ratio (CD/CS) 
Unigene ID Gene Symbol Description 4 wks 12 wks 80 wks Tumors 
Rn.98989 Sparc Secreted Acidic Cysteine Rich Glycoprotein -0.32 -0.30 -0.71 -0.98 
Rn.98989 Sparc Secreted Acidic Cysteine Rich Glycoprotein -1.17 -1.17 -0.92 -1.20 
Rn.1451 Sepp1 Selenoprotein P, Plasma, 1 -0.23 -0.29 -0.01 -0.07 
Rn.1451 Sepp1 Selenoprotein P, Plasma, 1 0.00 0.96 0.58 0.11 
Rn.109007 Sap Serum Amyloid P-Component 0.37 0.97 0.15 -0.01 
Rn.10467 Slc12a3 Solute Carrier Family 12, Member 3 0.18 1.28 0.31 -0.30 
Rn.3091 Sparcl1 Sparc-Like 1 (Mast9, Hevin) 0.29 0.43 0.70 0.35 
Rn.93208 Spnb2 Spectrin Beta 2 -0.31 -0.21 -0.18 0.06 
Rn.93208 Spnb2 Spectrin Beta 2 -0.12 -0.30 -0.07 -0.12 
Rn.49170 St14 Suppression Of Tumorigenicity 14 -0.22 -0.44 0.07 -0.04 
Rn.3926 Sftpc Surfactant Associated Protein C 0.42 0.43 -0.49 -0.40 
Rn.11348 Sftpd Surfactant Associated Protein D 0.46 0.06 -0.66 -0.13 
Rn.11343 Sftpa1 Surfactant, Pulmonary-Associated Protein A1 -0.40 -0.86 -0.62 -0.34 
Rn.11176 Sdc1 Syndecan 1 -0.63 -0.90 -0.61 -0.89 
Rn.11176 Sdc1 Syndecan 1 0.00 -0.29 -0.33 -0.26 
Rn.11127 Sdc2 Syndecan 2 -0.14 -0.15 -0.20 -0.15 
Rn.11127 Sdc2 Syndecan 2 0.27 -0.08 -0.63 -0.01 
Rn.10504 Sdc3 Syndecan 3 -0.07 -0.15 -0.18 -0.03 
Rn.2029 Sdc4 Syndecan 4 -0.16 -0.20 -0.15 -0.11 
Rn.70527 Ssx2ip Synovial Sarcoma, X Breakpoint 2 Interacting Protein -0.18 0.00 -0.07 -0.38 
Rn.11028 Tnr Tenascin R 0.50 0.94 0.37 -0.61 
Rn.32098 Tpx1 Testis Specific Protein 1 2.18 2.66 0.52 -0.03 
Rn.11207 Thbs4 Thrombospondin 4 1.07 1.63 0.68 0.00 
Rn.2605 Tmsb4x Thymosin Beta-4 -0.09 -0.23 -0.34 0.00 
Rn.25754 Timp1 Tissue Inhibitor Of Metalloproteinase 1 0.15 0.11 0.20 0.86 
Rn.10161 Timp2 Tissue Inhibitor Of Metalloproteinase 2 0.24 0.14 0.15 0.14 
Rn.119634 Timp3 Tissue Inhibitor Of Metalloproteinase 3 (Sorsby Fundus Dystrophy, Pseudoinflammatory) -0.18 -0.30 -0.03 -0.12 
Rn.28991 Tpp2 Tripeptidyl Peptidase Ii -0.12 -0.31 -0.18 -0.03 
Rn.43122 Tpbg Trophoblast Glycoprotein -0.15 -0.09 0.04 -0.15 
Rn.8816 Tpbpa Trophoblast Specific Protein Alpha -0.24 -0.24 -0.01 0.10 
Rn.1646 Tmod1 Tropomodulin 1 0.89 1.91 0.43 0.42 
Rn.74047 Tmod2 Tropomodulin 2 1.04 1.36 0.20 -0.28 
Rn.74047 Tmod2 Tropomodulin 2 -0.07 0.05 0.06 0.10 
Rn.87540 Tpm1 Tropomyosin 1, Alpha -0.03 -0.31 0.13 -0.14 
Rn.87540 Tpm1 Tropomyosin 1, Alpha -0.35 -0.36 -0.11 -0.24 
Rn.87540 Tpm1 Tropomyosin 1, Alpha 1.26 0.67 0.40 -0.11 
Rn.37575 Tpm3 Tropomyosin 3, Gamma 0.79 0.56 0.20 -0.08 
Rn.37575 Tpm3 Tropomyosin 3, Gamma 0.26 0.13 0.02 0.06 
Rn.108199 Tpm4 Tropomyosin 4 0.50 0.46 0.33 0.07 
--- LOC286890 Tropomyosin Isoform 6 1.22 0.85 0.25 -0.08 
Rn.37575 Tpm3 Tropomyosin Isoform 6 1.50 0.82 0.20 0.04 
--- LOC286890 Tropomyosin Isoform 6 -0.20 -0.23 0.28 -0.07 
--- LOC286890 Tropomyosin Isoform 6 -0.05 -0.36 0.00 -0.08 
Rn.37575 LOC286890 /// Tpm3 Tropomyosin Isoform 6 /// Tropomyosin 3, Gamma 0.93 1.14 0.70 0.61 
Rn.10699 TPSB1 Tryptase Beta 1 1.48 1.74 1.16 0.93 
Rn.35128 Ttl Tubulin Tyrosine Ligase 0.21 0.26 0.32 0.48 
Rn.54749 Tuba1 Tubulin, Alpha 1 0.75 0.76 0.07 0.25 
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   Log Ratio (CD/CS) 
Unigene ID Gene Symbol Description 4 wks 12 wks 80 wks Tumors 
Rn.2458 Tubb5 Tubulin, Beta 5 0.00 -0.08 -0.10 -0.13 
Rn.8218 Tubg1 Tubulin, Gamma 1 1.23 2.05 2.25 1.12 
Rn.8883 Tyro3 Tyro3 Protein Tyrosine Kinase 3 1.43 2.42 1.90 0.71 
Rn.112600 Src Tyrosine Protein Kinase Pp60-C-Src -0.09 -0.12 0.02 -0.16 
Rn.773 Vil2 Villin 2 0.57 0.64 0.63 -0.07 
Rn.2710 Vim Vimentin 0.65 0.40 0.16 0.06 
Rn.9978 Wap Whey Acidic Protein 2.54 3.08 0.55 -1.15 
Rn.7914 Waspip Wiskott-Aldrich Syndrome Protein Interacting Protein 2.16 2.82 0.46 -0.18 
Rn.107363 Zyx Zyxin 2.38 3.04 0.36 -0.08 
  139 
 
APPENDIX 2 
 
Biological processes associated with liver injury transition states in choline deficient 
rats 
 
Significant gene lists were generated using SAM (FDR < 5%) for each transition state 
(transition state 1 – chronic liver injury; transition state 2 – tumors) and cross-compared 
using Venn diagram (Figure 4). Those genes lists were submitted to GoMiner (34) to identify 
significantly enriched (p < 0.05) biological processes unique to transition state 1 (Appendix 
2A) and transition state 2 (Appendix 2B), or shared (Appendix 2C and 2D). Note that the 
genes in common between the two transitions states were directionally opposite in 
expression of one another and this is reflected in Appendices 2C and 2D. 
 
Appendix 2A Transition State 1 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
 Cellular Physiological Process  0.0005 
   Transport 0.0374  
   Ion Transport <0.0001  
    Cation Transport <0.0001  
     Metal Ion Transport <0.0001  
     Monovalent Inorganic Cation Transport <0.0001  
      Potassium Ion Transport <0.0001  
      Sodium Ion Transport 0.0038  
     Di-, Tri-valent Inorganic Ion Transport 0.0091  
      Transition Metal Ion Transport  0.0133 
       Iron Ion Transport  0.0024 
      Calcium Ion Transport <0.0001  
   Neurotransmitter Transport 0.0015  
   Vesicle-Mediated Transport   
    Exocytosis 0.0249  
     Calcium Ion-Dependent Exocytosis 0.0388  
     Regulation of Exocytosis   
      Regulation of Calcium Ion-Dependent Exocytosis 0.0390  
   Secretory Pathway   
    Regulated Secretory Pathway 0.0480  
   Intracellular Transport  0.0033 
     Intracellular Protein Transport   
      Protein Import  0.0397 
      Protein-Nucleus Import  0.0259 
     Nucleocytoplasmic Transport  0.0380 
      Nuclear Import  0.0259 
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Appendix 2A Transition State 1 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
     Cytoskeleton-Dependent Intracellular Transport  0.0404 
     Nuclear Transport  0.0227 
  Cell Cycle  <0.0001 
   Regulation of Cell Cycle  0.0004 
    Cell Cycle Arrest  0.0197 
    Regulation of Mitotic Cell Cycle  0.0240 
   Mitotic Cell Cycle  0.0001 
    M Phase of Mitotic Cell Cycle  0.0061 
      Mitosis  0.0045 
    M Phase  0.0329 
   Interphase  0.0478 
    Interphase of Mitotic Cell Cycle  0.0478 
   Chromosome Segregation  0.0429 
  Cell Death  0.0423 
  Programmed Cell Death  0.0397 
     Apoptosis  0.0343 
     Apoptotic Program  0.0304 
      Caspase Activation  0.0045 
     Regulation of Apoptosis  0.0017 
      Negative Regulation of Caspase Activation  0.0107 
      Negative Regulation of Apoptosis  0.0303 
      Positive Regulation of Apoptosis  0.0144 
       Regulation of Caspase Activation  0.0105 
    Regulation of Programmed Cell Death  0.0022 
     Negative Regulation of Programmed Cell Death  0.0303 
     Positive Regulation of Programmed Cell Death  0.0166 
    Induction of Programmed Cell Death  0.0128 
       Induction of Apoptosis  0.0128 
  Cell Proliferation   
   Regulation of Cell Proliferation   
    Negative Regulation of Cell Proliferation  0.0064 
  Cell Organization and Biogenesis  <0.0001 
   Organelle Organization and Biogenesis  <0.0001 
    Cytoskeleton Organization and Biogenesis  <0.0001 
     Microtubule-Based Process  0.0002 
      Microtubule Cytoskeleton Organization and Biogenesis  0.0015 
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Appendix 2A Transition State 1 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
       Microtubule Nucleation  0.0030 
       Spindle Organization and Biogenesis  0.0107 
        Mitotic Spindle Organization and Biogenesis  0.0107 
      Microtubule-Based Movement  0.0294 
     Actin Filament-Based Process  0.0020 
      Actin Cytoskeleton Organization and Biogenesis  0.0030 
      Actin Filament Severing  0.0209 
    Ribosome Biogenesis and Assembly  <0.0001 
     Ribosome Biogenesis  <0.0001 
    Chromosome Organization and Biogenesis  0.0175 
     Chromosome Organization and Biogenesis (Sensu Eukaryota)  0.0259 
   Cytoplasm Organization and Biogenesis  <0.0001 
  Cell Division  0.0021 
   Cytokinesis  0.0022 
  Response to Stimulus   
   Response to Stress   
    Response to Heat  0.0299 
    Response to Pain 0.0334  
    Response to Wounding   
     Wound Healing 0.0191  
   Response to External Stimulus 0.0015  
    Detection of External Stimulus <0.0001  
     Detection of Abiotic Stimulus 0.0013  
      Detection of Chemical Substance 0.0034  
      Detection of Mechanical Stimulus 0.0388  
       Sensory Perception of Mechanical    
      Stimulus 
0.0388  
    Response  to Abiotic Stimulus   
      Response to Organic Substance 0.0173  
   Response to Biotic Stimulus   
     Cellular Defense Response   
       Cell-mediated Immune Response  0.0404 
     Antigen Presentation   
      Antigen Presentation, Exogenous Antigen  0.0209 
     Antigen Processing    
      Antigen Processing, Exogenous Antigen via MHC Class I  0.0209 
  Localization 0.0385  
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Appendix 2A Transition State 1 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
   Protein Localization  0.0056 
    Establishment of Protein Localization  0.0094 
     Protein Transport  0.0086 
      Intracellular Protein Transport  0.0076 
       Protein Targeting  0.0091 
   Establishment of Localization 0.0403  
  Regulation of Cellular Physiological Process  0.0011 
   Negative Regulation of Cellular Physiological Process  0.0005 
 Cellular Process  0.0484 
  Cell Communication <0.0001  
   Cell Adhesion   
    Cell-Cell Adhesion 0.0376  
     Heterophilic Cell Adhesion 0.0074  
     Negative Regulation of Cell Adhesion 0.0334  
    Cell Recognition  0.0209 
     Neuronal Cell Recognition  0.0209 
   Signal Transduction 0.0001  
    Cell Surface Receptor Linked Signal Transduction <0.0001  
     G-protein Coupled Receptor Protein Signaling Pathway <0.0001  
      G-protein Signaling, Coupled to Cyclic Nucleotide Second  
       Messenger 
0.0001  
      G-protein Signaling, Coupled to cAMP Nucleotide Second 
       Messenger 
0.0001  
        G-protein Signaling, Adenylate Cyclase Activating  
          Pathway 
0.0032  
         Adenylate Cyclase Activation 0.0463  
        G-protein Signaling, Adenylate Cyclase Inhibiting  
          Pathway 
0.0167  
        Regulation of Adenylate Cyclase Activity 0.0134  
      Gamma-aminobutyric Acid Signaling Pathway 0.0102  
      Neuropeptide Signaling Pathway 0.0001  
     Glutamate Signaling Pathway 0.0252  
    Intracellular Signaling Cascade   
     Small GTPase Mediated Signal Transduction  0.0026 
      Ras Protein Signal Transduction  0.0135 
       Regulation of Ras Protein Signal Transduction  0.0429 
     Second-Messenger-Mediated Signaling <0.0001  
      Cyclic-Nucleotide-Mediated Signaling <0.0001  
       cAMP-Mediated Signaling <0.0001  
   Cell-Cell Signaling <0.0001  
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Appendix 2A Transition State 1 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
  Regulation of Cellular Process  0.0006 
   Negative Regulation of Cellular Process  0.0006 
 Development 0.0403  
  Sex Differentiation   
   Development of Primary Male Sexual Characteristics 0.0173  
  Morphogenesis   
   Cellular Morphogenesis  0.0076 
 Cell Differentiation   
   Neuron Cell Differentiation 0.0058  
   Regulation of Cell Differentiation 0.0151  
    Positive Regulation of Cell Differentiation 0.0075  
  Positive Regulation of Myeloid Blood Cell Differentiation 0.0390  
 Cell Development   
   Cellular Morphogenesis during Differentiation   
    Photoreceptor Cell Development 0.0034  
  Organ Development 0.0237  
 Organogenesis 0.0340  
   Eye Morphogenesis   
    Photoreceptor Cell Differentiation 0.0463  
     Eye Photoreceptor Cell Differentiation   
      Eye Photoreceptor Cell Development 0.0173  
   Gonad Development   
    Male Gonad Development 0.0173  
 Physiological Process  0.0072 
 Metabolism  0.0001 
   Biosynthesis  <0.0001 
    Cellular Biosynthesis  <0.0001 
     Macromolecule Biosynthesis  <0.0001 
      Protein Biosynthesis  <0.0001 
       Translation   
        Translational Elongation  0.0187 
      Pigment Biosynthesis 0.0077  
       Heme Biosynthesis 0.0173  
   Macromolecule Metabolism  <0.0001 
    Cellular Macromolecule Metabolism  <0.0001 
    Cellular Carbohydrate Metabolism   
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Appendix 2A Transition State 1 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
      Fructose Metabolism 0.0390  
       Fructose 2,6-bisphosphate Metabolism 0.0390  
      Glucose Metabolism 0.0497  
   Biopolymer Metabolism  0.0028 
   Cellular Metabolism  <0.0001 
    Nucleobase, Nucleoside, Nucleotide and Nucleic Acid Metabolism   
     DNA Metabolism  <0.0001 
      DNA Replication  0.0022 
       DNA-dependent DNA Replication  0.0083 
        DNA Replication Initiation  0.0209 
        Regulation of DNA Replication  0.0209 
      DNA Packaging  0.0197 
     Transcription   
      Regulation of Transcription from RNA Polymerase II Promoter  0.0437 
    Amino Acid and Derivative Metabolism   
     Amino Acid Metabolism   
      Serine Family Amino Acid Metabolism  0.0299 
       L-Serine Metabolism  0.0240 
        L-Serine Biosynthesis  0.0107 
     Amino Acid Derivative Metabolism 0.0261  
      Amino Acid Derivative Biosynthesis 0.0337  
      Biogenic Amine Metabolism 0.0047  
       Biogenic Amine Biosynthesis 0.0441  
       Catecholamine Metabolism   
        Catecholamine Biosynthesis 0.0334  
    Phosphorus Metabolism   
     Phosphate Metabolism   
      Dephosphorylation  0.0366 
   Primary Metabolism  <0.0001 
    Lipid Metabolism   
     Diacylglycerol Biosynthesis  0.0209 
     Acylglycerol Biosynthesis  0.0209 
     Neutral Lipid Biosynthesis  0.0209 
    Heterocycle Metabolism   
      Porphyrin Biosynthesis 0.0034  
    Protein Metabolism  <0.0001 
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Appendix 2A Transition State 1 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
     Cellular Protein Metabolism  <0.0001 
      Protein Folding   
       Tubulin Folding  0.0209 
        Chaperone-mediated Tubulin Folding  0.0209 
       Posttranslational Protein Folding  0.0209 
        Chaperone Cofactor Dependent Protein Folding  0.0209 
      Protein Modification   
       Autophosphorylation 0.0167  
      Protein Polymerization  0.0187 
      Receptor Metabolism  0.0030 
     Coagulation 0.0193  
   Blood Coagulation 0.0193  
   Extracellular Structure Organization and Biogenesis 0.0261  
   Extracellular Matrix Organization and Biogenesis 0.0261  
      Organismal Physiological Process <0.0001  
   Cell Activation  0.0434 
    Immune Cell Activation  0.0434 
     Lymphocyte Activation  0.0350 
      Lymphocyte Differentiation   
       Thymocyte Differentiation  0.0107 
      T-Cell Activation  0.0271 
       T-Cell Proliferation  0.0197 
    Digestion 0.0023  
   Muscle Contraction   
    Regulation of Muscle Contraction 0.0229  
   Neurophysiological Process <0.0001  
    Sensory Perception <0.0001  
     Perception of Pain 0.0252  
     Sensory Perception of Chemical Stimulus <0.0001  
      Perception of Smell 0.0002  
       Perception of Smell, Sensory Transduction of Chemical 
         Stimulus 
0.0390  
      Perception of Taste 0.0463  
     Sensory Transduction 0.0034  
      Sensory Transduction of Chemical Stimulus 0.0077  
     Sensory Perception of Light 0.0288  
      Visual Perception 0.0288  
  146 
 
Appendix 2A Transition State 1 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
    Transmission of Nerve Impulse <0.0001  
     Synaptic Transmission <0.0001  
      Nerve-nerve Synaptic Transmission 0.0441  
      Regulation of Neurotransmitter Levels 0.0005  
       Neurotransmitter Metabolism 0.0070  
        Neurotransmitter Biosynthesis 0.0173  
      Neurotransmitter Receptor Metabolism  0.0030 
   Regulation of Body Fluids 0.0097  
    Hemostasis 0.0193  
  Homeostasis   
   Metal Ion Homeostasis   
    Calcium Ion Homeostasis 0.0042  
   Transition Metal Ion Homeostasis  0.0442 
  Secretion   
   Neurotransmitter Secretion 0.0335  
    Regulation of Neurotransmitter Secretion 0.0173  
 Regulation of Biological Process  0.0010 
  Regulation of Gene Expression, Epigenetic  0.0404 
   Dosage Compensation  0.0107 
  Negative Regulation of Biological Process  0.0004 
  Regulation of Enzyme Activity  0.0461 
   Regulation of Cyclase Activity 0.0134  
    Positive Regulation of Adenylate Cyclase Activity 0.0463  
    Positive Regulation of Cyclase Activity 0.0463  
   Regulation of Hydrolase Activity  0.0045 
    Positive Regulation of Hydrolase Activity  0.0045 
    Regulation of Caspase Activity  0.0045 
     Positive Regulation of Caspase Activity  0.0045 
   Regulation of Lyase Activity 0.0134  
    Positive Regulation of Lyase Activity 0.0463  
  Regulation of Development   
   Positive Regulation of Development 0.0021  
  Regulation of Physiological Process  0.0018 
   Regulation of Metabolism   
    Regulation of Cellular Metabolism   
    Negative Regulation of Metabolism  0.0164 
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Appendix 2A Transition State 1 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
     Negative Regulation of Cellular Metabolism  0.0484 
   Regulation of Nucleobase, Nucleoside, Nucleotide and  Nucleic Acid   
    Metabolism 
  
    Negative Regulation of Nucleobase, Nucleoside, Nucleotide and Nucleic 
     Acid Metabolism 
 0.0179 
   Regulation of Cellular Physiological Process   
    Positive Regulation of Cellular Physiological Process   
     Positive Regulation of Transport   
      Positive Regulation of Endocytosis  0.0442 
   Negative Regulation of Physiological Process  0.0006 
 
Appendix 2B Transition State 2 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
Cellular Physiological Process   
   Transport   
   Di-, Tri-valent Inorganic Ion Transport   
    Plasma Membrane Copper Ion Transport 0.0212  
    Mitochondrial Calcium Ion Transport  0.0175 
   Cofactor Transport  0.0346 
   Vitamin Transport   
    Carnitine Transport  0.0175 
   Intracellular Transport   
    Protein-Nucleus Import   
     Protein-Nucleus Import, Docking  0.0346 
     Mitochondrial Inner Membrane Protein Import  0.0346 
  Cell Death   
   Induction of Apoptosis by Intracellular Signals 0.0114  
  Cell Proliferation  0.0058 
   Regulation of Cell Proliferation  0.0263 
    Negative Regulation of Fibroblast Proliferation 0.0419  
  Cell Organization and Biogenesis   
   Mitochondrial Genome Maintenance 0.0212  
   Peroxisome Membrane Biogenesis 0.0419  
  Response to Stress  0.0470 
   Response to DNA Damage Stimulus 0.0354 0.0189 
     DNA Repair  0.0074 
      Base Excision Repair 0.0018  
       Base Excision Repair, Gap-Filling 0.0212  
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Appendix 2B Transition State 2 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
      Pyrimidine Dimer Repair 0.0212  
      Transcription-Coupled Nucleotide-Excision Repair  0.0346 
     DNA Damage Response, Signal Transduction 0.0298  
      DNA Damage Response, Signal Transduction Resulting in  
       Induction of Apoptosis 
0.0026  
    DNA Damage Response, Signal Transduction by p53 Class  
      Mediator 
0.0212  
   Response to Pest, Pathogen, or Parasite   
    Response to Bacteria 0.0342  
    Response to Virus   
     Regulation of Antiviral Response  0.0175 
      Regulation of Antiviral Response by Host  0.0175 
   Response to External Stimulus   
     Detection of Biotic Stimulus 0.0419  
      Detection of Bacteria 0.0419  
    Response  to Abiotic Stimulus   
     Response to X-ray 0.0419  
     Response to UV 0.0419  
   Response to Biotic Stimulus   
    Humoral Immune Response   
     Positive Regulation of Complement Activation  0.0175 
    Innate Immune Response   
      Regulation of Innate Immune Response 0.0212  
       Positive Regulation of Innate Immune Response 0.0212  
     Antigen Presentation 0.0087  
      Antigen Presentation, Endogenous Antigen 0.0026  
       Antigen Presentation, Endogenous  Peptide Antigen 0.0419  
      Antigen Presentation, Lipid Antigen 0.0212  
       Antigen Presentation, Endogenous  Lipid Antigen 0.0212  
     Antigen Processing  0.0063  
   Response to Endogenous Stimulus  0.0274 
 Cellular Process   
  Cell Communication   
   Homophilic Cell Adhesion  0.0308 
 Development   
  Morphogenesis   
   Cellular Morphogenesis  0.0099 
  Cell Projection Organization and Biogenesis   
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Appendix 2B Transition State 2 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
   Flagellum Biogenesis  0.0346 
   Axoneme Biogenesis  0.0175 
   Flagellum Axoneme Biogenesis  0.0175 
  Endothelial Cell Morphogenesis  0.0346 
  Regulation of Cell Size   
        Negative Regulation of Cell Size  0.0308 
          Negative Regulation of Cell Growth  0.0308 
 Cell Differentiation   
   Cardiac Cell Differentiation 0.0212  
   Endothelial Cell Development  0.0346 
   Regulation of Cell Differentiation   
  Positive Regulation of Osteoblast Differentiation  0.0175 
 Cell Development   
   Sperm Axoneme Assembly  0.0175 
   Growth 0.0046  
   Regulation of Growth 0.0166  
    Regulation of Growth Rate 0.0212  
    Negative Regulation of Growth  0.0345 
  Tube Development 0.0226  
  Organ Development   
   Blood Vessel Development  0.0479 
   Heart Development   
    Embryonic Heart Tube Development 0.0013  
   Myogenesis 0.0342  
 Physiological Process   
 Metabolism   
   Nitrogen Fixation 0.0212  
   Biosynthesis   
    Protein Biosynthesis   
     Selenocysteine Incorporation  0.0175 
     Translational Readthrough  0.0175 
     Regulation of Translation  0.0149 
     Regulation of Protein Biosynthesis  0.0192 
    Regulation of Biosynthesis  0.0361 
   Cellular Metabolism   
    Alcohol Metabolism   
     Glycerol Metabolism   
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Appendix 2B Transition State 2 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
      Glycerol-3-phosphate Metabolism 0.0419  
    Nucleobase, Nucleoside, Nucleotide and Nucleic Acid Metabolism  0.0071 
     DNA Metabolism  0.0263 
      Negative Regulation of DNA Metabolism 0.0419  
      DNA Replication   
       Regulation of DNA Replication 0.0419  
        Negative Regulation of DNA Replication 0.0212  
      DNA Packaging   
       Covalent Chromatin Modification  0.0346 
     Transcription  0.0045 
      Transcription, DNA-dependent  0.0023 
       RNA Elongation  0.0346 
        RNA Elongation from RNA Polymerase II Promoter  0.0175 
       Regulation of Transcription, DNA-dependent  0.0050 
        Regulation of Transcription  0.0087 
      Transcription from RNA Polymerase II Promoter  0.0342 
     Regulation of Nucleobase, Nucleoside, Nucleotide and Nucleic Acid 
      Metabolism 
 0.0096 
     Nucleobase Metabolism   
      ‘de novo’ pyrimidine base biosynthesis  0.0175 
      Pyrimidine Base Biosynthesis  0.0346 
     Nucleotide Metabolism   
      cGMP Metabolism 0.0255  
      Nucleotide Biosynthesis   
       Cyclic Nucleotide Biosynthesis 0.0491  
       cGMP Biosynthesis 0.0179  
       Polyamine Metabolism   
        Spermine Metabolism  0.0346 
        Spermine Biosynthesis  0.0175 
        Spermidine Biosynthesis  0.0346 
    Sulfur Metabolism   
     Selenium Metabolism 0.0419  
    Phosphorus Metabolism   
     Polyphosphate Metabolism  0.0175 
      Polyphosphate Catabolism  0.0175 
     Phosphorylation   
      Hyperphosphorylation  0.0175 
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Appendix 2B Transition State 2 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
    Cofactor Metabolism   
     Coenzyme Metabolism   
      Ubiquinone Metabolism 0.0419  
      Uquinone Cofactor Biosynthesis 0.0419  
       Ubiquinone Biosynthesis 0.0419  
     Cofactor Catabolism   
       Heme Oxidation 0.0419  
   Primary Metabolism   
    Lipid Metabolism   
      Lipid Storage 0.0212  
       Bile Acid Biosynthesis 0.0419  
       Steroid Catabolism 0.0212  
        Bile Acid Catabolism 0.0212  
    Protein Metabolism   
      Protein Modification   
       Histone Modifcation  0.0346 
       Protein Amino Acid Acetylation  0.0175 
        Histone Acetylation  0.0175 
      Organismal Physiological Process   
   Cell Activation   
    Immune Cell Activation   
     Astrocyte Activation  0.0175 
       Extrathymic T-Cell Selection  0.0175 
      T-Cell Activation   
       NK T-Cell Proliferation  0.0175 
   Carbohydrate Utilization  0.0175 
   Circulation 0.0426  
  Homeostasis 0.0362  
   Cell Homeostasis 0.0109  
    Ion Homeostasis 0.0180  
     Cell Ion Homeostasis 0.0180  
      Cation Homeostasis 0.0145  
       Metal Ion Homeostasis 0.0270  
        Transition Metal Ion Homeostasis 0.0179  
       Di-, Tri-valent Inorganic Cation Homeostasis 0.0206  
        Iron Ion Homeostasis 0.0087  
 Regulation of Biological Process  0.0180 
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Appendix 2B Transition State 2 
Gene Ontology – Biological Processes Down-
Regulated 
Up-
Regulated 
  Regulation of Cellular Process  0.0082 
  Regulation of Physiological Process  0.0053 
   Regulation of Metabolism  0.0033 
    Regulation of Cellular Metabolism  0.0186 
   Regulation of Cellular Physiological Process  0.0055 
 
Appendix 2C  
Gene Ontology – Biological Processes ↑ Transition State 1 
↓ Transition State 2 
  Behavior 0.0015 
 Locomotory Behavior 0.0001 
   Locomotion 0.0001 
    Cell Motility 0.0001 
     Cell Migration 0.0001 
      Regulation of Cell Migration 0.0046 
      Positive Regulation of Cell Migration 0.0129 
     Regulation of Cell Motility 0.0046 
      Positive Regulation of Cell Motility 0.0129 
    Regulation of Locomotion 0.0059 
     Positive Regulation of Locomotion 0.0129 
  Regulation of Behavior 0.0075 
   Positive Regulation of Behavior 0.0129 
 Cellular Physiological Process 0.0310 
   Transport  
   Ion Transport  
    Phosphate Transport 0.0190 
   Lipid Transport 0.0477 
    Fatty Acid Transport  0.0302 
    Endocytosis  
     Phagocytosis 0.0173 
      Phagocytosis, Engulfment 0.0001 
      Phagocytosis, Recognition 0.0001 
      Regulation of Phagocytosis 0.0051 
       Positive Regulation of Phagocytosis 0.0051 
     Regulation of Endocytosis 0.0384 
     Positive Regulation of Endocytosis 0.0102 
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Appendix 2C  
Gene Ontology – Biological Processes ↑ Transition State 1 
↓ Transition State 2 
   Regulation of Transport  
    Positive Regulation of Transport 0.0173 
  Cell Organization and Biogenesis 0.0270 
   Organelle Organization and Biogenesis  
    Cytoskeleton Organization and Biogenesis 0.0199 
     Actin Filament-Based Process 0.0156 
      Actin Cytoskeleton Organization and Biogenesis 0.0111 
    Actin Filament Organization 0.0384 
  Response to Stimulus 0.0256 
   Response to Stress  
    Response to Wounding 0.0307 
   Response to External Stimulus  
    Response to Abiotic Stimulus  
     Response to Chemical Substance 0.0292 
   Response to Biotic Stimulus 0.0141 
    Defense Response 0.0212 
     Immune Response 0.0204 
      Cytokine Production  
       Regulation of Cytokine Production  
        Positive Regulation of Cytokine Production 0.0302 
        Positive Regulation of Cytokine Biosynthesis 0.0302 
      Cellular Defense Response 0.0113 
       Cellular Defense Response (Sensu  Vertebrata)  
        Cell-Mediated Immune Response 0.0267 
      Antigen Presentation 0.0410 
        Taxis 0.0156 
   Chemotaxis 0.0156 
 Cellular Process  
  Cell Communication  
   Cell Adhesion 0.0096 
    Cell-Matrix Adhesion 0.0190 
    Regulation of Signal Transduction  
     Regulation of G-protein Coupled Receptor Protein Signaling Pathway 0.0113 
      Positive Regulation of Small GTPase Mediated Signal  
       Transduction 
0.0129 
 Development  
  Morphogenesis  
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Appendix 2C  
Gene Ontology – Biological Processes ↑ Transition State 1 
↓ Transition State 2 
   Cellular Morphogenesis 0.0044 
  Organ Development  
   Vasculature Development 0.0073 
    Blood Vessel Development 0.0065 
     Blood Vessel Morphogenesis 0.0025 
   Angiogenesis 0.0057 
 Organogenesis  
   Neurogenesis  
    Gliogenesis 0.0173 
     Regulation of Axon Extension 0.0302 
 Physiological Process 0.0233 
      Regulation of Biosynthesis 0.0486 
   Macromolecule Metabolism 0.0320 
    Cellular Macromolecule Metabolism 0.0237 
    Nucleobase, Nucleoside, Nucleotide and Nucleic Acid Metabolism  
       Chromatin Assembly or Disassembly 0.0410 
        Nucleosome Assembly 0.0208 
     Nucleoside Metabolism 0.0135 
      Purine Nucleoside Metabolism 0.0129 
      Ribonucleoside Metabolism 0.0010 
       Purine Ribonucleoside Metabolism 0.0129 
       Pyrimidine Ribonucleoside Metabolism 0.0480 
   Vitamin Metabolism  
     Fat-Soluble Vitamin Metabolism 0.0384 
      Vitamin A Metabolism 0.0102 
       Retinoic Acid Metabolism 0.0410 
    Protein Metabolism 0.0043 
     Cellular Protein Metabolism 0.0057 
   Protein Complex Assembly 0.0136 
    Regulation of Protein Metabolism  
     Positive Regulation of Protein Metabolism 0.0173 
      Organismal Physiological Process  
   Cell Activation  
    Immune Cell Activation  
     Mast Cell Activation 0.0023 
   Bone Remodeling  
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Appendix 2C  
Gene Ontology – Biological Processes ↑ Transition State 1 
↓ Transition State 2 
    Regulation of Bone Remodeling 0.0323 
     Negative Regulation of Bone Remodeling 0.0208 
  Homeostasis  
   Cell Homeostasis  
    Ion Homeostasis 0.0258 
     Cell Ion Homeostasis 0.0258 
      Cation Homeostasis 0.0193 
       Metal Ion Homeostasis 0.0148 
       Di-, Tri-valent Inorganic Cation Homeostasis 0.0096 
  Secretion  
   Hormone Secretion 0.0267 
 
 
Appendix 2D 
 
 
Gene Ontology – Biological Processes ↓ Transition State 1 
↑ Transition State 2 
 Cellular Physiological Process  
   Transport  
   Ion Transport  
    Sulfate Transport 0.0357 
   Amine Transport 0.0405 
    Amino Acid Transport 0.0189 
     Basic Amino Acid Transport 0.0201 
     L-Amino Acid Transport 0.0447 
   Organic Acid Transport 0.0057 
    Carboxylic Acid Transport 0.0057 
     Dicarboxylic Acid Transport 0.0274 
 Physiological Process  
 Metabolism 0.0020 
   Nitrogen Compound Metabolism 0.0064 
    Nitrogen Compound Biosynthesis 0.0085 
    Nitrogen Compound Catabolism 0.0085 
    Urea Cycle 0.0010 
    Urea Cycle Intermediate Metabolism 0.0028 
     Arginine Metabolism 0.0028 
     Nitrogen Fixation  
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Appendix 2D 
 
 
Gene Ontology – Biological Processes ↓ Transition State 1 
↑ Transition State 2 
   Catabolism  
     Amine Catabolism <0.0001 
      Glutamine Family Amino Acid Catabolism 0.0018 
       Arginine Catabolism 0.0085 
      Aromatic Amino Acid Family Catabolism 0.0010 
   Biosynthesis  
      Amine Biosynthesis  
       Amino Acid Biosynthesis 0.0302 
   Cellular Metabolism 0.0099 
     Sterol Metabolism  0.0103 
      Cholesterol Metabolism 0.0333 
    Organic Acid Metabolism <0.0001 
     Carboxylic Acid Metabolism <0.0001 
    Generation of Precursor Metabolites and Energy 0.0079 
     Electron Transport 0.0055 
    Amino Acid and Derivative Metabolism <0.0001 
     Amino Acid Metabolism <0.0001 
      Glutamine Family Amino Acid Metabolism 0.0012 
      Glutamine Family Amino Acid Biosynthesis 0.0137 
       Arginine Biosynthesis 0.0085 
      Aromatic Amino Acid Family Metabolism 0.0056 
       L-Phenylalanine Metabolism 0.0010 
        L-Phenylalanine Catabolism 0.0005 
       Tyrosine Metabolism 0.0137 
        Tyrosine Catabolism 0.0043 
    Aromatic Compound Metabolism 0.0004 
     Aromatic Compound Catabolism 0.0028 
    Amine Metabolism <0.0001 
     Amino Acid Catabolism <0.0001 
    Cofactor Metabolism  
     Coenzyme Metabolism 0.0383 
      Acetyl-CoA Metabollism 0.0219 
   Primary Metabolism 0.0306 
    Lipid Metabolism  
     Cellular Lipid Metabolism 0.0426 
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Gene Ontology – Biological Processes ↓ Transition State 1 
↑ Transition State 2 
      Steroid Metabolism 0.0189 
  Secretion  
   Peptide Hormone Secretion 0.0357 
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APPENDIX 3 
Gene list of orthologous genes shared between rat and human HCCs 
Ensembl genome browser was used to identify orthologous genes shared between rat (this 
study) and human (160) HCC datasets.  Of the 2,121 genes that SAM (FDR < 5%) identified 
as differentially expressed in CD-induced tumors, a total of 492 orthologous genes were 
found.  Hierarchical clustering analysis of the integrated datasets (Figure 7) revealed two 
gene clusters of highly expressed genes that were shared between human and rat HCCs.  
Genes contained within those two clusters (outlined in red in Table below) were submitted to 
GoMiner (9) to identify significantly enriched biological processes.  *Average gene 
expression ratios (log2-transformed) between either human tumors and non-tumor liver 
tissue or choline deficient (CD) rat tumors and CD non-tumor liver tissue are shown.   
 
Unigene Gene Symbol  Log Ratio (A/B)* 
Human Rat Human Rat Description Human Rat 
Hs.413924 Rn.10584 CXCL10  Cxcl10 Chemokine (C-X-C motif) ligand 10 1.053 0.165 
Hs.77367 Rn.7391 CXCL9  Cxcl9  Chemokine (C-X-C motif) ligand 9 0.547 0.922 
Hs.146668 Rn.2078 TDE2  Tde2 Tumor differentially expressed 2 0.549 0.865 
Hs.6061 Rn.3619 PRKAB1  Prkab1 
Protein kinase, AMP-activated, beta 1 non-
catalytic subunit 0.904 1.622 
Hs.192619 Rn.17036 KIAA1600   KIAA1600 0.019 -0.165 
Hs.117747 Rn.97639 MMAA    
Methylmalonic aciduria (cobalamin 
deficiency) type A 0.363 -0.368 
Hs.487925 Rn.16575 PDE4DIP  Pde4Dip  
Phosphodiesterase 4D interacting protein 
(myomegalin) 0.064 -0.409 
Hs.480848 Rn.17881 USP38  Usp38  Ubiquitin specific protease 38 0.460 1.197 
Hs.276916 Rn.29848 NR1D1  Nr1d1 
Nuclear receptor subfamily 1, group D, 
member 1 0.616 -0.256 
Hs.233325 Rn.3977 HFE  Hfe Hemochromatosis 0.278 1.327 
Hs.352018 Rn.10763 TAP1  Tap1  
Transporter 1, ATP-binding cassette, sub-
family B  0.300 0.368 
Hs.7367 Rn.6057.2 BTBD6  Btbd6  BTB (POZ) domain containing 6 0.411 -0.489 
Hs.442182 Rn.29976 ABCC6  Abcc6 
ATP-binding cassette, sub-family C 
(CFTR/MRP), 6 0.383 1.350 
Hs.76392 Rn.6132 ALDH1A1  Aldh1a1 
Aldehyde dehydrogenase 1 family, 
member A1 0.756 -1.498 
Hs.97432 Rn.34966 PRKCE  Prkce Protein kinase C, epsilon 0.662 -0.186 
Hs.476209 Rn.26773 PLXNB1  Plxnb1  Plexin B1 1.235 -1.022 
Hs.315562 Rn.2460 GCLM  Gclm 
Glutamate-cysteine ligase, modifier 
subunit 0.784 -0.759 
Hs.29645 Rn.53355 LOC90826   Hypothetical protein BC004337 0.171 -0.173 
Hs.520494 Rn.6137.2 FLJ14525   Hypothetical protein FLJ14525 -0.055 -0.692 
Hs.78482 Rn.18947 PALM  Palm Paralemmin 0.291 -0.059 
Hs.437179 Rn.12866 HTPAP  Htpap  HTPAP protein -0.008 -1.964 
Hs.375108 Rn.6007 CD24  Cd24 
CD24 antigen (small cell lung carcinoma 
cluster 4 antigen) 0.582 -1.226 
Hs.468688 Rn.29813 C10orf137   Chromosome 10 open reading frame 137 -0.003 -0.128 
Hs.528006 Rn.41053 SPHK2  Sphk2  Sphingosine kinase 2 -0.232 -0.328 
Hs.253736 Rn.25344 LRIG3  Lrig3  
Leucine-rich repeats and immunoglobulin-
like domains 3 0.066 -0.117 
Hs.162121 Rn.6104.2 COPA  Copa  Coatomer protein complex, subunit alpha 0.447 -1.064 
Hs.156302 Rn.84872 GTF2IRD1  Gtf2ird1 GTF2I repeat domain containing 1 0.027 -0.316 
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Unigene Gene Symbol  Log Ratio (A/B)* 
Human Rat Human Rat Description Human Rat 
Hs.59757 Rn.22691 ZNF281  Znf281  Zinc finger protein 281 -0.154 0.143 
Hs.527412 Rn.4158 ASAH1  Asah 
N-acylsphingosine amidohydrolase (acid 
ceramidase) 1 0.278 0.825 
Hs.368421 Rn.54555 SMPD3  Smpd3 
Sphingomyelin phosphodiesterase 3, 
neutral membrane (neutral 
sphingomyelinase II) 0.394 -0.522 
Hs.280342 Rn.14623 PRKAR1A  Prkar1A  
Protein kinase, cAMP-dependent, 
regulatory, type I, alpha (tissue specific 
extinguisher 1) -0.032 -0.174 
Hs.162877 Rn.17106 PACSIN2  Pacsin2  
Protein kinase C and casein kinase 
substrate in neurons 2 -0.256 -0.176 
Hs.508461 Rn.11081 MAP3K1  Map3k1 
Mitogen-activated protein kinase kinase 
kinase 1 -0.338 -0.551 
Hs.79276 Rn.2473.2 KIAA0232   KIAA0232 gene product -0.545 -0.152 
Hs.503178 Rn.93208 SPTBN1  Spnb2 Spectrin, beta, non-erythrocytic 1 0.036 0.588 
Hs.180878 Rn.3834 LPL  Lpl Lipoprotein lipase 0.562 0.840 
Hs.76090 Rn.18199 TNFAIP1  Tnfaip1  
Tumor necrosis factor, alpha-induced 
protein 1 (endothelial) -0.060 1.073 
Hs.75372 Rn.55746 NAGA  Naga  N-acetylgalactosaminidase, alpha- -0.095 0.254 
Hs.368912 Rn.91364 DPP4  Dpp4 
Dipeptidylpeptidase 4 (CD26, adenosine 
deaminase complexing protein 2) 0.156 1.690 
Hs.62661 Rn.25736 GBP1  Gbp2 
Guanylate binding protein 1, interferon-
inducible, 67kDa -0.118 0.196 
Hs.513609 Rn.11020 RBL2  Rbl2 Retinoblastoma-like 2 (p130) 0.211 -0.850 
Hs.349656 Rn.3957 SCARB2  Scarb2 Scavenger receptor class B, member 2 -0.053 0.594 
Hs.314338 Rn.62770 WDR9  Wdr9  WD repeat domain 9 0.002 -0.220 
Hs.93836 Rn.19866 DFNB31  Dfnb31  Deafness, autosomal recessive 31 -0.092 -0.041 
Hs.440401 Rn.55275 RetSat  Retsat  All-trans-13,14-dihydroretinol saturase 0.439 -1.162 
Hs.436061 Rn.6396 IRF1  Irf1 Interferon regulatory factor 1 0.103 1.656 
Hs.12114 Rn.16319 VNN1  Vnn1 Vanin 1 -0.066 1.603 
Hs.284712 Rn.11129 BAAT  Baat 
Bile acid Coenzyme A: amino acid N-
acyltransferase (glycine N-
choloyltransferase) 0.227 -0.607 
Hs.103502 Rn.6318 GPT  Gpt 
Glutamic-pyruvate transaminase (alanine 
aminotransferase) 0.230 3.799 
Hs.108969 Rn.98317 PTD008   PTD008 protein -0.379 -1.228 
Hs.251526 Rn.4772 CCL7  Ccl2 Chemokine (C-C motif) ligand 7 -0.395 0.181 
Hs.315137 Rn.8645 AARS  Aars  Alanyl-tRNA synthetase 0.096 1.634 
Hs.311958 Rn.2490 IL15  Il15 Interleukin 15 0.327 -0.212 
Hs.624 Rn.10907 IL8  Cxcl1 Interleukin 8 -0.032 1.350 
Hs.5509 Rn.7907 EVI2B  Evi2B  Ecotropic viral integration site 2B -0.046 0.148 
Hs.99528 Rn.28921 RAB31  Rab31  RAB31, member RAS oncogene family 0.304 1.160 
Hs.43728 Rn.4130 GPX7  Gpx7  Glutathione peroxidase 7 -0.184 0.160 
Hs.102308 Rn.118306 KCNJ8  Kcnj8 
Potassium inwardly-rectifying channel, 
subfamily J, member 8 0.341 0.137 
Hs.159430 Rn.87271 FNDC3B  Fndc3B  Fibronectin type III domain containing 3B 0.240 0.199 
Hs.113912 Rn.23121 RAPGEF2  Rapgef2  
Rap guanine nucleotide exchange factor 
(GEF) 2 0.090 1.848 
Hs.471508 Rn.10476 IRS1  Irs1 Insulin receptor substrate 1 0.197 -0.027 
Hs.1183 Rn.19118 DUSP2  Dusp2  Dual specificity phosphatase 2 0.353 0.063 
Hs.110445 Rn.107123 SBDS  Sbds  Shwachman-Bodian-Diamond syndrome 0.594 1.748 
Hs.128453 Rn.12034 FRZB  Frzb  Frizzled-related protein 0.645 0.125 
  160 
 
Unigene Gene Symbol  Log Ratio (A/B)* 
Human Rat Human Rat Description Human Rat 
Hs.72912 Rn.10352 CYP1A1  Cyp1a1 
Cytochrome P450, family 1, subfamily A, 
polypeptide 1 0.302 -0.211 
Hs.502338 Rn.10240 SLC1A2  Slc1a2 
Solute carrier family 1 (glial high affinity 
glutamate transporter), member 2 0.546 -0.001 
Hs.525459 Rn.17605 DLST  Dlst  
Dihydrolipoamide S-succinyltransferase 
(E2 component of 2-oxo-glutarate 
complex) 0.367 -1.071 
Hs.6147 Rn.105953 TENC1  Tenc1  
Tensin like C1 domain containing 
phosphatase 0.866 -0.763 
Hs.182215 Rn.9538 ARL3  Arl3 ADP-ribosylation factor-like 3 0.341 -0.304 
Hs.371723 Rn.10070 ALDH5A1  Aldh5a1 
Aldehyde dehydrogenase 5 family, 
member A1 (succinate-semialdehyde 
dehydrogenase) 0.407 -0.816 
Hs.444319 Rn.31429 TPMT  Ocln Thiopurine S-methyltransferase 0.223 4.538 
Hs.188553 Rn.95305 RBBP6  Rbbp6  Retinoblastoma binding protein 6 -0.293 -0.010 
Hs.241579 Rn.98199 SERPINH1  Serpinh1 
Serine (or cysteine) proteinase inhibitor, 
clade H (heat shock protein 47), member 1, 
(collagen binding protein 1) -0.030 1.239 
Hs.8309 Rn.11636 MBC2  Mbc2 
Family with sequence similarity 62 (C2 
domain containing), member A -0.369 0.202 
Hs.434326 Rn.24897 EIF2AK3  Eif2ak3 
Eukaryotic translation initiation factor 2-
alpha kinase 3 -0.109 0.331 
Hs.429353 Rn.15108 SEPN1  Sepn1  Selenoprotein N, 1 -0.234 0.325 
Hs.466391 Rn.6445 C19orf2   Chromosome 19 open reading frame 2 -0.019 -0.297 
Hs.519909 Rn.9560 MARCKS  Marcks 
Myristoylated alanine-rich protein kinase C 
substrate -0.009 0.273 
Hs.297324 Rn.3467 TIMP3  Timp3  
Tissue inhibitor of metalloproteinase 3 
(Sorsby fundus dystrophy, 
pseudoinflammatory) -0.122 -0.001 
Hs.9754 Rn.30491 ATF5  Atf5 Activating transcription factor 5 0.489 0.698 
Hs.514220 Rn.5820 GRN  Grn Granulin 0.502 -0.932 
Hs.385986 Rn.20766 UBE2B  LOC81816 
Ubiquitin-conjugating enzyme E2B 
(RAD6 homolog) -0.184 1.359 
Hs.130989 Rn.9808 SCNN1A  Scnn1a Sodium channel, nonvoltage-gated 1 alpha 1.031 -0.027 
Hs.29706 Rn.105727 C14orf149   Chromosome 14 open reading frame 149 0.159 -0.062 
Hs.81337 Rn.64588 LGALS9  Lgals5/9 
Lectin, galactoside-binding, soluble, 9 
(galectin 9) 0.654 1.317 
Hs.148330 Rn.35935 ARF4  Arf4 ADP-ribosylation factor 4 0.168 -0.840 
Hs.298198 Rn.15332 CKLFSF3  Cklfsf3  Chemokine-like factor super family 3 0.158 0.661 
Hs.529989 Rn.18019 RNASET2  Rnaset2  Ribonuclease T2 -0.112 -1.500 
Hs.287362 Rn.24106 TLE3  Tle3 
Transducin-like enhancer of split 3 (E(sp1) 
homolog, Drosophila) 0.068 0.562 
Hs.485760 Rn.6598.2 SLC17A5  Slc17A5  
Solute carrier family 17 (anion/sugar 
transporter), 5 -0.108 -0.263 
Hs.24178 Rn.76362 EML2  Eml2 
Echinoderm microtubule associated protein 
like 2 -0.321 0.072 
Hs.75516 Rn.38688 TYK2  Tyk2  Tyrosine kinase 2 -0.473 -0.308 
Hs.252682 Rn.6487 TOR1B  Tor1B  Torsin family 1, member B (torsin B) -0.241 -0.085 
Hs.57698 Rn.12640 NSDHL  Nsdhl  
NAD(P) dependent steroid dehydrogenase-
like -0.216 0.696 
Hs.521640 Rn.67042 RAD23B  LOC298012 RAD23 homolog B (S. cerevisiae) -0.193 -0.634 
Hs.473937 Rn.6452 NDUFV3  Mipp65 
NADH dehydrogenase (ubiquinone) 
flavoprotein 3, 10kDa -0.082 0.684 
Hs.191887 Rn.103030 SEC61B  Sec61B  Sec61 beta subunit -0.244 -0.539 
Hs.51483 Rn.32292 MGC17301  Mgc17301  Hypothetical protein MGC17301 0.023 1.158 
Hs.349150 Rn.3147 PURB  Purb  Purine-rich element binding protein B -0.362 -0.212 
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Unigene Gene Symbol  Log Ratio (A/B)* 
Human Rat Human Rat Description Human Rat 
Hs.517240 Rn.23305 IFNGR2  Ifngr2  
Interferon gamma receptor 2 -interferon 
gamma transducer -0.162 0.132 
Hs.368255 Rn.22555 KIAA0368   KIAA0368 -0.177 -0.515 
Hs.313227 Rn.10301 CHRNE  Chrne 
Cholinergic receptor, nicotinic, epsilon 
polypeptide -0.100 -0.141 
Hs.518267 Rn.91296 TF  Tf Transferrin -0.176 -0.176 
Hs.381099 Rn.14256 LCP1  Lcp1  Lymphocyte cytosolic protein 1 (L-plastin) 0.195 -0.825 
Hs.477128 Rn.2193 URB  Ssg1 Steroid sensitive gene 1 0.213 -0.972 
Hs.529408 Rn.38581 BACE2  Bace2 Beta-site APP-cleaving enzyme 2 0.786 0.049 
Hs.73677 Rn.22170 RFX1  Rfx1  
Regulatory factor X, 1 influences HLA 
class II expression 0.040 0.477 
Hs.134544 Rn.55497 SLC25A21  Slc25a21 
Solute carrier family 25 (mitochondrial 
oxodicarboxylate carrier), member 21 -0.048 -0.323 
Hs.255664 Rn.10893 CYLN2  Cyln2 Cytoplasmic linker 2 0.070 0.071 
Hs.533934 Rn.126649 FLJ20254   Hypothetical protein FLJ20254 -0.318 1.099 
Hs.470316 Rn.87899 ACVR1  Acvr1 Activin A receptor, type I -0.134 0.059 
Hs.386434 Rn.106184 ANXA7  Anxa7 Annexin A7 -0.096 1.686 
Hs.91586 Rn.12071 TM9SF1  Tm9Sf1  Transmembrane 9 superfamily member 1 -0.310 -0.335 
Hs.463964 Rn.12436 WIPI49  Wipi49  
WD40 repeat protein Interacting with 
phosphoInositides of 49kDa -0.171 -0.319 
Hs.529846 Rn.63999 CAMLG  Camlg Calcium modulating ligand -0.174 -0.060 
Hs.292949 Rn.19822 INO80  Ino80  Homolog of yeast INO80 -0.411 -0.273 
Hs.165950 Rn.24104 FGFR4  Fgfr4  Fibroblast growth factor receptor 4 -0.156 -0.545 
Hs.76111 Rn.2065 DAG1  Dag1  
Dystroglycan 1 (dystrophin-associated 
glycoprotein 1) -0.552 -1.438 
Hs.492314 Rn.8123 LAPTM4B  Laptm4B  
Lysosomal associated protein 
transmembrane 4 beta -0.021 0.969 
Hs.523443 Rn.102461 HBB  Hbb Hemoglobin, beta 0.094 -3.100 
Hs.524224 Rn.3918 C1R  C1R  
Complement component 1, r 
subcomponent -0.634 1.339 
Hs.397153 Rn.39153 LOC126208   Hypothetical protein LOC126208 -0.385 -0.229 
Hs.5462 Rn.11114 SLC4A4  Slc4a4 
Solute carrier family 4, sodium bicarbonate 
cotransporter,4 -0.921 0.776 
Hs.82614 Rn.2906 GYS2  Gys2 Glycogen synthase 2 (liver) -1.319 -1.173 
Hs.181128 Rn.17303 ELK1  Elk1  ELK1, member of ETS oncogene family -0.059 -0.007 
Hs.299878 Rn.34792 DEGS1  Degs 
Degenerative spermatocyte homolog 1, 
lipid desaturase (Drosophila) -0.044 1.702 
Hs.374509 Rn.17785 UBQLN4  Ubqln4  Ubiquilin 4 -0.433 -0.329 
Hs.458390 Rn.17962 KIAA1698   KIAA1698 protein -0.096 -0.143 
Hs.521608 Rn.14754 CHPPR  Chppr  
Likely ortholog of chicken chondrocyte 
protein with a poly-proline region -0.064 0.439 
Hs.507087 Rn.5977 SPPL3  Sppl3  Signal peptide peptidase 3 -0.156 -1.362 
Hs.3447 Rn.24570 DKFZP564K1964  DKFZP564K1964 protein -0.180 -0.394 
Hs.380929 Rn.43996 LDHD  Ldhd  Lactate dehydrogenase D -0.674 -1.207 
Hs.2899 Rn.3664 HPD  Hpd 4-hydroxyphenylpyruvate dioxygenase -0.116 1.262 
Hs.509718 Rn.28520 ZNF318  Znf318  Zinc finger protein 318 -0.292 -0.167 
Hs.8821 Rn.7865 HAMP  Hamp Hepcidin antimicrobial peptide -2.580 -2.236 
Hs.144567 Rn.9931 AGXT  Agxt 
Alanine-glyoxylate aminotransferase 
(oxalosis I; hyperoxaluria I; 
glycolicaciduria; serine-pyruvate 
aminotransferase) -1.664 2.878 
Hs.522099 Rn.34735 PIGO  Pigo  Phosphatidylinositol glycan, class O -0.401 -0.133 
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Unigene Gene Symbol  Log Ratio (A/B)* 
Human Rat Human Rat Description Human Rat 
Hs.236030 Rn.20004 SMARCC2  Smarcc2  
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, 
subfamily c, member 2 -0.292 -0.447 
Hs.192326 Rn.7581 SNX27  Snx27 Sorting nexin family member 27 -0.553 -0.070 
Hs.389461 Rn.8798 SMAP-1  Smap-1  Smooth muscle cell associated protein-1 -0.264 -0.785 
Hs.439127 Rn.67071 CACH-1  rACH Cytosolic acetyl-CoA hydrolase -0.344 0.540 
Hs.103934 Rn.3625 FKBP9  Fkbp9  FK506 binding protein 9, 63 kDa -0.201 0.760 
Hs.507681 Rn.17231 MAP3K7IP1  Map3K7Ip1  
Mitogen-activated protein kinase kinase 
kinase 7 interacting protein 1 -0.204 -0.188 
Hs.386404 Rn.18962 UBE4B  Ube4B  
Ubiquitination factor E4B (UFD2 
homolog, yeast) -0.099 -2.213 
Hs.503022 Rn.23976 C11orf23   Chromosome 11 open reading frame 23 -0.019 -0.867 
Hs.96513 Rn.9343 USP40  Usp40  Ubiquitin specific protease 40 -0.225 -0.634 
Hs.12970 Rn.101332 PSMD3  Psmd3  
Proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 3 -0.029 -1.597 
Hs.369373 Rn.8735 SEC23B  Sec23B  Sec23 homolog B (S. cerevisiae) -0.016 -1.701 
Hs.146806 Rn.68078 CUL1  Cul1  Cullin 1 0.084 -0.761 
Hs.163867 Rn.42942 CD14  Cd14 CD14 antigen -0.782 1.053 
Hs.378505 Rn.3309 MOSPD1  Mospd1  Motile sperm domain containing 1 -0.096 -0.635 
Hs.238432 Rn.15048 SP192   Hypothetical protein SP192 -0.142 -0.316 
Hs.164410 Rn.18619 C16orf7   Chromosome 16 open reading frame 7 0.232 -2.077 
Hs.198158 Rn.2417 MAWBP  Mawbp MAWD binding protein -0.517 1.122 
Hs.449076 Rn.39242 PWP2H  Pwp2H  
PWP2 periodic tryptophan protein 
homolog (yeast) 0.132 -0.072 
Hs.159699 Rn.25752 FBXO21  Serpinb5 F-box protein 21 0.470 -0.297 
Hs.381072 Rn.2923 PPIF  Ppif Peptidylprolyl isomerase F (cyclophilin F) 0.350 0.472 
Hs.512815 Rn.8074 AP3D1  Ap3D1  
Adaptor-related protein complex 3, delta 1 
subunit 0.340 0.424 
Hs.310591 Rn.8844 SLC22A4  Slc22a5 
Solute carrier family 22 (organic cation 
transporter), member 4 -0.047 -0.557 
Hs.531615 Rn.34645 MtFMT  Mtfmt  
Methionyl-tRNA formyltransferase, 
mitochondrial 0.184 -0.092 
Hs.1422 Rn.11309 FGR  Fgr 
Gardner-Rasheed feline sarcoma viral (v-
fgr) oncogene homolog 0.141 0.399 
Hs.16004 Rn.8704 C10orf76   Chromosome 10 open reading frame 76 -0.030 -0.111 
Hs.507916 Rn.3545 TGFB1I4  Tgfb1i4 TSC22 domain family 1 -0.055 -1.202 
Hs.508545 Rn.2539 PHGDHL1  Phgdhl1  Phosphoglycerate dehydrogenase like 1 0.008 -0.572 
Hs.157351 Rn.5874 PTD004  Ptd004  GTP-binding protein PTD004 0.175 -0.802 
Hs.307734 Rn.33598 MME  Mme 
Membrane metallo-endopeptidase (neutral 
endopeptidase, enkephalinase, CALLA, 
CD10) 0.169 -0.272 
Hs.391561 Rn.4258 FABP4  Fabp4 Fatty acid binding protein 4, adipocyte 0.364 0.970 
Hs.181301 Rn.11347 CTSS  Ctss Cathepsin S 0.873 -1.944 
Hs.433300 Rn.9277 FCER1G  Fcer1g 
Fc fragment of IgE, high affinity I, receptor 
for; gamma polypeptide 0.299 -2.848 
Hs.372679 Rn.23977 FCGR3B  LOC304966 
Fc fragment of IgG, low affinity IIIb, 
receptor (CD16b) 0.154 0.307 
Hs.375115 Rn.20089 HLA-DQB2  RT1-Bb 
Major histocompatibility complex, class II, 
DQ beta 2 1.576 0.681 
Hs.128846 Rn.53971 PTPNS1  Ptpns1 
Protein tyrosine phosphatase, non-receptor 
type substrate 1 0.706 0.556 
Hs.1166 Rn.10576 THPO  Thpo 
Thrombopoietin (myeloproliferative 
leukemia virus oncogene ligand, 
megakaryocyte growth and development 1.086 -0.040 
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Hs.91109 Rn.37820 LOC222171   Hypothetical protein LOC222171 0.058 -0.956 
Hs.42853 Rn.18179 CREBL1  Crebl1 
CAMP responsive element binding 
protein-like 1 -0.192 -0.249 
Hs.529285 Rn.15324 SLC40A1  Slc40a1 
Solute carrier family 40 (iron-regulated 
transporter), member 1 1.871 -2.049 
Hs.5710 Rn.3532 CREG1  Creg1  
Cellular repressor of E1A-stimulated genes 
1 2.169 0.812 
Hs.8867 Rn.22129 CYR61  Cyr61 Cysteine-rich, angiogenic inducer, 61 1.095 0.139 
Hs.490892 Rn.9048 MCPH1  Agpt2 
Microcephaly, primary autosomal 
recessive 1 -0.040 -0.020 
Hs.386866 Rn.18956 PTPRG  Ptprg  
Protein tyrosine phosphatase, receptor 
type, G 0.117 -0.064 
Hs.369615 Rn.21048 FLJ20551   Hypothetical protein FLJ20551 0.065 -1.246 
Hs.76206 Rn.7055 CDH5  Cdh5  
Cadherin 5, type 2, VE-cadherin (vascular 
epithelium) 0.620 0.539 
Hs.310421 Rn.38834 APBB1IP  Apbb1Ip  
Amyloid beta (A4) precursor protein-
binding, family B, member 1 interacting 
protein -0.346 0.500 
Hs.77890 Rn.87228 GUCY1B3  Gucy1b3 Guanylate cyclase 1, soluble, beta 3 0.203 0.073 
Hs.338182 Rn.14938 UNQ9217   AASA9217 -0.032 0.088 
Hs.546267 Rn.74064 MMP16  Mmp16 
Matrix metalloproteinase 16 (membrane-
inserted) 0.113 0.029 
Hs.50282 Rn.11259 RRAGB  RragB Ras-related GTP binding B 0.100 -0.006 
Hs.11170 Rn.15446 RBM14  Rbm14  RNA binding motif protein 14 0.063 -0.178 
Hs.479634 Rn.19979 SLC30A9  Slc30A9  
Solute carrier family 30 (zinc transporter), 
member 9 0.125 -0.248 
Hs.516341 Rn.34623 FLJ10081   Hypothetical protein FLJ10081 0.004 -0.279 
Hs.443057 Rn.31988 CD53  Cd53 CD53 antigen 0.351 1.121 
Hs.481980 Rn.14763 DAB2  Dab2 
Disabled homolog 2, mitogen-responsive 
phosphoprotein (Drosophila) 0.161 1.356 
Hs.550470 Rn.32777 CP  Cp Ceruloplasmin (ferroxidase) -0.185 -1.008 
Hs.325404 Rn.1652 PAH  Pah Phenylalanine hydroxylase 0.064 0.751 
Hs.128065 Rn.107912 CTSC  Ctsc Cathepsin C 0.094 -1.165 
Hs.516700 Rn.94956 CYP27A1  Cyp27a1 
Cytochrome P450, family 27, subfamily A, 
polypeptide 1 0.041 0.770 
Hs.146447 Rn.12759 FBN1  Fbn1 Fibrillin 1 (Marfan syndrome) 0.087 0.204 
Hs.489142 Rn.107239 COL1A2  Col1a2 Collagen, type I, alpha 2 0.122 1.034 
Hs.410037 Rn.17145 CTGF  Ctgf Connective tissue growth factor 0.408 0.658 
Hs.430551 Rn.12233 IQGAP1  Iqgap1  
IQ motif containing GTPase activating 
protein 1 0.243 0.495 
Hs.389733 Rn.10995 RAB8B  Rab8b RAB8B, member RAS oncogene family 0.131 0.079 
Hs.498143 Rn.3547 TBCE  Tbce  Tubulin-specific chaperone e -0.155 -0.234 
Hs.500526 Rn.1237 BTAF1  Btaf1  
BTAF1 RNA polymerase II, B-TFIID 
transcription factor-associated, 170kDa 
(Mot1 homolog, S. cerevisiae) 0.101 -0.189 
Hs.515469 Rn.98750 VASP  Vasp  Vasodilator-stimulated phosphoprotein 0.179 1.341 
Hs.5353 Rn.54474 CASP10  Casp8 
Caspase 10, apoptosis-related cysteine 
protease -0.041 0.129 
Hs.90232 Rn.7646 ProSAPiP1   ProSAPiP1 protein -0.063 -0.199 
Hs.131933 Rn.3413 FLJ22662   Hypothetical protein FLJ22662 0.200 -1.350 
Hs.529044 Rn.37799 RAB22A  Rab22A  RAB22A, member RAS oncogene family 0.077 0.865 
Hs.410092 Rn.3798 KIAA0652   KIAA0652 gene product 0.431 -3.839 
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Hs.135087 Rn.1716 IL6R  Il6r Interleukin 6 receptor 1.602 -1.852 
Hs.436410 Rn.127 TBRG1  Tbrg1  
Transforming growth factor beta regulator 
1 0.187 -2.094 
Hs.477009 Rn.24190 USP24  Usp24  Ubiquitin specific protease 24 0.123 0.841 
Hs.98041 Rn.16048 ZFYVE26  Zfyve26  Zinc finger, FYVE domain containing 26 -0.131 -1.309 
Hs.19383 Rn.6319 AGT  Agt 
Angiotensinogen (serine (or cysteine) 
proteinase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 8) 1.638 1.891 
Hs.84928 Rn.90077 NFYB  Nfyb Nuclear transcription factor Y, beta -0.093 0.021 
Hs.482043 Rn.3128 NNT  Nnt Nicotinamide nucleotide transhydrogenase 0.143 
-
00.859 
Hs.88025 Rn.1508 VPS39  Vps39  Vacuolar protein sorting 39 (yeast) 0.105 -0.047 
Hs.481371 Rn.8633 FAT  Fat 
FAT tumor suppressor homolog 1 
(Drosophila) 0.100 -1.146 
Hs.546303 Rn.8796 ST13  St13 
Suppression of tumorigenicity 13 (colon 
carcinoma) (Hsp70 interacting protein) -0.052 -1.591 
Hs.173859 Rn.1806 FZD7  Fzd7  Frizzled homolog 7 (Drosophila) 0.215 -0.226 
Hs.482976 Rn.17425 LOC90355   
Hypothetical gene supported by 
AF038182; BC009203 0.230 0.614 
Hs.43670 Rn.47400 KIF3A   Kinesin family member 3A 0.022 0.070 
Hs.146339 Rn.3973 PPP2R2A  Rpl29 
Protein phosphatase 2 (formerly 2A), 
regulatory subunit B (PR 52), alpha 
isoform 0.191 -0.574 
Hs.26333 Rn.38478 CXorf37   Chromosome X open reading frame 37 -0.113 -0.449 
Hs.524579 Rn.2283 LYZ  Lyz Lysozyme (renal amyloidosis) 0.521 -1.387 
Hs.510833 Rn.12180 TJP1  Tjp1  Tight junction protein 1 (zona occludens 1) 0.130 -1.614 
Hs.434951 Rn.6294 USP15  Usp15  Ubiquitin specific protease 15 0.309 -0.194 
Hs.516119 Rn.22161 GCS1  Gcs1 Glucosidase I -0.108 1.608 
Hs.403010 Rn.15339 TTRAP  Ttrap  TRAF and TNF receptor associated protein -0.117 -0.058 
Hs.406590 Rn.3393 PGR1  Pgr1 Mof4 family associated protein 1 0.108 -0.823 
Hs.348921 Rn.3080 PHF3  Phf3  PHD finger protein 3 -0.005 -0.113 
Hs.332138 Rn.81052 PPT2  Ppt2 Palmitoyl-protein thioesterase 2 -0.068 -0.165 
Hs.500066 Rn.8027 TADA2L  Tada2L  
Transcriptional adaptor 2 (ADA2 homolog, 
yeast)-like 0.094 -0.048 
Hs.437084 Rn.29454 NKRF  Nkrf  NF-kappaB repressing factor 0.214 -0.426 
Hs.273621 Rn.31762 CNP  Cnp1 2',3'-cyclic nucleotide 3' phosphodiesterase 0.022 1.255 
Hs.311072 Rn.8870 MRPS35  Mrps35  Mitochondrial ribosomal protein S35 0.207 -0.713 
Hs.52788 Rn.93013 FXR2  Fxr2  
Fragile X mental retardation, autosomal 
homolog 2 0.104 -0.252 
Hs.80720 Rn.1725 GAB1  Gab1  GRB2-associated binding protein 1 0.216 -0.872 
Hs.201398 Rn.53880 C1QTNF1  C1Qtnf1  
C1q and tumor necrosis factor related 
protein 1 0.339 0.082 
Hs.478150 Rn.1176 PDCD10  Pdcd10  Programmed cell death 10 0.038 0.682 
Hs.277721 Rn.7811 M17S2  M17S2  Neighbor of BRCA1 gene 1 0.021 1.180 
Hs.471851 Rn.122675 HDLBP  Hdlbp 
High density lipoprotein binding protein 
(vigilin) 0.075 0.865 
Hs.524491 Rn.3668 PAPSS2  Papss2  
3'-phosphoadenosine 5'-phosphosulfate 
synthase 2 0.075 1.735 
Hs.440961 Rn.17481 CAST  Cast Calpastatin -0.013 0.376 
Hs.250009 Rn.6283 ARL10C  Arl10C  ADP-ribosylation factor-like 10C 0.091 0.784 
Hs.114033 Rn.25091 SSR1  Ssr1  
Signal sequence receptor, alpha 
(translocon-associated protein alpha) -0.008 -1.077 
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Hs.191334 Rn.6357 UNG  Ung  Uracil-DNA glycosylase -0.005 1.114 
Hs.180877 Rn.9454 H3F3B  H3F3B  H3 histone, family 3B (H3.3B) 0.146 -1.674 
Hs.155827 Rn.6165 GOLGA2  Golga2 Golgi autoantigen, golgin subfamily a, 2 -0.048 -0.100 
Hs.201641 Rn.37779 BASP1  Basp1 
Brain abundant, membrane attached signal 
protein 1 0.609 0.032 
Hs.104879 Rn.95177 SERPINB9  Serpinb9  
Serine (or cysteine) proteinase inhibitor, 
clade B (ovalbumin), member 9 0.269 -0.760 
Hs.79769 Rn.8926 PCDH1  Pcdh1  Protocadherin 1 (cadherin-like 1) 0.074 -0.340 
Hs.210850 Rn.36797 HECTD1  Hectd1  HECT domain containing 1 0.226 0.619 
Hs.546298 Rn.5958 SUMO2  Sumo2 
SMT3 suppressor of mif two 3 homolog 2 
(yeast) 0.122 -1.341 
Hs.464595 Rn.16065 PPP4R1  Ppp4r1 Protein phosphatase 4, regulatory subunit 1 0.177 -0.320 
Hs.500842 Rn.1048 MGEA5  Mgea5  
Meningioma expressed antigen 5 
(hyaluronidase) 0.108 1.970 
Hs.212046 Rn.22211 KIAA0433   KIAA0433 protein 0.179 -0.199 
Hs.216653 Rn.3335 FBXO9  Fbxo9  F-box protein 9 0.017 1.715 
Hs.109051 Rn.18564 SH3BGRL3  Sh3Bgrl3  
SH3 domain binding glutamic acid-rich 
protein like 3 0.212 1.748 
Hs.462278 Rn.36639 COX10  Cox10  
COX10 homolog, cytochrome c oxidase 
assembly protein, heme A: 
farnesyltransferase (yeast) 0.218 -0.306 
Hs.469537 Rn.13913 MRPS9  Mrps9  Mitochondrial ribosomal protein S9 0.287 -0.229 
Hs.471675 Rn.17832 DGKD  Dgkd  Diacylglycerol kinase, delta 130kDa 0.164 -0.089 
Hs.85951 Rn.2238 XPOT  Xpot  
Exportin, tRNA (nuclear export receptor 
for tRNAs) 0.199 0.713 
Hs.432424 Rn.28991 TPP2  Tpp2 Tripeptidyl peptidase II 0.325 -0.474 
Hs.268849 Rn.108014 GLO1  Glo1 Glyoxalase I 0.179 -0.810 
Hs.549238 Rn.46749 LOC126731   LOC126731 0.084 -0.050 
Hs.445000 Rn.10361 PTGER3  Ptger3 Prostaglandin E receptor 3 (subtype EP3) 0.161 0.432 
Hs.433653 Rn.106312 MDC1  Mdc1 Mediator of DNA damage checkpoint 1 0.077 -0.037 
Hs.474069 Rn.11954 PCNT2  Pcnt2  Pericentrin 2 (kendrin) 0.106 -0.031 
Hs.412707 Rn.47 HPRT1  Hprt 
Hypoxanthine phosphoribosyltransferase 1 
(Lesch-Nyhan syndrome) 0.296 -1.194 
Hs.466714 Rn.40291 PD2  Pd2  Hypothetical protein F23149_1 0.157 -0.117 
Hs.46523 Rn.94638 ELK3  Elk3  
ELK3, ETS-domain protein (SRF 
accessory protein 2) 0.164 0.246 
Hs.444870 Rn.13505 ORC2L  Orc2L  
Origin recognition complex, subunit 2-like 
(yeast) 0.304 -0.233 
Hs.523594 Rn.5598 CTSK  Ctsk Cathepsin K (pycnodysostosis) 0.312 0.096 
Hs.83286 Rn.14013 KDELC2  Kdelc2  KDEL (Lys-Asp-Glu-Leu) containing 2 0.212 0.110 
Hs.79402 Rn.22044 POLR2C  Polr2C  
Polymerase (RNA) II (DNA directed) 
polypeptide C, 33kDa 0.273 -0.263 
Hs.301419 Rn.2055 TERF2IP  Terf2Ip  
Telomeric repeat binding factor 2, 
interacting protein 0.298 -1.062 
Hs.377360 Rn.22855 KIAA1971   
Similar to junction-mediating and 
regulatory protein p300 JMY 0.242 -0.101 
Hs.433269 Rn.55623 C14orf11   Chromosome 14 open reading frame 11 0.155 -0.255 
Hs.549082 Rn.13007 BCL10  Bcl10 B-cell CLL/lymphoma 10 0.153 0.903 
Hs.427284 Rn.4237 ZNRF1  Znrf1  Zinc and ring finger 1 0.217 -0.064 
Hs.6877 Rn.7690 C14orf130   Chromosome 14 open reading frame 130 0.207 -0.138 
Hs.516468 Rn.39047 ARL6IP6  Arl6Ip6  
ADP-ribosylation-like factor 6 interacting 
protein 6 0.179 0.009 
Hs.406461 Rn.8024 ALG1  Alg1  Asparagine-linked glycosylation 1 0.159 -0.025 
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homolog (yeast, beta-1,4-
mannosyltransferase) 
Hs.323583 Rn.20514 DKFZp434L142  MGC72614 Hypothetical protein DKFZp434L142 0.170 0.383 
Hs.270543 Rn.10844 GNB4  Gnb4  
Guanine nucleotide binding protein (G 
protein), beta polypeptide 4 0.300 0.146 
Hs.336916 Rn.870 DAXX  Daxx Death-associated protein 6 0.167 0.289 
Hs.525238 Rn.2583 C14orf119   Chromosome 14 open reading frame 119 0.149 -0.156 
Hs.410406 Rn.7758 SMARCAD1  Smarcad1  
SWI/SNF-related, matrix-associated actin-
dependent regulator of chromatin, 
subfamily a, containing DEAD/H box 1 0.303 -0.094 
Hs.173162 Rn.6292 NOC4  Noc4  Neighbor of COX4 0.268 -0.376 
Hs.469030 Rn.11744 MTHFD2  Mthfd2  
Methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 0.350 0.281 
Hs.81791 Rn.9792 TNFRSF11B  Tnfrsf11b 
Tumor necrosis factor receptor 
superfamily, member 11b (osteoprotegerin) 0.437 0.373 
Hs.87595 Rn.41817 TIMM22  Timm22  
Translocase of inner mitochondrial 
membrane 22 homolog (yeast) 0.322 -0.025 
Hs.74471 Rn.10346 GJA1  Gja1 
Gap junction protein, alpha 1, 43kDa 
(connexin 43) 0.336 0.218 
Hs.435215 Rn.6913 VEGFC  Vegfc Vascular endothelial growth factor C 0.378 0.186 
Hs.494173 Rn.1792 ANXA1  Anxa1 Annexin A1 0.416 1.472 
Hs.156519 Rn.3174 MSH2  Msh2 
MutS homolog 2, colon cancer, 
nonpolyposis type 1 (E. coli) 0.221 -0.034 
Hs.289044 Rn.106264 LOC493869   Similar to RIKEN cDNA 2310016C16 0.332 0.068 
Hs.425427 Rn.33249 LYAR  Lyar  Hypothetical protein FLJ20425 0.303 -0.268 
Hs.12109 Rn.108832 WDR39  Ciao1 WD repeat domain 39 0.225 -0.302 
Hs.474436 Rn.49122 HPS4  Hps4  Hermansky-Pudlak syndrome 4 0.237 -0.326 
Hs.409137 Rn.5910 EIF2B2  Eif2b2 
Eukaryotic translation initiation factor 2B, 
subunit 2 beta, 39kDa 0.214 1.285 
Hs.258209 Rn.31889 RAB3IP  RABIN3 RAB3A interacting protein (rabin3) 0.129 -0.099 
Hs.76556 Rn.2232 PPP1R15A  Myd116 
Protein phosphatase 1, regulatory 
(inhibitor) subunit 15A 0.209 -0.131 
Hs.406423 Rn.103341 SF3B2  Sf3B2  Splicing factor 3b, subunit 2, 145kDa 0.085 0.107 
Hs.181112 Rn.6309 MED4  Med4  
Mediator of RNA polymerase II 
transcription, subunit 4 homolog (yeast) 0.289 -0.335 
Hs.425091 Rn.27518 FAM44B  Fam44B  
Family with sequence similarity 44, 
member B 0.102 -0.168 
Hs.284141 Rn.22402 TSPYL4  Tspyl4  TSPY-like 4 0.241 -0.514 
Hs.396447 Rn.47229 FLJ32065   Hypothetical protein FLJ32065 0.195 -0.905 
Hs.461361 Rn.123614 CFDP1  Cfdp1 Craniofacial development protein 1 0.191 -0.688 
Hs.3100 Rn.46563 KARS  Kars Lysyl-tRNA synthetase 0.309 3.232 
Hs.12013 Rn.2961 ABCE1  Abce1  
ATP-binding cassette, sub-family E 
(OABP), member 1 0.367 2.339 
Hs.127092 Rn.35093 DHX38  Dhx38  
DEAH (Asp-Glu-Ala-His) box polypeptide 
38 0.245 2.134 
Hs.75890 Rn.2362 MBTPS1  Mbtps1 
Membrane-bound transcription factor 
protease, site 1 0.247 1.731 
Hs.16355 Rn.98166 MYH10  Myh10 Myosin, heavy polypeptide 10, non-muscle 0.371 0.378 
Hs.401509 Rn.8822 RBM10  Rbm10 RNA binding motif protein 10 0.116 -0.166 
Hs.482390 Rn.8191 TGFBR3  Tgfbr3  
Transforming growth factor, beta receptor 
III (betaglycan, 300kDa) 0.236 0.415 
Hs.292493 Rn.27023 G22P1  G22p1 Thyroid autoantigen 70kDa (Ku antigen) 0.163 -0.043 
Hs.380403 Rn.19047 PCGF4  Pcgf4  Polycomb group ring finger 4 0.128 -0.473 
Hs.497039 Rn.7145 LAMC1  Lamc1 Laminin, gamma 1 (formerly LAMB2) 0.240 0.146 
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Hs.435413 Rn.94848 MTA3  Mta3  Metastasis associated 1 family, member 3 0.124 0.320 
Hs.472010 Rn.3936 PRNP  Prnp 
Prion protein (p27-30) (Creutzfeld-Jakob 
disease, Gerstmann-Strausler-Scheinker 
syndrome, fatal familial insomnia) 0.477 0.947 
Hs.500572 Rn.8225 FER1L3  Fer1L3  Fer-1-like 3, myoferlin (C. elegans) 0.337 0.142 
Hs.332197 Rn.8933 D2S448  D2S448  Melanoma associated gene 0.347 0.690 
Hs.101302 Rn.11218 COL12A1  Col12a1 Collagen, type XII, alpha 1 0.283 0.084 
Hs.500013 Rn.21289 DNAJB12  Dnajb12  
DnaJ (Hsp40) homolog, subfamily B, 
member 12 0.124 -0.094 
Hs.173001 Rn.8773 ZNF644  Znf644  Zinc finger protein 644 0.135 -0.299 
Hs.27184 Rn.11039 GFER  Gfer 
Growth factor, augmenter of liver 
regeneration (ERV1 homolog, S. 
cerevisiae) 0.198 -0.591 
Hs.443625 Rn.3247 COL3A1  Col3a1 
Collagen, type III, alpha 1 (Ehlers-Danlos 
syndrome type IV, autosomal dominant) 0.259 -2.945 
Hs.269512 Rn.95652 FSTL1  Fstl1 Follistatin-like 1 0.235 0.317 
Hs.511952 Rn.12512 CBX6  Cbx7 Chromobox homolog 6 0.265 -0.005 
Hs.381985 Rn.56270  Amd1 
Homo sapiens, clone IMAGE:4337652, 
mRNA 0.198 -1.085 
Hs.509909 Rn.24380 NUMB  Numb  Numb homolog (Drosophila) 0.209 -1.141 
Hs.416049 Rn.8631 TNPO2  Tnpo2  
Transportin 2 (importin 3, karyopherin beta 
2b) 0.148 1.986 
Hs.55041 Rn.102111 MRPL2  Mrpl2  Mitochondrial ribosomal protein L2 0.095 -0.883 
Hs.158688 Rn.107482 EIF5B  Eif5b Eukaryotic translation initiation factor 5B 0.144 -0.741 
Hs.406534 Rn.79731 HMG20B  Hmg20B  High-mobility group 20B 0.250 -1.722 
Hs.532091 Rn.11685 AP3B1  Ap3B1  
Adaptor-related protein complex 3, beta 1 
subunit 0.079 1.000 
Hs.435231 Rn.11634 ZFR  Zfr  Zinc finger RNA binding protein 0.155 -1.049 
Hs.6076 Rn.3963 COPS3  Cops3 
COP9 constitutive photomorphogenic 
homolog subunit 3 (Arabidopsis) 0.347 0.669 
Hs.445748 Rn.2386 FCHSD2  Fchsd2  FCH and double SH3 domains 2 0.209 0.556 
Hs.5120 Rn.35769 DNCL1  Pin Dynein, cytoplasmic, light polypeptide 1 0.026 -2.154 
Hs.474949 Rn.8068 RBX1  Rbx1  Ring-box 1 0.144 -0.962 
Hs.268177 Rn.11243 PLCG1  Plcg1 Phospholipase C, gamma 1 0.178 -2.454 
Hs.250493 Rn.47120 ZNF219  Znf219  Zinc finger protein 219 0.124 -0.078 
Hs.187763 Rn.9365 BRD4  Brd4  Bromodomain containing 4 0.127 -1.451 
Hs.106674 Rn.3382 BAP1  Bap1  
BRCA1 associated protein-1 (ubiquitin 
carboxy-terminal hydrolase) 0.036 -0.537 
Hs.496068 Rn.16871 PCTK1  Pctk1 PCTAIRE protein kinase 1 0.016 -1.054 
Hs.475401 Rn.6207 TATDN2  Tatdn2  TatD DNase domain containing 2 0.041 -0.565 
Hs.378532 Rn.2852 HBS1L  Hbs1L  HBS1-like (S. cerevisiae) 0.231 -0.408 
Hs.534312 Rn.20041 TOR1A  Dyt1 Torsin family 1, member A (torsin A) 0.165 -0.056 
Hs.133044 Rn.18832 RAPTOR   Raptor 0.031 -0.727 
Hs.532216 Rn.64629 MTERF  Mterf 
Transcription termination factor, 
mitochondrial 0.213 -0.690 
Hs.63348 Rn.99346 EMILIN1  Emilin1  Elastin microfibril interfacer 1 0.204 1.740 
Hs.75231 Rn.6085 SLC16A1  Slc16a1 
Solute carrier family 16 (monocarboxylic 
acid transporters), member 1 0.286 -1.217 
Hs.160958 Rn.17982 CDC37  Cdc37 
CDC37 cell division cycle 37 homolog (S. 
cerevisiae) 0.135 -0.477 
Hs.131151 Rn.24127 PSMD9  Psmd9 
Proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 9 -0.005 1.468 
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Hs.522418 Rn.40526 GLE1L  Gle1L  GLE1 RNA export mediator-like (yeast) 0.163 -0.036 
Hs.150749 Rn.9996 BCL2  Bcl2 B-cell CLL/lymphoma 2 0.237 0.056 
Hs.474053 Rn.107165 COL6A1  Col6A1  Collagen, type VI, alpha 1 0.298 1.162 
Hs.198281 Rn.1556 PKM2  Pkm2 Pyruvate kinase, muscle 0.173 1.561 
Hs.146585 Rn.94288 LEPROTL1  Leprotl1  
Leptin receptor overlapping transcript-like 
1 0.225 2.123 
Hs.270532 Rn.29982 PEX12  Pex12 Peroxisomal biogenesis factor 12 0.006 -0.065 
Hs.413801 Rn.16691 PSME4  Psme4  
Proteasome (prosome, macropain) 
activator subunit 4 0.121 0.601 
Hs.500419 Rn.28390 FAM35A  Fam35A  
Family with sequence similarity 35, 
member A 0.112 -0.127 
Hs.443240 Rn.8177.2 FLJ12716   FLJ12716 protein 0.188 -0.080 
Hs.192039 Rn.14233 PTPRC  Ptprc  
Protein tyrosine phosphatase, receptor 
type, C 0.344 0.522 
Hs.128067 Rn.7914 WASPIP  Waspip 
Wiskott-Aldrich syndrome protein 
interacting protein 0.227 0.318 
Hs.515524 Rn.1492 NUCB1  Nucb Nucleobindin 1 0.172 -0.802 
Hs.9731 Rn.8395 NFKBIB  Nfkbib 
Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, beta 0.182 -0.140 
Hs.2411 Rn.10217 P2RY1  P2ry1 
Purinergic receptor P2Y, G-protein 
coupled, 1 0.294 0.038 
Hs.429581 Rn.1348 RTN4  Rtn4 Reticulon 4 0.184 0.686 
Hs.132439 Rn.98353 RELN  Reln Reelin 0.480 0.324 
Hs.483454 Rn.57635 CNN3  Cnn3 Calponin 3, acidic -0.008 -1.361 
Hs.368808 Rn.7771 EHD3  Ehd3 EH-domain containing 3 0.666 0.261 
Hs.472854 Rn.106880 C20orf161   Chromosome 20 open reading frame 161 -0.167 -0.150 
Hs.189915 Rn.22664 KIF13A  Kif13A  Kinesin family member 13A 0.117 -0.181 
Hs.529959 Rn.11982 KIAA0274   KIAA0274 -0.028 -0.072 
Hs.274184 Rn.9231.2 TFE3  Tfe3  
Transcription factor binding to IGHM 
enhancer 3 -0.163 -0.291 
Hs.239663 Rn.19646 MLLT7  Mllt7  
Myeloid/lymphoid or mixed-lineage 
leukemia (trithorax homolog, Drosophila); 
translocated to, 7 -0.173 -0.432 
Hs.44070 Rn.8770 SFXN2  Sfxn2  Sideroflexin 2 0.066 0.965 
Hs.12457 Rn.91990 NUP133  Nup133  Nucleoporin 133kDa 0.121 -0.082 
Hs.469386 Rn.11215 INPP4A  Inpp4a 
Inositol polyphosphate-4-phosphatase, type 
I, 107kDa 0.097 -0.396 
Hs.153310 Rn.14163 PREX1  Prex1  
Phosphatidylinositol 3,4,5-trisphosphate-
dependent RAC exchanger 1 0.233 0.244 
Hs.502876 Rn.2042 RHOB  Rhob Ras homolog gene family, member B -0.183 -0.103 
Hs.95120 Rn.105938 CYGB  Cygb Cytoglobin 0.399 0.802 
Hs.190783 Rn.10037 HAL  Hal Histidine ammonia-lyase 0.605 1.314 
Hs.513153 Rn.3220 FURIN  Pcsk3 
Furin (paired basic amino acid cleaving 
enzyme) 1.317 2.113 
Hs.369440 Rn.2009 SFXN1  Sfxn1  Sideroflexin 1 0.283 1.690 
Hs.440332 Rn.9093 ERF  Erf  Ets2 repressor factor 0.050 -0.303 
Hs.474536 Rn.8338 MTMR3  Mtmr3  Myotubularin related protein 3 0.179 -1.121 
Hs.497159 Rn.35474 C1orf21   Chromosome 1 open reading frame 21 0.182 0.216 
Hs.350756 Rn.73714 STAU2  Stau2 
Staufen, RNA binding protein, homolog 2 
(Drosophila) -0.272 -0.875 
Hs.3416 Rn.101967 ADFP  ADRP Adipose differentiation-related protein -0.600 -0.676 
Hs.528299 Rn.6629 HTATIP  Htatip HIV-1 Tat interacting protein, 60kDa -0.089 -0.186 
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Hs.137427 Rn.3765 IRF8  Irf8  Interferon regulatory factor 8 -0.319 0.384 
Hs.494163 Rn.24783 GDA  Gda Guanine deaminase 1.362 -1.212 
Hs.78824 Rn.13171 TIE1  Tie1 
Tyrosine kinase with immunoglobulin-like 
and EGF-like domains 1 1.260 0.120 
Hs.24258 Rn.1974 GUCY1A3  Gucy1a3 Guanylate cyclase 1, soluble, alpha 3 1.084 0.629 
Hs.385861 Rn.8854 KLHL7  Klhl7  Kelch-like 7 (Drosophila) 0.124 -0.048 
Hs.169378 Rn.6684 MPDZ  Mpdz Multiple PDZ domain protein 0.500 -0.229 
Hs.546248 Rn.11085 CTSD  Ctsd Cathepsin D (lysosomal aspartyl protease) 1.639 -1.069 
Hs.3873 Rn.1574 PPT1  Ppt 
Palmitoyl-protein thioesterase 1 (ceroid-
lipofuscinosis, neuronal 1, infantile) 1.018 1.616 
Hs.272062 Rn.11386 PTPRF  Ptprf 
Protein tyrosine phosphatase, receptor 
type, F 1.212 0.999 
Hs.408062 Rn.16800 KNSL8  Knsl8  Kinesin-like 8 0.898 1.950 
Hs.76364 Rn.32080 AIF1  Aif1 Allograft inflammatory factor 1 1.262 0.383 
Hs.126521 Rn.10945 HCK  Hck Hemopoietic cell kinase 1.053 0.335 
Hs.514193 Rn.107168 RAMP2  Ramp2 
Receptor (calcitonin) activity modifying 
protein 2 1.543 0.242 
Hs.124649 Rn.8398 ABCG1  Abcg1 
ATP-binding cassette, sub-family G 
(WHITE), member 1 2.250 0.666 
Hs.24678 Rn.8423 SGPP1  Sgpp1  Sphingosine-1-phosphate phosphatase 1 0.586 1.611 
Hs.433702 Rn.40123 EIF5  Eif5 Eukaryotic translation initiation factor 5 0.666 0.651 
Hs.200841 Rn.21475 LAMA2  Lama2  
Laminin, alpha 2 (merosin, congenital 
muscular dystrophy) 0.900 0.296 
Hs.74615 Rn.55127 PDGFRA  Pdgfra 
Platelet-derived growth factor receptor, 
alpha polypeptide 1.195 0.522 
Hs.23388 Rn.32388 DKFZP434F0318  Hypothetical protein DKFZp434F0318 1.656 -0.294 
Hs.422688 Rn.13092 RBP7  Rbp7  Retinol binding protein 7, cellular 3.399 -0.740 
Hs.75799 Rn.107364 PRSS8  Prss8 Protease, serine, 8 (prostasin) 1.609 1.443 
Hs.512843 Rn.17097 NAPSA  Napsa Napsin A aspartic peptidase 0.853 0.179 
Hs.162963 Rn.6715 ANTXR2  Antxr2  Anthrax toxin receptor 2 1.207 2.110 
Hs.172631 Rn.54465 ITGAM  Itgam 
Integrin, alpha M (complement component 
receptor 3, alpha; also known as CD11b 
(p170), macrophage antigen alpha 
polypeptide) 1.088 0.074 
Hs.90753 Rn.103263 HTATIP2  Htatip2  HIV-1 Tat interactive protein 2, 30kDa 2.240 0.666 
Hs.522730 Rn.7755 GPRASP1  Gprasp1  
G protein-coupled receptor associated 
sorting protein 1 1.484 0.024 
Hs.194121 Rn.22496 RCL1  Rcl1  RNA terminal phosphate cyclase-like 1 1.021 0.789 
Hs.82407 Rn.7070 CXCL16  Cxcl16  Chemokine (C-X-C motif) ligand 16 1.856 0.627 
Hs.221847 Rn.16393 SLC38A2  Slc38a2 Solute carrier family 38, member 2 0.859 0.882 
Hs.523332 Rn.1430 OAT  Oat 
Ornithine aminotransferase (gyrate 
atrophy) 0.731 3.815 
Hs.370666 Rn.102196 FOXO1A  Foxo1a Forkhead box O1A (rhabdomyosarcoma) 0.778 -0.178 
Hs.42217 Rn.3622 CDA08  Cda08 T-cell immunomodulatory protein 1.603 -0.397 
Hs.75294 Rn.10349 CRH  Crh Corticotropin releasing hormone 0.825 0.003 
Hs.1799 Rn.11120 CD1D  Cd1d1 CD1D antigen, d polypeptide 0.528 0.791 
Hs.514535 Rn.3251 LGALS3BP  Lgals3bp 
Lectin, galactoside-binding, soluble, 3 
binding protein 1.093 1.517 
Hs.118681 Rn.12019 ERBB3  Erbb3  
V-erb-b2 erythroblastic leukemia viral 
oncogene homolog 3 (avian) 0.805 1.799 
Hs.247460 Rn.11029 NLN  Nln Neurolysin (metallopeptidase M3 family) 0.203 0.221 
Hs.489849 Rn.9699 SLC13A1  Slc13a1 **Solute carrier family 13 (sodium/sulfate 0.451 0.003 
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symporters), member 1 
Hs.516376 Rn.22892 WDR33  Wdr33  WD repeat domain 33 0.128 -0.532 
Hs.396740 Rn.6506 NIP30  Nip30  NEFA-interacting nuclear protein NIP30 0.058 -0.258 
Hs.131776 Rn.23058 PGPEP1  Pgpep1  Pyroglutamyl-peptidase I 0.934 0.459 
Hs.524625 Rn.6500 GRK5  Gprk5 G protein-coupled receptor kinase 5 0.361 0.051 
Hs.9688 Rn.11988 CMRF-35H  Cmrf-35H  CD300A antigen 0.212 0.598 
Hs.500101 Rn.13776 VCL  Vcl  Vinculin 0.167 1.033 
Hs.357128 Rn.100030 MOCS1  Mocs1  Molybdenum cofactor synthesis 1 1.532 -0.929 
Hs.408846 Rn.18573 SEMA4A  Sema4A  
Sema domain, immunoglobulin domain 
(Ig), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 
4A 0.041 -2.042 
Hs.75275 Rn.102204 UBE4A  Ube4a 
Ubiquitination factor E4A (UFD2 
homolog, yeast) -0.124 -0.994 
Hs.351558 Rn.21476 U2AF1L3   
U2(RNU2) small nuclear RNA auxiliary 
factor 1-like 3 0.025 0.091 
Hs.102402 Rn.3279 MXD4  Mxd4  MAX dimerization protein 4 -0.250 1.064 
Hs.110849 Rn.53888 ESRRA  Esrra Estrogen-related receptor alpha -0.030 -0.288 
Hs.296169 Rn.3016 RAB4A  Rab4a RAB4A, member RAS oncogene family -0.333 -0.459 
Hs.380906 Rn.106161 MYADM  Myadm Myeloid-associated differentiation marker 0.420 -0.818 
Hs.303669 Rn.17455 MGC26694   Hypothetical protein MGC26694 0.738 1.490 
Hs.418198 Rn.6410 PAPD4  Papd4  PAP associated domain containing 4 0.274 -0.010 
Hs.8261 Rn.8693 SSB1  Ssb1  
SPRY domain-containing SOCS box 
protein SSB-1 0.238 -0.367 
Hs.125039 Rn.4896 CROT  Crot Carnitine O-octanoyltransferase 0.141 0.822 
Hs.55131 Rn.20696 DKFZp313N0621   Chromosome 3 open reading frame 23 -0.041 -0.337 
Hs.149414 Rn.5825 CR1L  Crry 
Complement component (3b/4b) receptor 
1-like -0.344 1.109 
Hs.300834 Rn.12691 GALNT2  Galnt2  
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 2 
(GalNAc-T2) 0.565 -0.691 
Hs.304376 Rn.23619 PPP1R15B  Ppp1R15B  
Protein phosphatase 1, regulatory 
(inhibitor) subunit 15B -0.111 2.001 
Hs.514373 Rn.2567 MTMR4  Mtmr4  Myotubularin related protein 4 -0.108 -0.494 
Hs.471917 Rn.17460 PSMF1  Psmf1  Proteasome inhibitor subunit 1 PI31 -0.150 -1.270 
Hs.253903 Rn.16958 STOM  Stom  Stomatin 0.181 0.119 
Hs.821 Rn.783 BGN  Bgn Biglycan -0.155 -2.507 
Hs.522578 Rn.6312 STS  Sts 
Steroid sulfatase microsomal, arylsulfatase 
C, isozyme S -0.081 -0.668 
Hs.499222 Rn.2549 CES1  Es2 
Carboxylesterase 1 (monocyte/macrophage 
serine esterase 1) 0.702 -0.911 
Hs.149387 Rn.18047 MYO6  Myo6  Myosin VI 0.579 -0.252 
Hs.264 Rn.16693 PNPLA4  Pnpla4  
Patatin-like phospholipase domain 
containing 4 0.338 -0.022 
Hs.434961 Rn.88438 ATXN1  Sca1 Ataxin 1 -0.202 -0.011 
Hs.410388 Rn.73451 LACTB  Lactb  Lactamase, beta 0.780 0.169 
Hs.453951 Rn.37438 NRG1  Nrg1 Neuregulin 1 1.188 0.044 
Hs.414473 Rn.15657 C6orf110   Chromosome 6 open reading frame 110 0.281 -0.639 
Hs.533055 Rn.4126 PCAF  Pcaf  P300/CBP-associated factor 0.119 0.288 
Hs.232194 Rn.2250 KIAA0174   KIAA0174 gene product -0.181 1.440 
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Hs.132314 Rn.8731 ELTD1  Etl 
EGF, latrophilin and seven transmembrane 
domain containing 1 0.578 0.213 
Hs.2006 Rn.9158 GSTM3  Gstm5 Glutathione S-transferase M3 (brain) 0.208 0.078 
Hs.398157 Rn.12100 PLK2  Plk2 Polo-like kinase 2 (Drosophila) 0.099 0.950 
Hs.270570 Rn.8820 DBT  Dbt  
Dihydrolipoamide branched chain 
transacylase E2 0.268 -0.626 
Hs.76494 Rn.65510 PRELP  Prelp  
Proline arginine-rich end leucine-rich 
repeat protein -0.622 0.908 
Hs.19156 Rn.28222 DAAM1  Daam1  
Dishevelled associated activator of 
morphogenesis 1 0.654 1.157 
Hs.1041 Rn.87436 ROS1  Ros1 
V-ros UR2 sarcoma virus oncogene 
homolog 1 (avian) 0.444 -0.042 
Hs.529735 Rn.11133 AADAT  Aadat Aminoadipate aminotransferase 0.502 1.624 
Hs.160562 Rn.6282 IGF1  Igf1 
Insulin-like growth factor 1 (somatomedin 
C) -0.923 0.600 
Hs.519276 Rn.6276 MAPKAPK2  Mapkapk2 
Mitogen-activated protein kinase-activated 
protein kinase 2 0.171 2.764 
Hs.408312 Rn.54443 TP53  Tp53 
Tumor protein p53 (Li-Fraumeni 
syndrome) 0.001 0.303 
Hs.517033 Rn.10 TGM2  Tgm2 
Transglutaminase 2 (C polypeptide, 
protein-glutamine-gamma-
glutamyltransferase) -2.015 -2.435 
Hs.46319 Rn.37473 SHBG  Shbg Sex hormone-binding globulin -1.162 -0.058 
Hs.481342 Rn.24612 ARGBP2  Argbp2 Arg/Abl-interacting protein ArgBP2 1.252 -0.864 
Hs.156727 Rn.81030 ANKH  Ank Ankylosis, progressive homolog (mouse) 0.941 0.996 
Hs.5476 Rn.17644 SLC25A25  Pcscl 
Solute carrier family 25 (mitochondrial 
carrier; phosphate carrier), member 25 0.597 2.431 
Hs.446077 Rn.73202 SLC38A4  Slc38A4  Solute carrier family 38, member 4 -0.099 3.487 
Hs.494496 Rn.15319 FBP1  Fbp2 Fructose-1,6-bisphosphatase 1 -0.594 -0.879 
Hs.514489 Rn.12104 WBP2  Wbp2  WW domain binding protein 2 0.317 0.132 
Hs.8375 Rn.3219 TRAF4  Traf4  TNF receptor-associated factor 4 0.005 0.542 
Hs.498543 Rn.6923 FBXO18  Fbxo18  F-box protein, helicase, 18 -0.059 -1.000 
Hs.189641 Rn.24238 SEC24D  Sec24D  
SEC24 related gene family, member D (S. 
cerevisiae) 0.338 -2.250 
Hs.193566 Rn.15254 ZDHHC9  Zdhhc9  Zinc finger, DHHC domain containing 9 1.370 0.145 
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APPENDIX 4 
 
Unsupervised hierarchical clustering of 15,866 genes in liver distinguishes 
between choline sufficient (CS) and choline deficient (CD) treated rats 
 
Hierarchical clustering analysis was conducted on control choline sufficient (CS) or 
choline deficient (CD) liver samples collected between 4 and 80 weeks. Tumor (T) 
samples were collected at 80 weeks from CD-treated rats. The dendrogram shows that 
the samples clustered into two groups according to treatment. The color of each gene is 
proportional to the mean expression level (in log2 units, see color bar) of the gene across 
the entire set of samples (red - median, black – no change, and green - below median 
value). 
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APPENDIX 5 
KEGG-annotated pathways that are significantly enriched in CD rats 
Two significant gene lists were generated using intrinsic gene identifier (white bar) or 
SAM (grey bar) and the number of genes (as identified by each procedure) for a given 
KEGG pathway is shown in comparison to a total number of genes in that representative 
pathway (black bar).  
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